Reference Committee B

BOT Report(s)

09 Council on Legislation Sunset Review of 2012 House Policies

17 Expungement, Destruction, and Sealing of Criminal Records for Legal Offenses Related to Cannabis Use or Possession

Resolution(s)

201 The Impact of Midlevel Providers on Medical Education
202 AMA Position on All Payer Database Creation
203 Ban the Gay/Trans (LGBTQ+) Panic Defense
204 Insurance Claims Data
205 Insurers and Vertical Integration
206 Medicare Advantage Plan Mandates
207 Physician Tax Fairness
208 Prohibit Ghost Guns
209 Supporting Collection of Data on Medical Repatriation
210 Reducing the Prevalence of Sexual Assault by Testing Sexual Assault Evidence Kits
211 Repeal or Modification of the Medicare Appropriate Use Criteria (AUC) Program
212 Medication for Opioid Use Disorder in Physician Health Programs
213 Resentencing for Individuals Convicted of Marijuana-Based Offenses
214 Eliminating Unfunded or Unproven Mandates and Regulations
215 Transforming Professional Licensure to the 21st Century
216 Advocating for the Elimination of Hepatitis C Treatment Restrictions
217 Preserving the Practice of Medicine
218 Expedited Immigrant Green Card Visa for J-1 Visa Waiver Physicians Serving in Underserved Areas
219 Due Process and Independent Contractors
220 Vital Nature of Board-Certified Physicians in Aerospace Medicine

REPORT OF THE BOARD OF TRUSTEES

B of T Report 9-A-22

Subject: Council on Legislation Sunset Review of 2012 House Policies

Presented by: Bobby Mukkamala, MD, Chair

Referred to: Reference Committee B

Policy G-600.110, "Sunset Mechanism for AMA Policy," calls for the decennial review of American Medical Association (AMA) policies to ensure that our AMA's policy database is current, coherent, and relevant. Policy G-600.010 reads as follows, laying out the parameters for review and specifying the procedures to follow:

1. As the House of Delegates (HOD) adopts policies, a maximum ten-year time horizon shall exist. A policy will typically sunset after ten years unless action is taken by the HOD to retain it. Any action of our AMA HOD that reaffirms or amends an existing policy position shall reset the sunset "clock," making the reaffirmed or amended policy viable for another 10 years.

2. In the implementation and ongoing operation of our AMA policy sunset mechanism, the following procedures shall be followed: (a) Each year, the Speakers shall provide a list of policies that are subject to review under the policy sunset mechanism; (b) Such policies shall be assigned to the appropriate AMA councils for review; (c) Each AMA council that has been asked to review policies shall develop and submit a report to the HOD identifying policies that are scheduled to sunset; (d) For each policy under review, the reviewing council can recommend one of the following actions: (i) retain the policy; (ii) sunset the policy; (iii) retain part of the policy; or (iv) reconcile the policy with more recent and like policy; (e) For each recommendation that it makes to retain a policy in any fashion, the reviewing council shall provide a succinct, but cogent justification; or (f) The Speakers shall determine the best way for the HOD to handle the sunset reports.

3. Nothing in this policy shall prohibit a report to the HOD or resolution to sunset a policy earlier than its 10-year horizon if it is no longer relevant, has been superseded by a more current policy, or has been accomplished.

4. The AMA councils and the HOD should conform to the following guidelines for sunset: (a) when a policy is no longer relevant or necessary; (b) when a policy or directive has been accomplished; or (c) when the policy or directive is part of an established AMA practice that is transparent to the House and codified elsewhere such as the AMA Bylaws or the AMA HOD Reference Manual: Procedures, Policies and Practices.

5. The most recent policy shall be deemed to supersede contradictory past AMA policies.

6. Sunset policies will be retained in the AMA historical archives.

RECOMMENDATION

The Board of Trustees recommends that the House of Delegates policies that are listed in the appendix to this report be acted upon in the manner indicated and the remainder of this report be filed.

APPENDIX – Recommended Actions

Policy Number	Title	Text	Recommendation
D-155.990	Responsibility for Transparency	Our AMA will actively oppose any legislation and/or regulation that deems the physician the responsible party to inform patients of their anticipated health care costs where the practitioner does not set reimbursement rates. (Res. 819, I-12)	Retain – this policy remains relevant.
D-160.999	Opposition to Criminalizing Health Care Decisions	Our AMA will educate physicians regarding the continuing threat posed by the criminalization of healthcare decision-making and the existence of our model legislation "An Act to Prohibit the Criminalization of Healthcare Decision-Making." (Res. 228, I-98; Reaffirmed: BOT Rep. 5, A-08; Reaffirmation: I-12)	Retain – this policy remains relevant.
D-185.986	Third Party Payer Coverage Process Reform and Advocacy	1. Our AMA, working with interested state medical and national specialty societies, will develop model legislation and/or regulations to require that commercial insurance companies, state Medicaid agencies, or other third-party payers utilize transparent and accountable processes for developing and implementing coverage decisions and policies, and will actively seek the implementation of such model legislation and/or regulations at the national and state levels. 2. Our AMA will work with specialty and service organizations to advocate that private insurance plans and benefit management companies develop transparent clinical protocols as well as formal processes to write / revise them; that those processes should seek input from the relevant national physician	Retain – this policy remains relevant.

		organizations; and that such clinical coverage protocols should be easily and publicly accessible on their websites, just as Medicare national and local coverage determinations are publicly available. 3. Our AMA will advocate that when private insurance plans and benefit management companies make changes to or revise clinical coverage protocols, said companies must inform all insured individuals and participating providers in writing no less than 90 days prior to said change(s) going into effect. (Res. 820, I-11; Appended: Res. 807, I-12)	
D-190.984	HIPAA	Our AMA continue to identify and work toward the repeal of the onerous provisions in the Health Insurance Portability and Accountability Act legislation and regulations, including its criminal liability provisions, and that our AMA work to redress the breaches of patient confidentiality that the HIPAA regulations have allowed. (Res. 901, I-02; Reaffirmed: CCB/CLRPD Rep. 4, A-12)	Retain – this policy remains relevant.
D-190.988	HIPAA interference with Peer Review Activities	Our AMA shall seek immediate clarification from the Department of Health and Human Services of the impact of the Health Insurance Portability and Accountability Act Privacy Rule on the peer review process. (Res. 721, A-02; Reaffirmed: CCB/CLRPD Rep. 4, A-12)	Sunset this policy. HIPAA does not pose issues with the peer review process; presumably when the law first came out, physicians may have thought they would not be able to share protected health information for peer review, but HIPAA's regulations allow that type of discussion.
D-190.989	HIPAA Law And Regulations	(1) Our AMA shall continue to aggressively pursue modification of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule to remove burdensome regulations that could interfere with efficient patient care. ~~(2) If satisfactory modification to the~~	Retain and modify part of this policy. Rescind clause 2 and 3, and renumber and modify clause 4. Clause 2 is outdated and no longer applicable. Regarding clause 3, opposing unique patient

		~~HIPAA Privacy Rule is not obtained, our AMA shall aggressively pursue appropriate legislative and/or legal relief to prevent implementation of the HIPAA Privacy Rule.~~ ~~(3) Our AMA shall continue to oppose the creation or use of any unique patient identification number, including the Social Security number, as it might permit unfettered access by governmental agencies or other entities to confidential patient information.~~ ~~(4)~~(2) Our AMA shall ~~immediately begin working~~ continue to work with the appropriate parties and trade groups to explore ways to help offset the costs ~~of implementing the changes required by the Health Insurance Portability and Accountability Act~~ associated with HIPAA compliance so as to reduce the fiscal burden on physicians. (Sub. Res. 207, A-02; Reaffirmed: CCB/CLRPD Rep. 4, A-12)	identification number policies harms more than helps in certain stakeholder circles. Renumber clause 4 to be clause 2 and modify the clause by updating the language to be more in line with the wording of clause 1.
D-230.991	Inspector General to Rule on Exclusivity Restrictions for Medical Staff Membership	Our AMA will (1) continue its discussions with the Office of Inspector General of Health and Human Services and urge the OIG to issue a fraud alert on the practice of exclusive credentialing; and (2) take other appropriate action, which may include administrative action, litigation, and/or legislation, to protect our patients from being denied quality medical care through exclusive (including economic) credentialing by hospitals. (Res. 714, I-02; Reaffirmed: CCB/CLRPD Rep. 4, A-12)	Retain – this policy remains relevant.
D-235.987	Medical Staff Bylaws as Binding Contracts	Our AMA will actively pursue the enactment of federal legislation and/or regulation that will recognize medical staff bylaws as a binding contract, not subject to unilateral amendment, between the organized medical staff and the governing board of a hospital or health care delivery system. (Sub. Res. 818, I-12)	Sunset this policy. This resolution was based on a Minnesota trial court case that held that medical staff bylaws should not be deemed a contract between the medical staff and the hospital. Subsequent to the HOD's adoption of this

			resolution, in December 2014, the Minnesota Supreme Court overruled the trial court's decision and held that medical staff bylaws could be enforced as a contract. The AMA's Litigation Center supported this case. Medical staff contract issues are primarily regulated at the state level. The AMA's Advocacy Resource Center, through the Council on Legislation, has developed model state legislation entitled an "Act to Ensure the Autonomy of Hospital Medical Staffs." In addition, AMA Policy H-235.976 recognizes that medical staff bylaws are a contract between the organized medical staff and the hospital.
D-315.991	Medical Records with Bills	Our AMA shall cause to be introduced legislation that would: (1) establish criteria defining when the request for medical records from a third party payer is appropriate, and (2) require insurance companies to pay for copied medical records requested by said insurance company at the rate established by law. (Res. 218, A-02; Reaffirmed: CCB/CLRPD Rep. 4, A-12)	Retain – this policy remains relevant.
D-330.915	RAC Audits of E&M Codes	1. Our AMA opposes Recovery Audit Contractor audits of E&M codes with the Centers for Medicare & Medicaid Services (CMS) and will explain to CMS and Congress why these audits as currently conducted are deleterious to the provision of care to patients with complex health needs. 2. If our AMA is unsuccessful in reversing the audits, our AMA will urge CMS and elected Washington officials to require physician reimbursement for time and expense of appeals. 3. Our AMA will urge CMS and elected	Retain – this policy remains relevant.

		Washington officials to provide statistical data regarding the audits, including the specialties most affected by these audits, and the percentage of denied claims for E&M codes which, when appealed, are reversed on appeal. (Res. 224, I-12)	
D-330.966	Medicare Program Safeguard Contractors	Our AMA, consistent with the principles set forth in its September 2001 letter to the Centers for Medicare & Medicaid Services, shall continue to press for legislative and/or administrative relief from the creation of Program Safeguard Contractors and other abusive contracting authority by CMS. (Res. 709, A-02; Reaffirmed: CCB/CLRPD Rep. 4, A-12)	Retain – this policy remains relevant.
D-35.987	Evaluation of the Expanding Scope of Pharmacists' Practice	Our AMA: (1) will re-evaluate the expanding scope of practice of pharmacists in America and develop additional policy to address the proposed new services provided by pharmacists that may constitute the practice of Medicine; (2) will continue to collect and disseminate state specific information in collaboration with state medical societies regarding the current scope of practice for pharmacists in each state; studying if and how each state is addressing these expansions of practice; (3) will develop model state legislation to address the expansion of pharmacist scope of practice that is found to be inappropriate or constitutes the practice of medicine, including but not limited to the issue of interpretations or usage of independent practice arrangements without appropriate physician supervision and work with interested states and specialties to advance such legislation; (4) opposes federal and state legislation allowing pharmacists to independently prescribe or dispense prescription medication without a valid order by, or under the supervision of, a licensed doctor of medicine, osteopathy, dentistry or podiatry; (5) opposes federal and state legislation allowing	Retain – this policy remains relevant.

		pharmacists to dispense medication beyond the expiration of the original prescription; and (6) opposes the inclusion of Doctors of Pharmacy (PharmD) among those health professionals designated as a "Physician" by the Centers for Medicare & Medicaid Services. (Res. 219, A-11; Appended: Res. 218, A-12)	
D-383.984	ERISA and Managed Care Oversight	Our AMA will develop, propose, and actively support (1) federal legislation clarifying that ERISA preemption does not apply to physician/insurer contracting issues; (2) federal legislation that requires all third party payers serving as administrators for ERISA plans to accept assignment of benefits by patients to physicians; and (3) federal and state legislation prohibiting "all products" clauses or linking participation in one product to participation in other products ("tied") administered or offered by third party payers or their affiliates. (Res. 915, I-06; Reaffirmed: Res. 223, I-10; Reaffirmed: CMS Rep. 6, A-12)	Retain – this policy remains relevant. This policy supports changes to the scope of ERISA preemption. ERISA preemption is a barrier to the AMA's and the Federation's advocacy in support of protecting physicians through state regulations from the adverse business practices of many of the payers with whom physicians contract.
D-390.986	Medicare Balance Billing	Our American Medical Association: (1) advocate that physicians be allowed to balance bill Medicare recipients to the full amount of their normal charge with the patient responsible for the difference between the Medicare payment and the physician charges; (2) seek introduction of national legislation to bring about implementation of balance billing of Medicare recipients; and (3) further advocate that such federal laws and regulations pre-empt state laws that prohibit balance billing. (Res. 713, I-02; Reaffirmation A-04; Reaffirmation A-06; Reaffirmed per BOT Action in response to referred for decision Res. 236, A-06; Reaffirmed: CMS Rep. 5, I-12)	Retain – this policy remains relevant.
D-478.984	Clinical Data Repositories for Physicians, Patients	Our American Medical Association will (1) collect and make available the best practices resulting from existing pilot Clinical Data Repository (CDR) projects	Retain – this policy remains relevant.

	and Continuous Quality Improvement	to demonstrate the most appropriate measures and data aggregation methods for assessing physician performance, and to demonstrate how best to use clinical data to improve quality of patient care; and (2) identify and disseminate educational materials to be used by physician organizations and communities on how to best use data from CDRs in practice improvement, quality improvement, and contracting. (BOT Rep. 3, I-09; Reaffirmed in lieu of Res. 704, A-12)	
D-525.998	Mammography Screening for Breast Cancer	In order to assure timely access to breast cancer screening for all women, our AMA shall advocate for legislation that ensures adequate funding for mammography services. (Res. 120, A-02; Reaffirmed: CCB/CLRPD Rep. 4, A-12)	Retain – this policy remains relevant
D-85.994	Strengthening Medicolegal Death Investigations	Our AMA will work with interested states on legislation to facilitate the transition from coroner systems to medical examiner systems. (Res. 718, A-12)	Retain – this policy remains relevant.
H-100.954	Stimulate Antibiotic Research and Development	Our AMA supports legislation requiring the re-evaluation of FDA guidelines for clinical trials of antibiotics, including an increase in the period of market exclusivity. (Res. 210, A-12)	Sunset this policy. The Generating Antibiotic Incentives Now (GAIN) Act of 2012 was enacted after this resolution was adopted. The law increased exclusivity for antibiotics for 5 years and required FDA to evaluate ways to ensure continued research on antibiotics (which FDA subsequently did in updates to 3 different guidances).
H-100.957	Repeal of the Federal Restriction on the Use of Tax Exempt Funds to Buy Medications Without a Prescription in the PPACA (Health Reform Law)	Our AMA supports the repeal of the federal restriction on the use of tax-exempt funds to buy medications without a prescription and will formally notify the appropriate federal legislative bodies and regulatory agencies of this support for repeal. (Res. 211, A-11; Reaffirmation A-12)	Retain – this policy remains relevant.

H-120.938	Opposition to FDA's Rx to OTC Paradigm Shift	Our AMA will: (1) submit comments during the public comment period expressing our concerns with the Food and Drug Administration's (FDA's) proposed paradigm shift; (2) continue to monitor FDA's action on this issue; (3) encourage the FDA to study the cost implications switching prescription drugs to over-the-counter status will have on patient out of pocket costs; and (4) strongly encourage the FDA to initiate a formal public comment process before reclassifying any prescription drug to over-the-counter status. (Res. 235, A-12)	Retain – this policy remains relevant.
H-160.946	The Criminalization of Health Care Decision Making	The AMA opposes the attempted criminalization of health care decision-making especially as represented by the current trend toward criminalization of malpractice; it interferes with appropriate decision making and is a disservice to the American public; and will develop model state legislation properly defining criminal conduct and prohibiting the criminalization of health care decision-making, including cases involving allegations of medical malpractice, and implement an appropriate action plan for all components of the Federation to educate opinion leaders, elected officials and the media regarding the detrimental effects on health care resulting from the criminalization of health care decision-making. (Sub. Res. 202, A-95; Reaffirmed: Res. 227, I-98; Reaffirmed: BOT Rep. 2, A-07; Reaffirmation A-09; Reaffirmation: I-12)	Retain – this policy remains relevant.
H-165.841	Comprehensive Health System Reform	Our AMA supports the overall goal of ensuring that every American has access to affordable high quality health care coverage and will work with interested members of Congress to seek legislation consistent with AMA policy. (Sub. Res. 924, I-07; Reaffirmed: Res. 239, A-12)	Sunset this policy. This has been accomplished through the Affordable Care Act and superseded by more recent policy, H-165.838.

H-175.985	Kennedy-Kassebaum: Fraud and Abuse	Our AMA: (1) will work to alleviate the oppressive, burdensome effects on physicians of the Health Insurance Portability and Accountability Act of 1996 (HIPAA); (2) opposes efforts to repeal provisions in Health Insurance Portability and Accountability Act of 1996 (HIPAA) that would alter the standard of proof in criminal and civil fraud cases or that would eliminate the ability of physicians to obtain advisory opinions regarding anti-kickback issues; and thoroughly evaluate and oppose other fraud and abuse proposals that are inappropriately punitive to physicians; (3) will ensure that any proposed criminal fraud and abuse proposals retain the current intent standard of "willfully and knowingly" to be actionable fraud; and that the AMA oppose any effort to lower this evidentiary standard; (4) will vigorously oppose efforts by the Department of Justice to punish and harass physicians for unintentional errors in Medicare claims submissions and the legitimate exercise of professional judgment in determining medically necessary services; (5) continues its efforts to educate the entire Federation about the AMA's successful amendment of the Health Insurance Portability and Accountability Act (also commonly referred to as the Kassebaum-Kennedy bill) which resulted in language being added so that physicians cannot be prosecuted or fined for inadvertent billing errors, absent an intent to "knowingly and willfully" defraud; (6) educates the public and government officials about the distinction under the law, between inadvertent billing errors and fraud and abuse; and (7) responds vigorously to any public statements that fail to distinguish between inadvertent billing errors and fraud and abuse. (Sub. Res. 222, A-97; Appended: Res. 202, I-98; Reaffirmation A-99;	Retain – this policy remains relevant.

		Reaffirmation A-01; Reaffirmation I-01; Reaffirmation A-02; Reaffirmed: BOT Rep. 19, A-12)	
H-175.989	Health Care Fraud Legislation	Our AMA: (1) should continue to scrutinize current and future key legislation regarding health care fraud and abuse; (2) should use all appropriate resources available to ensure that any proposed sanctions, penalties, or sentences be commensurate with the offense committed, especially regarding the imposition of criminal penalties in measures that fail even to define the boundaries of a "health care offense" or to establish the requisite intent necessary for conviction; (3) should work with appropriate federal agencies and congressional committees in studying the extent to which health care fraud pervades the current environment; (4) should continue to support legislative measures such as HR 5120, which would establish a national commission to investigate the nature, magnitude, and cost of health care fraud and abuse; (5) should conduct surveys and research in order to develop data on possible abuses in the system; (6) should continue to support the Principles of Medical Ethics concerning fraud by encouraging physicians to accept the responsibility to expose those engaged in fraud and deception; (7) should continue to pursue recent initiatives, including providing assistance to the FBI in a cooperative endeavor as it attempts to identify and prosecute health care fraud, and continue ongoing efforts with the FTC to remove the current legal barriers to professional self-regulatory activity that would assist in the elimination of fraud and abuse; (8) should pursue legislative efforts to enact a program that would award grants to medical societies for the creation of programs specifically targeted at fraud and abuse; and (9) continue to make the relief of oppressive and overzealous application	Sunset this policy. This policy is very specific to a policy trend that was occurring in 1992 that has long been eclipsed by other issues and approaches regarding fraud and abuse issues. Also, the HOD has adopted more current and relevant policy addressing fraud and abuse since 1992, including: H-175.979, Medicare "Fraud and Abuse" Update; H-175.981, Fraud and Abuse Within the Medicare System; H-175.982, Due Process for Physicians; H-175.984, Health Care Fraud and Abuse Update; H-70.952, Medicare Guidelines for Evaluation and Management Codes

		of fraud and abuse regulations a high priority and take whatever action is necessary to challenge improprieties in the application of fraud and abuse laws against physicians. (BOT Rep. Z, I-92; Reaffirmed: Sub. Res. 232, A-96; Reaffirmation A-99; Appended: Sub. Res. 244, A-00; Reaffirmed: Res. 201, I-00; Reaffirmation I-00; Reaffirmation A-02; Reaffirmed: BOT Rep. 19, A-12)	
H-180.954	Privacy of Physician Medical Information	It is the policy of the AMA that a physician's personal medical history is private and should remain confidential. Only information regarding current health status should be required for credentialing purposes. (BOT Rep. 7, I-02; Reaffirmed: CMS Rep. 4, A-12)	Retain – this policy remains relevant.
H-190.960	HIPAA Law and Regulations	Our AMA believes that inadvertent disclosures of protected health information should not lead to the imposition of criminal sanctions. (Sub. Res. 207, A-02; Reaffirmed: CMS Rep. 4, A-12)	Retain – this policy remains relevant.
H-285.909	Designation of Electrodiagnosis / Other Services as Separate Category in Provider Network	Our AMA will: (1) oppose the re-designation of services traditionally provided by broader medical specialties as a separate specialty category for inclusion into a payor's provider network unless compelling evidence shows it will improve patient care; and (2) support the ability for all appropriately trained neurologists and physiatrists to perform electrodiagnosis on patients within their provider network. (Res. 814, I-12)	Retain – this policy remains relevant.
H-285.933	Financial Liability Encountered in Referrals for Alternative Care	The AMA supports legislation that managed care organizations that offer alternative medicine as a covered service not require referral by the primary care physician for that service, and that the primary care physician not be held at risk financially for the costs of those provided alternative medical services.	Retain – this policy remains relevant. Primary care physicians should not be required by health plans to authorize alternative medicine that they do not provide

		(Res. 702, A-98; Reaffirmed: BOT Rep. 36, A-02; Reaffirmed: CMS Rep. 4, A-12)	themselves (e.g., acupuncture).
H-30.938	Support for Medical Amnesty Policies for Underage Alcohol Intoxication	Our AMA supports efforts among universities, hospitals, and legislators to establish medical amnesty policies that protect underage drinkers from punishment for underage drinking when seeking emergency medical attention for themselves or others. (Res. 202, A-12)	Retain – this policy remains relevant.
H-335.964	Funding for the Agency for Healthcare Research and Quality	Our AMA: (1) strongly supports the AHRQ in its activities, programs and initiatives designed to provide evidence-based information to evaluate and improve health care in practice settings; and (2) supports legislation that would greatly expand the scope and budget of the AHRQ as the central federal agency coordinating the issues involved in implementing the changes discussed in the IOM report, Crossing the Quality Chasm. (Res. 811, A-02; Appended: BOT Rep. 14, I-02; Reaffirmed: CMS Rep. 4, A-12)	Retain – this policy remains relevant.
H-383.989	Protecting Physicians with Multiple Tax ID Numbers	Our AMA will support legislation and/or regulation to prevent managed care organizations from requiring physicians to participate under all of their Tax ID Numbers if they participate under one Tax ID Number. (Res. 215, A-12)	Retain – this policy remains relevant.
H-385.971	Physician Negotiations with Third Party Payers	The AMA (1) will aid, encourage and guide medical societies in efforts to directly negotiate with any larger payer of medical services; (2) will negotiate with national third party payers with regard to national policies which arbitrarily interfere with patient care; and (3) will use its legal and legislative resources to the maximum extent to change the laws to permit physicians to fairly and collectively deal with third party payers.	Retain – this policy remains relevant.

		(BOT Rep. MMM, A-91; Reaffirmation A-97; Reaffirmation I-06; Reaffirmed: BOT action in response to referred for decision Res. 201, I-12)	
H-435.944	Clinical Decision Support and Malpractice Risk	Our AMA will: (1) advocate in interested states for legislation that would create a "safe harbor" for physicians who use a consensus-based drug-drug interaction list in their clinical decision support software package; and (2) communicate to governmental authorities in interested states that patients, physicians, hospitals, and the government will all lose out if a "safe harbor" for physicians who use a consensus-based drug-drug interaction list in their clinical decision support software package is not developed. (Res. 228, A-12)	Sunset this policy. This policy was very specific to a policy trend that was occurring in 2012. This has not been an area of recent activity in the states.
H-440.859	American's Health	Our AMA will: (1) make improving health through increased activity and proper diet a priority; (2) propose legislation calling on the federal government and state governments to develop new and innovative programs in partnership with the private sector that encourage personal responsibility for proper dietary habits and physical activity of individual Americans; and (3) continue to work in conjunction with the American College of Sports Medicine, American Heart Association, US Department of Health and Human Services and any other concerned organizations to provide educational materials that encourage a healthier America through increased physical activity and improved dietary habits. (Res. 201, A-09; Reaffirmation A-12)	Retain – this policy remains relevant.
H-478.994	Health Information Technology	Our AMA will support the principles that when financial assistance for Health IT originates from an inpatient facility: (1) it not unreasonably constrains the physician's choice of which ambulatory HIT system to purchase; and (2) it promotes voluntary rather than mandatory sharing of Protected Health	Retain – this policy remains relevant.

		Information (HIPAA-PHI) with the facility consistent with the patient's wishes as well as applicable legal and ethical considerations. (Res. 723, A-05; Reaffirmation A-10; Reaffirmed in lieu of Res. 237, A-12)	
H-510.987	Support Integration of Care for Returning Military, Veterans and Their Families by Opening Access to the States' Prescription Monitoring Programs by VA Prescribing Providers	Our AMA urges the Secretary of the Department of Veterans Affairs to implement procedures allowing and encouraging VA-based health care providers to access and utilize state-based prescription drug monitoring programs in order to improve risk assessment and medical management of their patients receiving prescriptions for controlled substances. (BOT action in response to referred for decision Res. 710, A-12)	Sunset this policy. The AMA has extensive policy regarding the use of PDMPs, including VA-specific provisions within H-95.947, "Prescription Drug Monitoring to Prevent Abuse of Controlled Substances," which provides for support for the VA to report prescription information required by the state into the state PDMP; and that physicians and other health care professionals employed by the VA to be eligible to register for and use the state PDMP in which they are practicing even if the physician or other health care professional is not licensed in the state.

REPORT OF THE BOARD OF TRUSTEES

B of T Report 17-A-22

Subject:	Expungement, Destruction, and Sealing of Criminal Records for Legal Offenses Related to Cannabis Use or Possession
Presented by:	Bobby Mukkamala, MD, Chair
Referred to:	Reference Committee B

INTRODUCTION

At the November 2020 Special Meeting of the AMA House of Delegates (HOD), Policy D-95.960 was adopted asking "That our AMA study the expungement, destruction, and sealing of criminal records for legal offenses related to cannabis use or possession."

During the meeting, there was testimony in support of an amendment on the expungement of criminal records for cannabis-related offenses. The AMA Council on Legislation testified that given the legal nature of the proposed recommendation, the issue would benefit from further study. This report discusses the issues raised and provides general information and background for the purposes of informing the AMA HOD. This report should not be relied upon as legal advice or for applicability to any particular factual scenario. An individual interested in pursuing legal action related to the issues raised in this report should consult with a licensed attorney in the state in which the individual resides or action in question occurred. This report also provides relevant AMA policy and presents recommendations for HOD consideration.

BACKGROUND

The legal status of cannabis is a patchwork of state and federal law and federal guidance. Colorado and Washington were the first states to legalize cannabis for medical use in 2012. In 2013, the U.S. Department of Justice (DOJ) issued what is referred to as the "Cole Memo." The Cole Memo essentially stated that the federal government would not interfere with state cannabis laws if the state had a strict regulatory system to protect against criminal activity.[1] At least eight states legalized medical cannabis between 2013-2018. In 2018, the DOJ rescinded the Cole Memo.[2]

Currently, adult use of cannabis is legal in at least 18 states and two territories, and for medical use, cannabis is legal in at least 37 states and four territories.[3] Cannabis remains a Schedule I Controlled Substance at the federal level, which is defined as having, "a high potential for abuse…no currently accepted medical use in treatment in the United States…[and] There is a lack of accepted safety for use of the drug or other substance under medical supervision."[4]

Between 2010 and 2018, there were more than six million arrests related to cannabis. Young people and young adults are the ones primarily arrested, and when charged, prosecuted, or incarcerated, may suffer significant trauma.[5] People who are Black are 3.6 times more likely to be arrested than people who are white, despite similar rates in usage. Even following legalization, disparities in arrest rates continue.[6]

Issues relating to expungement should not, however, be confused with issues relating to the health effects of cannabis use on youth and adolescents. Researchers have found that, "Marijuana use has been associated with several adverse mental health outcomes, including increased incidence of addiction and comorbid substance use, suicidality, and new-onset psychosis. Negative impacts on cognition and academic performance have also been observed."[7] A study looking at youth perception of risk done when only eight states legalized cannabis for medical use found youth in these states tended to use cannabis more frequently than in states that did not legalize its use and that youth had lower perceptions of health risks associated with cannabis use.[8]

DISCUSSION

As a threshold matter, it is important to recognize that expungement, destruction, and sealing are legal processes. An expungement process may involve multiple steps where the end result is to remove a record of arrest and/or conviction from the official state or federal record. The idea is that post-expungement, the record never existed. While an expungement may "erase" a record, "sealing" hides the record from public view. More specifically, when "sealed," the record can be accessed under certain circumstances.[9] Finally, "destruction" of a record generally means to physically destroy it. When a record is "destroyed," there is no record remaining whatsoever.[10] It is important to note that specific definitions may vary by state.

The Council on Science and Public Health (CSAPH) has previously discussed how having a criminal record can negatively affect an individual's employment, housing, education, receipt of public benefits, and other social determinants of health and public health effects.[11] There are additional implications for medical students,[12] residents, and other physicians who, if there is a record of a prior cannabis possession arrest or conviction, may be asked to disclose that record on a licensing or employment application. As discussed below, depending on the applicable state and/or federal law, it may not be clear whether expungement or sealing requires or protects against future disclosure. It is beyond the scope of this report to discuss in depth what might occur if a medical student, resident, or physician does disclose the existence of a prior arrest or conviction for a cannabis-related offense.

Under federal law, the record of a conviction for drug possession may be able to be expunged depending on the circumstances. An individual must qualify for expungement and undertake the process to formally seek expungement. There are different requirements for those 21 years of age and older and those younger than 21. The record of the underlying expungement also offers protection against future adverse use, but it is retained by the DOJ.[13]

Approximately 20 states have enacted laws or other policies providing for expungement, record sealing, or other similar actions based on acts that are no longer crimes post-enactment of cannabis legalization.[14,15] Illinois, for example, has created a detailed pathway for expungement of cannabis-related offenses. The specific process and qualification for potential expungement, including automatic expungement, depends on whether the arrest was "minor," the date of the arrest, whether the individual was an adult or minor, how long it has been since the arrest, whether there were charges filed, amount of cannabis for which the arrest occurred, and other factors.[16] Under California's Proposition 64, acts that were committed prior to the legalization of adult use cannabis, were made eligible for resentencing, dismissal, or sealing.[17] As in Illinois, eligibility for expungement and sealing of records in California is subject to a wide variety of different requirements. Approximately 500,000 cannabis-related arrest records have been expunged in Illinois following enactment of the law.[18] Despite a law requiring records of cannabis-related offenses to be sealed in California, hundreds of thousands of records remain open, according to pro-cannabis sources.[19]

Substantial barriers to expungement remain,[20] depending on the state, including individual petition requirements, complex filing processes necessitating legal representation, filing fees, hearings without sufficient notice, fingerprinting requirements, and ineligibility due to unpaid debt—even when this debt (fines, fees, or restitution) is related to the offense being expunged.[21] Further, there is evidence of disparate access to expungement for historically marginalized and minoritized individuals. In fact, a 2017 study reviewing Wisconsin expungements showed that:

> [s]tatewide, only 10 percent of those granted expungements since 2010 are African-American and only 2 percent are Hispanic—much lower numbers than appear to have been eligible (23 percent and 6 percent, respectively). Conversely, statewide, 79 percent of those granted expungements were white, while only 63 percent of those generally eligible were white.[22]

Even if a record is expunged or sealed, however, that may not address collateral consequences of the arrest or conviction, e.g., potential professional licensing sanctions, adverse employment actions, and qualification for government benefits, including loans and housing. These collateral consequences can also suppress the local tax base by locking people into unemployment or lower paying jobs and increase taxpayer costs due to increasing likelihood of further involvement in the criminal legal system.[23] As noted by Marion County (Indiana) prosecutor Terry Curry, "If our goal is to have individuals not reoffend, then in our mind it's appropriate to remove obstacles that are going to inhibit their ability to become productive members of our community."

Finally, very few states have enacted laws addressing these collateral effects, and these issues remain controversial at the federal level.[24] In addition, state-specific expungement laws have trailed behind legalization efforts.[25] Potential interstate conflicts also may arise when an individual has an arrest or conviction in one state but then goes on to reside in a different state. Further complicating the issue, is the fact that without legal representation, it may not be clear whether an individual should seek expungement, sealing, or other legal avenues. This is why the Lawyers' Committee for Civil Rights Under the Law emphasizes that the legal strategy depends on the situation.[26]

In addition, the net social benefits to expungement should not be used to set aside or minimize the health risks associated with cannabis use—particularly for youth and adolescents. Even when states take action to positively address legal inequities and support social determinants of health, there remain significant adverse health effects of cannabis use for youth and adolescents.

AMA POLICY CONSIDERATIONS

The AMA opposes legalization of cannabis for medical use, "through the state legislative, ballot initiative, or referendum process." (D-95.969, "Cannabis Legalization for Medicinal Use") As explained above, however, expungement of cannabis-related offenses is a process that occurs after-the-fact. The AMA also opposes legalization of cannabis for adult use while supporting, "public health-based strategies, rather than incarceration, in the handling of individuals possessing cannabis for personal use." (H-95.924, "Cannabis Legalization for Adult Use" [commonly referred to as recreational use]) The expungement process—to the extent that it helps prevent the loss of public health benefits and supports the continuity of social determinants of health—is in line with a public health-based strategy.

Consistent with this report, the AMA also, "encourages research on the impact of legalization and decriminalization of cannabis in an effort to promote public health and public safety; [and] encourages dissemination of information on the public health impact of legalization and decriminalization of cannabis." (H-95.924, "Cannabis Legalization for Adult Use" [commonly referred to as recreational use]).

The AMA also supports, "fairness in the expungement and sealing of records" for juveniles. (H-60.916, "Youth Incarceration in Adult Facilities") The AMA further, "[e]ncourages continued research to identify programs and policies that are effective in reducing disproportionate minority contact across all decision points within the juvenile justice system" (H-60.919, "Juvenile Justice System Reform"). As discussed above, arrest and conviction rates for cannabis possession are disproportionately felt by Black and Brown youth and adults. As a result, policies and procedures to facilitate expungement or other legal strategies would appear beneficial to restore future rights and benefits.

Fundamental fairness and equity principles argue that individuals with an arrest or conviction for cannabis-related offenses—that occurred before legalization that would make such action legal—should not suffer further legal or public health adverse effects. Such a direction from the AMA would not alter its underlying policy opposing legalization of cannabis for medical or adult use. Supporting efforts to improve public health effects, however, would be directly in line with AMA policy on numerous fronts, including support for youth adversely affected by the justice system. Analyzing the relative strengths and weaknesses of every state's expungement, sealing, and other policies, is beyond the scope of this report. There are, however, multiple national and other resources the AMA could provide as guidance to others when considering options relating to post-arrest and post-conviction policies in states that have legalized cannabis for medical or adult use.

RECOMMENDATIONS

The Board recommends that the following recommendations be adopted, and the remainder of the report be filed:

1. That our American Medical Association (AMA) support automatic expungement, sealing, and similar efforts regarding an arrest or conviction for a cannabis-related offense for use or possession that would be legal under subsequent state legalization of adult use or medicinal cannabis. (New HOD Policy)

2. That our AMA support automatic expungement, sealing, and similar efforts regarding an arrest or conviction of a cannabis-related offense for use or possession for a minor upon the minor reaching the age of majority. (New HOD Policy)

3. That our AMA inquire to the Association of American Medical Colleges, Accreditation Council for Graduate Medical Education, Federation of State Medical Boards, and other relevant medical education and licensing authorities, as to the effects of disclosure of a cannabis related offense on a medical school, residency, or licensing application. (Directive to Take Action)

4. That AMA Policy D-95.960, "Public Health Impacts of Cannabis Legalization" be rescinded since this report fulfills the directive contained in the policy. (Rescind HOD Policy)

Fiscal Note: $5000.

REFERENCES

[1] Guidance Regarding Marijuana Enforcement. U.S. Department of Justice. August 29, 2013. Available at https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
[2] Marijuana Enforcement. U.S. Department of Justice. January 4, 2018. Available at January 4, 2018
[3] State Medical Cannabis Laws. National Conference of State Legislatures. Available at https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx Last accessed February 25, 2022.
[4] 21 U.S.C. §812 Schedules of controlled substances.
[5] Pediatrics (2015) 135 (3): e769–e785. https://doi.org/10.1542/peds.2014-4147
[6] A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform. ACLU Research Report. 2020. Available at https://www.aclu.org/sites/default/files/field_document/marijuanareport_03232021.pdf
[7] Kristie Ladegard, Christian Thurstone, Melanie Rylander; Marijuana Legalization and Youth. *Pediatrics* May 2020; 145 (Supplement_2): S165–S174. 10.1542/peds.2019-2056D. Available at https://publications.aap.org/pediatrics/article/145/Supplement_2/S165/34451/Marijuana-Legalization-and-Youth
[8] Wall, Melanie M et al. "Adolescent marijuana use from 2002 to 2008: higher in states with medical marijuana laws, cause still unclear." *Annals of epidemiology* vol. 21,9 (2011): 714-6. doi:10.1016/j.annepidem.2011.06.001. Available at https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3358137/
[9] "Restoration of Rights." National Association of Criminal Defense Lawyers. "Expungement results in deletion of any record that an arrest or criminal conviction ever occurred. A sealed record is removed from general review; the record still exists and can be reviewed under limited circumstances." Last accessed February 14, 2022. Available at https://nacdl.org/Landing/RestorationofRightsandStatusAfterConviction
[10] "What is expungement?" American Bar Association. November 20, 2018. Available at https://www.americanbar.org/groups/public_education/publications/teaching-legal-docs/what-is-_expungement-/
[11] Public Health Impacts of Cannabis Legalization. Report 4 of the Council on Science and Public Health. November 2020. Available at https://www.ama-assn.org/system/files/2020-10/nov20-csaph04.pdf
[12] "Sections 1-3 of the AMCAS® Application: Your Background Information." American Association of Medical Colleges. Last accessed February 9, 2022. Available at https://students-residents.aamc.org/how-apply-medical-school-amcas/sections-1-3-amcas-application-your-background-information
[13] 18 U.S.C. § 3607. Special probation and expungement procedures for drug possessors. Available at https://www.govinfo.gov/content/pkg/USCODE-2001-title18/pdf/USCODE-2001-title18-partII-chap229-subchapA-sec3607.pdf
[14] *See*, 50-State Comparison: Marijuana Legalization, Decriminalization, Expungement, and Clemency." Restoration of Rights Project. Updated Jan. 2022. Available at https://ccresourcecenter.org/state-restoration-profiles/50-state-comparison-marijuana-legalization-expungement/
[15] "Expungement." NORML. Available at https://norml.org/laws/expungement/
[16] Cannabis Expungement Information and Forms. Office of the State Appellate Defender. State of Illinois. Last accessed February 25, 2022. Available at https://www2.illinois.gov/osad/Expungement/Pages/Cannabis-Expungement.aspx
[17] Proposition 64, "Adult Use of Marijuana Act." Resentencing Procedures and Other Selected Provisions.
[18] "State Officials: Nearly 500,000 Marijuana Arrest Records Have Been Expunged." By Amanda Vinicky. WTTW. December 31, 2021. Available at https://news.wttw.com/2020/12/31/state-officials-nearly-500000-marijuana-arrest-records-have-been-expunged
[19] "California Officials Have Failed to Seal Thousands Of Marijuana Conviction Records." Marijuana Moment. October 18, 2021. Available at https://www.marijuanamoment.net/california-officials-have-failed-to-seal-thousands-of-marijuana-conviction-records-by-the-legally-required-deadline/
[20] Prescott, J.J. "Expungement of Criminal Convictions: An Empirical Study." Sonja B. Starr, co-author. Harv. L. Rev. 133, no. 8 (2020): 2460-555. Available at https://repository.law.umich.edu/cgi/viewcontent.cgi?article=3167&context=articles
[21] "Fines and Fees Are a Barrier to Criminal Record-Clearing." Center for American Progress. November 30, 2021. Available at https://www.americanprogress.org/article/fines-and-fees-are-a-barrier-to-criminal-record-clearing/?_ga=2.120630408.188333240.1646612331-783047533.1646612331

[22] Problems with Wisconsin's Expungement Law. How the Law is Used and How to Make it More Equitable and Effective. Badger Institute. Available at https://www.badgerinstitute.org/BI-Files/Reports/ExpungementstoryMay2017.pdf

[23] "Scrubbing The Past To Give Those With A Criminal Record A Second Chance." By Barbara Brosher. NPR. February 1, 2019. Available at https://www.npr.org/2019/02/19/692322738/scrubbing-the-past-to-give-those-with-a-criminal-record-a-second-chancehttps://www.npr.org/2019/02/19/692322738/scrubbing-the-past-to-give-those-with-a-criminal-record-a-second-chance

[24] Clearing Criminal Records for Cannabis Offenses. National Conference on State Legislatures. April 21, 2020. Available at https://www.ncsl.org/research/civil-and-criminal-justice/clearing-criminal-records-for-cannabis-offenses.aspx

[25] "In These States, Past Marijuana Crimes Can Go Away." By Sophie Quinton. November 20, 2017. Available at https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/11/20/in-these-states-past-marijuana-crimes-can-go-away

[26] The Lawyers' Committee's Expungement Toolkit. The Lawyers' Committee for Civil Rights Under Law. September 2020. Available at https://lawyerscommittee.org/wp-content/uploads/2020/10/Expungement-Now-Toolkit-FINAL.pdf

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 201
(A-22)

Introduced by: Resident and Fellow Section

Subject: The Impact of Midlevel Providers on Medical Education

Referred to: Reference Committee B

Whereas, A survey in 2017 published in Worldviews Evidence Based Nursing revealed that a majority of the 2,300 nurse respondents did not feel competent in evidence-based practice[1]; and

Whereas, Physicians that speak out about the differences in training received by physicians vs. by mid-level providers are being fired, labeled “disrespectful” or labeled “not team players” in the interdisciplinary team treating patients[1]; and

Whereas, More non-physician post-graduate training programs are being formed across the nation; there is still no mandatory requirement for non-physicians to pursue post-graduate training[1]; and

Whereas, Physicians are expected to continue to maintain certification by proving they continue to educate themselves; mid-level providers are not held to the same standard[1]; and

Whereas, Currently mid-level providers can switch between specialties and subspecialties of medicine and surgery without any formal or regulated training or education[1]; and

Whereas, Physicians are limited in their practice abilities by the post-graduate training they receive[1]; therefore be it

RESOLVED, That our American Medical Association study, using surveys among other tools that protect identities, how commonly bias against physician-led healthcare is experienced within undergraduate medical education and graduate medical education, interprofessional learning and team building work and publish these findings in peer-reviewed journals (Directive to Take Action); and be it further

RESOLVED, That our AMA work with the Liaison Committee on Medical Education and the Accreditation Council for Graduate Medical Education to ensure all physician undergraduate and graduate training programs recognize and teach physicians that they are the leaders of the healthcare team and are adequately equipped to diagnose and treat patients independently only because of the intensive, regulated, and standardized education they receive (Directive to Take Action); and be it further

RESOLVED, That our AMA study the harms and benefits of establishing mandatory postgraduate clinical training for nurse practitioners and physician assistants prior to working within a specialty or subspecialty field (Directive to Take Action); and be it further

RESOLVED, That our AMA study the harms and benefits of establishing national requirements for structured and regulated continued education for nurse practitioners and physician assistants in order to maintain licensure to practice. (Directive to Take Action)

Fiscal Note: Estimated cost of $50,000 to implement resolution.

Received: 04/04/22

References:

1. Al-Agba, Niran, and Rebekah Bernard. *Patients at Risk: the Rise of the Nurse Practitioner and Physician Assistant in Healthcare*. Universal-Publishers, Inc., 2020.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 202
(A-22)

Introduced by: New York

Subject: AMA Position on All Payer Database Creation

Referred to: Reference Committee B

Whereas, Organized medicine worked hard to push for the creation of the FAIRHEALTH database, an independent database of charges; and

Whereas, Private health insurers are now pushing for legislation to create alternate databases at the state and federal levels known as an All Payer Database; and

Whereas, The All Payer Database will reflect payments from all payers and as such will be heavily weighted towards poor payments for physicians such as Medicare and Medicaid which are generally lower payments than issued by commercial and self-insured plans; and

Whereas, Much of this information is already available; and

Whereas, The private insurers interest in such a database is to use it to replace the FAIRHEALTH database and justify lower payments to physicians; and

Whereas, Much of the payment data for hospitals is not reliable because hospitals frequently pay employed physicians at a much higher rate than the professional collections; therefore be it

RESOLVED, That our American Medical Association advocate that any All Payer Database should also provide true payments that hospitals are making to their employed physicians, not just the amount of payment that the insurer is making on the physician's behalf to the hospital. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 03/22/22

RELEVANT AMA POLICY

Price Transparency D-155.987
1. Our AMA encourages physicians to communicate information about the cost of their professional services to individual patients, taking into consideration the insurance status (e.g., self-pay, in-network insured, out-of-network insured) of the patient or other relevant information where possible.
2. Our AMA advocates that health plans provide plan enrollees or their designees with complete information regarding plan benefits and real time cost-sharing information associated with both in-network and out-of-network provider services or other plan designs that may affect patient out-of-pocket costs.
3. Our AMA will actively engage with health plans, public and private entities, and other stakeholder groups in their efforts to facilitate price and quality transparency for patients and physicians, and help ensure that entities promoting price transparency tools have processes in place to ensure the accuracy and relevance of the information they provide.
4. Our AMA will work with states and the federal government to support and strengthen the development of all-payer claims databases.
5. Our AMA encourages electronic health records vendors to include features that assist in facilitating price transparency for physicians and patients.
6. Our AMA encourages efforts to educate patients in health economics literacy, including the development of resources that help patients understand the complexities of health care pricing and encourage them to seek information regarding the cost of health care services they receive or anticipate receiving.
7. Our AMA will request that the Centers for Medicare and Medicaid Services expand its Medicare Physician Fee Schedule Look-up Tool to include hospital outpatient payments.
Citation: CMS Rep. 4, A-15; Reaffirmed in lieu of: Res. 121, A-16; Reaffirmed in lieu of: Res. 213, I-17; Reaffirmed: BOT Rep. 14, A-18; Reaffirmed in lieu of: Res. 112, A-19; Modified: Res. 213, I-19

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 203
(A-22)

Introduced by: New York, Minority Affairs Consortium

Subject: Ban the Gay/Trans (LGBTQ+) Panic Defense

Referred to: Reference Committee B

Whereas, The gay or trans panic (to be more inclusive will use “LGBTQ+ panic”) defense strategy is a legal strategy that uses a victim’s sexual orientation or gender identity/expression as an excuse for a defendant’s violent reaction, seeking to legitimize and even to excuse violent and lethal behavior (1); and

Whereas, The LGBTQ+ “panic” defense strategy gives defendants three options of defense: 1) Defense of insanity or diminished capacity 3) Defense of provocation 3) Defense of self-defense (3); and

Whereas, To claim insanity, defendants claim that the sexual orientation or gender of the victim is enough to induce insanity (1); and

Whereas, To claim provocation, defendants claim “victim’s proposition, sometimes termed a “non-violent sexual advance,” was sufficiently “provocative” to induce the defendant to kill the victim”(1); and

Whereas, To claim self defense, “defendants claim they believed that the victim, because of their sexual orientation or gender identity/expression, was about to cause the defendant serious bodily harm (3)”; and

Whereas, Studies have shown that jurors with higher in homonegativity and religious fundamentalism ratings assigned higher victim blame, lower defendant responsibility, and more lenient verdicts in the “LGBTQ+ panic” conditions (5,6,7); and

Whereas, “Gay panic disorder” was removed from the DSM in 1973 because the APA recognized that no such condition exists; and

Whereas, Many murder sentences have been reduced or defendants have been acquitted using the LGBTQ+ “panic” defense strategy such as in the Matthew Shepard case has been used successfully to mitigate a charge from murder to criminally negligent manslaughter as recently as 2018 (1); and

Whereas, The LGBTQ community makes up 3.5% of the US population yet, sexual orientation is the motivator of 17% of hate crime attacks with one in four transgender people becoming the victim of a hate crime in their lifetime (4, 5); and

Whereas, The LGBTQ+ “panic” defense has only been banned in 11 states as of February 2021, with legislation having been introduced in 12 more states (1, 2); and

Whereas, At least 57 Transgender or Gender Non-Conforming persons were killed in the US during the year 2021, the highest total since HRC started tracking in 2013, breaking a record from the previous year 2020 (9); and

Whereas, LGBTQ people over 16 years age are: 4 times more likely to become victims of violence compared to non-LGBTQ people; 6 times more likely to experience violence by someone known to them and 2.5 times more likely to be a victim of violence by a stranger; LBT women are 5 times more likely than non-LBT women to experience violent victimization; GBT men face more than twice the risk of violence compared to non-GBT men; and most violent victimization of LGBTQ people is not reported to law enforcement (10, 11); and

Whereas, A legal defense based on panic because of the race, ethnicity or sex of the victims of a violent crimes is not permitted, and similar reasoning must disallow a gay or trans (LGBTQ+) panic defense; therefore be it

RESOLVED, That our American Medical Association seek a federal law banning the use of the so-called “gay or trans (LGBTQ+) panic” defense in homicide, manslaughter, physical or sexual assault cases (Directive to Take Action); and be it further

RESOLVED, That our AMA develop draft legislation, an issue brief and talking points on the topic of so called “gay or trans (LGBTQ+) panic” defense, that can be used by the AMA in seeking federal legislation, and can be used and adapted by state and specialty medical societies, other allies, and stakeholders when seeking state legislation to ban the use of so-called “gay or trans (LGBTQ+) panic” defense to mitigate personal responsibility for violent crimes such as assault, rape, manslaughter, or homicide. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 03/22/22

References

1. “Gay and Trans ‘Panic’ Defense.” Gay and Trans "Panic" Defense, The National LGBT Bar Ass’n, 2019, lgbtbar.org/programs/advocacy/gay-trans-panic-defense/.
2. The LGBTQ+ “Panic” Defense Map. LGBTQ Bar Association. Downloaded 18 February 2021 at: https://lgbtbar.org/programs/advocacy/gay-trans-panic-defense/gay-trans-panic-defense-legislation/
3. Holden, A. (2019). *The gay/Trans panic defense: What it is, and how to end it.* American Bar Association. https://www.americanbar.org/groups/crsj/publications/member-features/gay-trans-panic-defense/
4. Federal Bureau of Investigation, U.S. Dep’t of Justice. “Table 5, Offenses, Known Offender’s Race by Bias Motivation, 2007.” Hate Crime Statistics, 2007d (released Oct. 2008). www.fbi.gov/ucr/hc2007/ table_05.htm (accessed Jan. 11, 2009).
5. Coston, Liz. “Understanding and Handling Hate Crimes against Gay, Bisexual, and Transgender People.” Scholars Strategy Network, 9 Nov. 2018, scholars.org/brief/understanding-and-handling-hate-crimes-against-gay-bisexual-and-transgender-people.
6. Michalski N D and Nunez N. When is Gay Panic Accepted? Exploring Juror Characteristics and Case Type as Predictors of a Successful Gay Panic Defense. *Journal of Interpersonal Violence;* first published online 22 April 2020. Downloaded at: https://journals-sagepub-com.proxy.library.stonybrook.edu/doi/pdf/10.1177/0886260520912595
7. Tomei J, etl al. The Gay Panic Defense: Legal Defense Strategy or Reinforcement of Homophobia in Court. *Journal of Interpersonal Violence; 2020 Nov;35(21-22):4239-4261*
8. Salerno, J. M., Najdowski, C. J., Bottoms, B. L., Harrington, E., Kemner, G., & Dave, R. (2015). Excusing murder? Conservative jurors’ acceptance of the gay-panic defense. *Psychology, Public Policy, and Law, 21*(1), 24–34
9. Fatal Violence Against the Transgender and Gender Non-Conforming Community in 2021. Downloaded 23 March 2022 at: https://www.hrc.org/resources/fatal-violence-against-the-transgender-and-gender-non-conforming-community-in-2021
10. R. Flores, L. Langton, I. H. Meyer, A. P. Romero, Victimization rates and traits of sexual and gender minorities in the United States: Results from the National Crime Victimization Survey, 2017. Sci. Adv.6, eaba6910 (2020).
11. LGBT people are four times more likely than non-LGBT people to be victims of violent crime. Williams Institute, Press Release 2 October 2020. Downloaded 23 March 2022 at: https://williamsinstitute.law.ucla.edu/press/ncvs-lgbt-violence-press-release/

RELEVANT AMA POLICY

Preventing Anti-Transgender Violence H-65.957
Our AMA will: (1) partner with other medical organizations and stakeholders to immediately increase efforts to educate the general public, legislators, and members of law enforcement using verified data related to the hate crimes against transgender individuals highlighting the disproportionate number of Black transgender women who have succumbed to violent deaths: (2) advocate for federal, state, and local law enforcement agencies to consistently collect and report data on hate crimes, including victim demographics, to the FBI; for the federal government to provide incentives for such reporting; and for demographic data on an individual's birth sex and gender identity be incorporated into the National Crime Victimization Survey and the National Violent Death Reporting System, in order to quickly identify positive and negative trends so resources may be appropriately disseminated; (3) advocate for a central law enforcement database to collect data about reported hate crimes that correctly identifies an individual's birth sex and gender identity, in order to quickly identify positive and negative trends so resources may be appropriately disseminated; (4) advocate for stronger law enforcement policies regarding interactions with transgender individuals to prevent bias and mistreatment and increase community trust; and (5) advocate for local, state, and federal efforts that will increase access to mental health treatment and that will develop models designed to address the health disparities that LGBTQ individuals experience.
Citation: Res. 008, A-19

Access to Basic Human Services for Transgender Individuals H-65.964
Our AMA: (1) opposes policies preventing transgender individuals from accessing basic human services and public facilities in line with ones gender identity, including, but not limited to, the use of restrooms; and (2) will advocate for the creation of policies that promote social equality and safe access to basic human services and public facilities for transgender individuals according to ones gender identity.
Citation: Res. 010, A-17

Support of Human Rights and Freedom H-65.965
Our AMA: (1) continues to support the dignity of the individual, human rights and the sanctity of human life, (2) reaffirms its long-standing policy that there is no basis for the denial to any human being of equal rights, privileges, and responsibilities commensurate with his or her individual capabilities and ethical character because of an individual's sex, sexual orientation, gender, gender identity, or transgender status, race, religion, disability, ethnic origin, national origin, or age; (3) opposes any discrimination based on an individual's sex, sexual orientation, gender identity, race, religion, disability, ethnic origin, national origin or age and any other such reprehensible policies; (4) recognizes that hate crimes pose a significant threat to the public health and social welfare of the citizens of the United States, urges expedient passage of appropriate hate crimes prevention legislation in accordance with our AMA's policy through letters to members of Congress; and registers support for hate crimes prevention legislation, via letter, to the President of the United States.
Citation: CCB/CLRPD Rep. 3, A-14; Reaffirmed in lieu of: Res. 001, I-16; Reaffirmation: A-17

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 204
(A-22)

Introduced by: New York

Subject: Insurance Claims Data

Referred to: Reference Committee B

Whereas, Insurance company claims data is a repository of public health information, utilization information, practice patterns, and other important information; and

Whereas, The insurers utilize their claims data in order to develop policy, coverage determinations, and pricing; and

Whereas, The insurers obtain the data from both at risk plans and plans for which they act in the capacity of Third-Party Administrator (TPA); and

Whereas, Insurers typically do not share this data, asserting that it is proprietary; and

Whereas, Asymmetry of information is an impediment to more robust health policy, better and more responsive health policy, more cost-effective policy and new entrants into the insurance marketplace; therefore be it

RESOLVED, That our American Medical Association seek legislation and regulation to promote open sharing of de-identified health insurance claims data. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 03/22/22

RELEVANT AMA POLICY

Work of the Task Force on the Release of Physician Data H-406.990

Release of Claims and Payment Data from Governmental Programs

The AMA encourages the use of physician data to benefit both patients and physicians and to improve the quality of patient care and the efficient use of resources in the delivery of health care services. The AMA supports this use of physician data only when it preserves access to health care and is used to provide accurate physician performance assessments.

Raw claims data used in isolation have significant limitations. The release of such data from government programs must be subject to safeguards to ensure that neither false nor misleading conclusions are derived that could undermine the delivery of appropriate and quality care. If not addressed, the limitations of such data are significant. The foregoing limitations may include, but are not limited to, failure to consider factors that impact care such as specialty, geographic location, patient mix and demographics, plan design, patient compliance, drug and supply costs, hospital and service costs, professional liability coverage, support staff and other practice costs as well as the potential for mistakes and errors in the data or its attribution.

Raw claims and payment data resulting from government health care programs, including, but not limited to, the Medicare and Medicaid programs should only be released:

1. when appropriate patient privacy is preserved via de-identified data aggregation or if written authorization for release of individually identifiable patient data has been obtained from such patient in accordance with the requirements of the Health Insurance Portability and Accountability Act (HIPAA) and applicable regulations;
2. upon request of physicians [or their practice entities] to the extent the data involve services that they have provided;
3. to law enforcement and other regulatory agencies when there is reasonable and credible reason to believe that a specific physician [or practice entity] may have violated a law or regulation, and the data is relevant to the agency's investigation or prosecution of a possible violation;
4. to researchers/policy analysts for bona fide research/policy analysis purposes, provided the data do not identify specific physicians [or their practice entities] unless the researcher or policy analyst has (a) made a specific showing as to why the disclosure of specific identities is essential; and, (b) executed a written agreement to maintain the confidentiality of any data identifying specific physicians [or their practice entities];
5. to other entities only if the data do not identify specific physicians [or their practice entities]; or
6. if a law is enacted that permits the government to release raw physician-specific Medicare and/or Medicaid claims data, or allows the use of such data to construct profiles of identified physicians or physician practices. Such disclosures must meet the following criteria:
(a) the publication or release of this information is deemed imperative to safeguard the public welfare;
(b) the raw data regarding physician claims from governmental healthcare programs is:
(i) published in conjunction with appropriate disclosures and/or explanatory statements as to the limitations of the data that raise the potential for specific misinterpretation of such data. These statements should include disclosure or explanation of factors that influence the provision of care including geographic location, specialty, patient mix and demographics, health plan design, patient compliance, drug and supply costs, hospital and service costs, professional liability coverage, support staff and other practice costs as well as the potential for mistakes and errors in the data or its attribution, in addition to other relevant factors.
(ii) safeguarded to protect against the dissemination of inconsistent, incomplete, invalid or inaccurate physician-specific medical practice data.
(c) any physician profiling which draws upon this raw data acknowledges that the data set is not representative of the physicians' entire patient population and uses a methodology that ensures the following:
(i) the data are used to profile physicians based on quality of care provided - never on utilization of resources alone - and the degree to which profiling is based on utilization of resources is clearly identified.
(ii) data are measured against evidence-based quality of care measures, created by physicians across appropriate specialties.
(iii) the data and methodologies used in profiling physicians, including the use of representative and statistically valid sample sizes, statistically valid risk-adjustment methodologies and statistically valid attribution rules produce verifiably accurate results that reflect the quality and cost of care provided by the physicians.
(d) any governmental healthcare data shall be protected and shared with physicians before it is released or used, to ensure that physicians are provided with an adequate and timely opportunity to review, respond and appeal the accuracy of the raw data (and its attribution to individual physicians) and any physician profiling results derived from the analysis of physician-specific medical practice data to ensure accuracy prior to their use, publication or release.
Citation: BOT Rep. 18, A-09; Reaffirmed: BOT Rep. 09, A-19; Modified: Speakers Rep., A-19

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 205
(A-22)

Introduced by: New York

Subject: Insurers and Vertical Integration

Referred to: Reference Committee B

Whereas, Insurers already enjoy significant marketplace advantages, such as keeping healthcare data opaque from other stakeholders, marketplace consolidation, and monopsony power; and

Whereas, These advantages have not resulted in cost savings (or even stability) for consumers--in fact cost increases born by consumers have been outsized and correlated with consolidation; and

Whereas, Insurers have increasingly been pursuing mergers--in the name of promoting efficiency; and

Whereas, These “efficiencies” rarely, if ever, benefit the consumer; and

Whereas, These combined entities (especially vertical ones) are more competitive among their competitors than the uncombined ones (accelerating further consolidation); and

Whereas, The combined entities are also positioned (due to their superior access to capital) to unfairly disrupt entities at other points in the supply chain such as medical practices, community pharmacies, and safety net hospitals; therefore be it

RESOLVED, That our American Medical Association seek legislation and regulation to prevent health payers (except non-profit HMO’s) from owning or operating other entities in the health care supply chain. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 03/22/22

RELEVANT AMA POLICY

Health Insurance Company Purchase by Pharmacy Chains D-160.920
Our AMA will: (1) continue to analyze and identify the ramifications of the proposed CVS/Aetna or other similar merger in health insurance, pharmacy benefit manager (PBM), and retail pharmacy markets and what effects that these ramifications may have on physician practices and on patient care; (2) continue to convene and activate its AMA-state medical association and national medical specialty society coalition to coordinate CVS/Aetna-related advocacy activity; (3) communicate our AMAs concerns via written statements and testimony (if applicable) to the U.S. Department of Justice (DOJ), state attorneys general and departments of insurance; (4) work to secure state level hearings on the merger; and (5) identify and work with national antitrust and other legal and industry experts and allies.
Citation: BOT Action in response to referred for decision Res. 234, I-17

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 206
(A-22)

Introduced by: New York

Subject: Medicare Advantage Plan Mandates

Referred to: Reference Committee B

Whereas, Some municipalities are requiring their retirees to change from traditional Medicare health insurance coverage to Medicare Advantage plans; and

Whereas, Medicare Advantage plans may have restrictive networks; and

Whereas, Medicare Advantage plans further privatize patients' Medicare, without discussion or agreement by the persons concerned, all in the interest of saving money for the employer; and

Whereas, Forcing use of Medicare Advantage plans does not consider the retiree's personal health concerns, including the ability to find continued care with their own doctors or hospitals with whom they may have long relationships; therefore be it

RESOLVED, That our American Medical Association advocate for federal legislation to ensure that no person should be mandated to change from traditional Medicare to Medicare Advantage plans. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 03/22/22

RELEVANT AMA POLICY

Ending Medicare Advantage Auto-Enrollment H-285.905
Our AMA will work with the Centers for Medicare and Medicaid Services and/or Congress to end the procedure of "auto-enrollment" of individuals into Medicare Advantage Plans.
Citation: Res. 216, I-16

Deemed Participation and Misleading Marketing by Medicare Advantage Private Fee for Service Plans D-330.930
Our AMA will continue its efforts to educate physicians and the general public on the implications of participating in programs offered under Medicare Advantage and educate physicians and the public about the lack of secondary coverage (Medigap policies) with Medicare Advantage plans and how this may affect enrollees.
Citation: BOT Action in response to referred for decision Res. 711, I-06; Reaffirmation A-08; Modified: CMS Rep. 01, A-19

Elimination of Subsidies to Medicare Advantage Plans D-390.967
1. Our AMA will seek to have all subsidies to private plans offering alternative coverage to Medicare beneficiaries eliminated, that these private Medicare plans compete with traditional

Medicare fee-for-service plans on a financially neutral basis and have accountability to the Centers for Medicare and Medicaid Services.
2. Our AMA will seek to prohibit all private plans offering coverage to Medicare beneficiaries from deeming any physician to be a participating physician without a signed contract specific to that product, and that our AMA work with CMS to prohibit all-products clauses from applying to Medicare Advantage plans and private fee-for-service plans.
Citation: Res. 229, A-07; Modified: CMS Rep. 01, A-17

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 207
(A-22)

Introduced by: New York

Subject: Physician Tax Fairness

Referred to: Reference Committee B

Whereas, In 2018, President Trump signed the Tax Cuts and Jobs Act; and

Whereas, This legislation includes a tax break for owners of certain pass-through entities, many of which include physician practices structured as such and can include S corporations, partnerships and some limited liability companies; and

Whereas, This may benefit those who earn below the threshold of $207,500 or less for a single filer (where the deduction phases out when taxable income exceeds $157,500) or $415,000 or less for a married couple filing jointly (where the deduction phases out starting at $315,000); and

Whereas, The new tax law disallows this 20% deduction for taxpayers with income above the threshold in specified service businesses which are defined as those in which the principal asset is the reputation or skill of the owners and which category includes physicians; and

Whereas, Many physicians, especially those in two physician households, will not qualify under the new tax law, and combined with the decrease in the deductions allowed for state and local taxes, home mortgage, etc., many physicians have been adversely affected and will pay more in taxes; and

Whereas, The effect of this law will be a continued trend of decreased physician self-employment and thus overall lower physician reimbursement; therefore be it

RESOLVED, That our American Medical Association lobby that physicians be excluded from being considered a specified service business as defined by the Internal Revenue Service. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 03/22/22

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 208
(A-22)

Introduced by: New York

Subject: Prohibit Ghost Guns

Referred to: Reference Committee B

Whereas, Homemade, difficult to trace firearms are increasingly turning up at crime scenes; and

Whereas, The most important part of a gun is the lower receiver - the 'chassis' of the weapon, the part housing vital components such as the hammer and trigger; and

Whereas, Under federal law, the lower receiver is considered a firearm - while other gun components do not require a background check for purchase; and

Whereas, Dozens of companies sell what are known as "80%" lower receivers - ones that are 80% finished, lack a serial number and can be used to make a homemade gun; and

Whereas, The Gun Control Act (1968) and the Brady Gun Violence Prevention Act (1993) allow for homemade weapons; and

Whereas, Ghost guns don't have any unique markings and therefore present black holes to police investigators; and

Whereas, Ghost guns provide an easy avenue for people banned from owning guns to obtain them; and

Whereas, According to the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) 30% of all weapons recovered by the bureau in California were homemade; and

Whereas, These weapons have been connected with mass shootings, police shootouts and arms trafficking; therefore be it

RESOLVED, That our American Medical Association support state and federal legislation and regulation that would subject homemade weapons to the same regulations and licensing requirements as traditional weapons. (New HOD Policy)

Fiscal Note: Minimal - less than $1,000

Received: 03/22/22

RELEVANT AMA POLICY

Firearms as a Public Health Problem in the United States - Injuries and Death H-145.997
1. Our AMA recognizes that uncontrolled ownership and use of firearms, especially handguns, is a serious threat to the public's health inasmuch as the weapons are one of the main causes of intentional and unintentional injuries and deaths.
Therefore, the AMA:
(A) encourages and endorses the development and presentation of safety education programs that will engender more responsible use and storage of firearms;
(B) urges that government agencies, the CDC in particular, enlarge their efforts in the study of firearm-related injuries and in the development of ways and means of reducing such injuries and deaths;
(C) urges Congress to enact needed legislation to regulate more effectively the importation and interstate traffic of all handguns;
(D) urges the Congress to support recent legislative efforts to ban the manufacture and importation of nonmetallic, not readily detectable weapons, which also resemble toy guns; (5) encourages the improvement or modification of firearms so as to make them as safe as humanly possible;
(E) encourages nongovernmental organizations to develop and test new, less hazardous designs for firearms;
(F) urges that a significant portion of any funds recovered from firearms manufacturers and dealers through legal proceedings be used for gun safety education and gun-violence prevention; and
(G) strongly urges US legislators to fund further research into the epidemiology of risks related to gun violence on a national level.
2. Our AMA will advocate for firearm safety features, including but not limited to mechanical or smart technology, to reduce accidental discharge of a firearm or misappropriation of the weapon by a non-registered user; and support legislation and regulation to standardize the use of these firearm safety features on weapons sold for non-military and non-peace officer use within the U.S.; with the aim of establishing manufacturer liability for the absence of safety features on newly manufactured firearms.
Citation: CSA Rep. A, I-87; Reaffirmed: BOT Rep. I-93-50; Appended: Res. 403, I-99; Reaffirmation A-07; Reaffirmation A-13; Appended: Res. 921, I-13; Reaffirmed: CSAPH Rep. 04, A-18; Reaffirmation: A-18; Reaffirmation: I-18; Appended: Res. 405, A-19

Firearm Availability H-145.996
1. Our AMA: (a) advocates a waiting period and background check for all firearm purchasers; (b) encourages legislation that enforces a waiting period and background check for all firearm purchasers; and (c) urges legislation to prohibit the manufacture, sale or import of lethal and non-lethal guns made of plastic, ceramics, or other non-metallic materials that cannot be detected by airport and weapon detection devices.
2. Our AMA supports requiring the licensing/permitting of firearms-owners and purchasers, including the completion of a required safety course, and registration of all firearms.
3. Our AMA supports “gun violence restraining orders” for individuals arrested or convicted of domestic violence or stalking, and supports extreme risk protection orders, commonly known as “red-flag” laws, for individuals who have demonstrated significant signs of potential violence. In supporting restraining orders and “red-flag” laws, we also support the importance of due process so that individuals can petition for their rights to be restored.
Citation: Res. 140, I-87; Reaffirmed: BOT Rep. 8, I-93; Reaffirmed: BOT Rep. 50, I-93; Reaffirmed: CSA Rep. 8, A-05; Reaffirmed: CSAPH Rep. 1, A-15; Modified: BOT Rep. 12, A-16; Appended: Res. 433, A-18; Reaffirmation: I-18; Modified: BOT Rep. 11, I-18

Ban on Handguns and Automatic Repeating Weapons H-145.985
It is the policy of the AMA to:
(1) Support interventions pertaining to firearm control, especially those that occur early in the life of the weapon (e.g., at the time of manufacture or importation, as opposed to those involving possession or use). Such interventions should include but not be limited to:
(a) mandatory inclusion of safety devices on all firearms, whether manufactured or imported into the United States, including built-in locks, loading indicators, safety locks on triggers, and increases in the minimum pressure required to pull triggers;
(b) bans on the possession and use of firearms and ammunition by unsupervised youths under the age of 21;
(c) bans of sales of firearms and ammunition from licensed and unlicensed dealers to those under the age of 21 (excluding certain categories of individuals, such as military and law enforcement personnel);
(d) the imposition of significant licensing fees for firearms dealers;
(e) the imposition of federal and state surtaxes on manufacturers, dealers and purchasers of handguns and semiautomatic repeating weapons along with the ammunition used in such firearms, with the attending revenue earmarked as additional revenue for health and law enforcement activities that are directly related to the prevention and control of violence in U.S. society; and
(f) mandatory destruction of any weapons obtained in local buy-back programs.
(2) Support legislation outlawing the Black Talon and other similarly constructed bullets.
(3) Support the right of local jurisdictions to enact firearm regulations that are stricter than those that exist in state statutes and encourage state and local medical societies to evaluate and support local efforts to enact useful controls.
(4) Oppose concealed carry reciprocity federal legislation that would require all states to recognize concealed carry firearm permits granted by other states and that would allow citizens with concealed gun carry permits in one state to carry guns across state lines into states that have stricter laws.
(5) Support the concept of gun buyback programs as well as research to determine the effectiveness of the programs in reducing firearm injuries and deaths.
Citation: BOT Rep. 50, I-93; Reaffirmed: CSA Rep. 8, A-05; Reaffirmation A-14; Appended: Res. 427, A-18; Reaffirmation: A-18; Modified: Res. 244, A-18

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 209
(A-22)

Introduced by: Medical Student Section

Subject: Supporting Collection of Data on Medical Repatriation

Referred to: Reference Committee B

Whereas, Forced medical repatriation is the involuntary return of civilians in need of medical treatment to their country of origin by healthcare professionals[1]; and

Whereas, Forced medical repatriation results in an involuntary transfer of a patient to a foreign country, provoking an unwarranted intersection between immigration enforcement and the healthcare system[2]; and

Whereas, Of the estimated 10.5 million undocumented immigrants in the United States in 2017, a study found expenditures on immigrants in 2016 accounted for less than 10% of the overall healthcare spending in a population with the highest risk of being uninsured among the non-elderly population[2-4]; and

Whereas, Under the Emergency Medical Treatment and Labor Act of 1986 (EMTALA), federally funded health institutions with emergency care capabilities are mandated to treat all patients with emergent medical conditions who present to their facility until deemed stable, regardless of their insurance coverage or financial status[5]; and

Whereas, Once deemed stable, medical centers must consider medical repatriation if no long-term care alternative is available to the patient as a cost-saving mechanism[6]; and

Whereas, Care centers like St. Joseph's Hospital and Medical Center in Phoenix, Arizona, partake in forced medical repatriation for undocumented immigrant patients and a Florida patient experienced involuntary deportation prior to the completion of their appeal or asylum verdict[7-9]; and

Whereas, Forced medical repatriation has led to serious medical consequences for patients, including the exacerbation of existing medical conditions[10,11]; and

Whereas, Patients experienced a lapse and deterioration of care due to the inability of the patient's country of origin to provide adequate treatment and concurrent separation from their community in the U.S. during a time which may require emotional, physical and financial support[6,7,9,12]; and

Whereas, Hospitals fail to inform patients, or their guardians of potential adverse medical consequences related to repatriation[7,13]; and

Whereas, Forced medical repatriation increases health disparities among migrant communities and deters immigrants from seeking necessary medical services[14,15];and

Whereas, Forced medical repatriation often violates the Centers for Medicare and Medicaid Services' Conditions of Participation regulation which commits hospitals to ensure patients have the right to conduct informed decisions regarding their care[16,17]; and

Whereas, Forced medical repatriation violates the patient's constitutional right to due process, especially if the patient is able to claim asylum[18]; and

Whereas, The *AMA Journal of Ethics* encourages health care systems to seek routes of care to avoid forced medical repatriation and the *AMA Code of Ethics* Opinion 1.1.8 states that "physicians should resist any discharge requests that are likely to compromise a patient's safety" and that the "discharge plan should be developed without regard to socioeconomic status, immigration status, or other clinically irrelevant considerations" [2,19,20]; and

Whereas, The AMA is pursuing policy focused on alternative routes for immigrant healthcare through Health Care Payment for Undocumented Persons (D-440.985) and Federal Funding for Safety Net Care for Undocumented Aliens (H-160.956)[21,22]; and

Whereas, Data on repatriation of civilians is not reported through any government agency or otherwise, and there is a lack of documentation[7,23]; therefore be it

RESOLVED, That our American Medical Association ask the Department of Health and Human Services to collect and de-identify any and all instances of medical repatriations from the United States to other countries by medical centers to further identify the harms of this practice (Directive to Take Action); and be it further

RESOLVED, That our AMA denounce the practice of forced medical repatriation. (New HOD Policy)

Fiscal Note: Modest - between $1,000 - $5,000

Date Received: 04/08/22

References:

1. Schumann J. When The Cost Of Care Triggers A Medical Deportation. https://www.npr.org/sections/health-shots/2016/04/09/473358504/when-the-cost-of-care-triggers-a-medical-deportation. Published April 2016. Accessed August 23rd, 2019.
2. Kuczewski M. How Medicine May Save the Life of US Immigration Policy: From Clinical and Educational Encounters to Ethical Public Policy. *AMA J Ethics.* 2017;19(3):221-233.
3. Pew Research Center. 5 facts about illegal immigration in the U.S. https://www.pewresearch.org/fact-tank/2019/06/12/5-facts-about-illegal-immigration-in-the-u-s/. Published 2019. Accessed August 23rd, 2019.
4. L Flavin, L Zallman, D McCormick, Et al. Medical Expenditures on and by Immigrant Populations in the United States: A Systematic Review. *International Journal of Health Services.* 2018:1-20.
5. U.S.C., § 1395dd.
6. Stead K. Critical Condition: Using Asylum Law to Contest Forced Medical Repatriation of Undocumented Immigrants. *Northwestern University Law Review.* 2010;104(1):307-333.
7. Fruth S. Medical Repatriation: The Intersection of Mandated Emergency Care, Immigration Consequences, and International Obligations. *J Leg Med.* 2015;36(1):45-72.
8. The Center for Social Justice at Seton Hall University Law School, Health Justice Program at New York Lawyers for the Public Interest. *Discharge, Deportation, and Dangerous Journeys.* 2012.
9. *Montejo V. Martin Memorial Medical Center Inc,* (District Court of Appeal of Florida,Fourth District. 2006).
10. Sabin M, Sabin K, Kim HY, Vergara M, Varese L. The mental health status of Mayan refugees after repatriation to Guatemala. *Rev Panam Salud Publica* 2006(19):163-171.
11. Banatvala N, Roger AJ, Denny A, Howarth JP. Mortality and morbidity among Rwandan refugees repatriated from Zaire. *Prehosp Disaster Med* 1996(13):17-21.
12. Graham J, Schlikerman B, Uribe A. Undocumented worker who became quadriplegic is moved to Mexico against his will. *Chicago Tribune*2011.
13. Sontag D. Immigrants Facing Deportation by U.S. Hospitals. *New York Times*2008.
14. National Latina Institute for Reproductive Health. *Cervical Cancer & Latinxs: The Fight for Prevention & Health Equity.* 2019.
15. Center for Reproductive Rights. *Nuestra Voz, Nuestra Salud, Nuestro Texas: The Fight for Women's Reproductive Health in the Rio Grande Valley.* 2013.

16. Seton Hall University School of Law. *Medical Repatriation Advocacy Packet.* 2015.
17. U.S. Centers for Medicare & Medicaid Services. Conditions for Coverage (CfCs) & Conditions of Participations (CoPs). https://www.cms.gov/Regulations-and-Guidance/Legislation/CFCsAndCoPs/index.html?redirect=/CFCsAndCoPs/06_Hospitals.asp. Published 2019. Accessed August 23rd, 2019.
18. The Universal Declaration of Human Rights, United Nations General Assembly resolution 217A(1948).
19. American Medical Association. AMA Code of Ethics Opinion 1.1.8: Physician Responsibilities for Safe Patient Discharge. https://www.ama-assn.org/delivering-care/ethics/physician-responsibilities-safe-patient-discharge. Accessed September 18th, 2019.
20. William Greenough MD. Treating and Repatriating: An Unacceptable Policy. https://journalofethics.ama-assn.org/article/treating-and-repatriating-unacceptable-policy/2009-07. Published July 2019. Accessed September 18th, 2019.
21. American Medical Association. Health Care Payment for Undocumented Persons D-440.985. 2019.
22. American Medical Association. Federal Funding for Safety Net Care for Undocumented Aliens H-160.956. 2019.
23. MJ Young, L Soleymani Lehmann. Undocumented Injustice? Medical Repatriation and the Ends of Health Care. *New England Journal of Medicine.* 14 February 2014;370(7):669-673.

RELEVANT AMA POLICY

EMTALA -- Major Regulatory and Legislative Developments D-130.982

Our AMA: (1) continue to work diligently to clarify and streamline the EMTALA requirements to which physicians are subject; (2) continue to work diligently with the Department of Health and Human Services (HHS) to further limit the scope of EMTALA, address the underlying problems of emergency care, and provide appropriate compensation and adequate funding for physicians providing EMTALA-mandated services; (3) communicate to physicians its understanding that following inpatient admission of a patient initially evaluated in an emergency department and stabilized, care will not be governed by the EMTALA regulations; and (4) continue strongly advocating to the Federal government that, following inpatient admission of a patient evaluated in an emergency department, where a patient is not yet stable, EMTALA regulations shall not apply.
BOT Rep. 17, I-02, Reaffirmation: A-07, Modified: BOT Rep. 22, A-17

Access to Emergency Services H-130.970

1. Our AMA supports the following principles regarding access to emergency services; and these principles will form the basis for continued AMA legislative and private sector advocacy efforts to assure appropriate patient access to emergency services:
(A) Emergency services should be defined as those health care services that are provided in a hospital emergency facility after the sudden onset of a medical condition that manifests itself by symptoms of sufficient severity, including severe pain, that the absence of immediate medical attention could reasonably be expected by a prudent layperson, who possesses an average knowledge of health and medicine, to result in: (1) placing the patient's health in serious jeopardy; (2) serious impairment to bodily function; or (3) serious dysfunction of any bodily organ or part.
(B) All physicians and health care facilities have an ethical obligation and moral responsibility to provide needed emergency services to all patients, regardless of their ability to pay. (Reaffirmed by CMS Rep. 1, I-96)
(C) All health plans should be prohibited from requiring prior authorization for emergency services.
(D) Health plans may require patients, when able, to notify the plan or primary physician at the time of presentation for emergency services, as long as such notification does not delay the initiation of appropriate assessment and medical treatment.
(E) All health payers should be required to cover emergency services provided by physicians and hospitals to plan enrollees, as required under Section 1867 of the Social Security Act (i.e., medical screening examination and further examination and treatment needed to stabilize an "emergency medical condition" as defined in the Act) without regard to prior authorization or the emergency care physician's contractual relationship with the payer.

(F) Failure to obtain prior authorization for emergency services should never constitute a basis for denial of payment by any health plan or third-party payer whether it is retrospectively determined that an emergency existed or not.
(G) States should be encouraged to enact legislation holding health plans and third-party payers liable for patient harm resulting from unreasonable application of prior authorization requirements or any restrictions on the provision of emergency services.
(H) Health plans should educate enrollees regarding the appropriate use of emergency facilities and the availability of community-wide 911 and other emergency access systems that can be utilized when for any reason plan resources are not readily available.
(I) In instances in which no private or public third-party coverage is applicable, the individual who seeks emergency services is responsible for payment for such services.
2. Our AMA will work with state insurance regulators, insurance companies and other stakeholders to immediately take action to halt the implementation of policies that violate the "prudent layperson" standard of determining when to seek emergency care.
CMS Rep. A, A-89, Modified: CMS Rep. 6, I-95, Reaffirmation: A-97, Reaffirmed: Sub. Res. 707, A-98, Reaffirmed: Res. 705, A-99, Reaffirmed: CMS Rep. 3, I-99, Reaffirmation: A-00, Reaffirmed: Sub. Res. 706, I-00, Amended: Res. 229, A-01, Reaffirmation and Reaffirmed: Res. 708, A-02, Reaffirmed: CMS Rep. 4, A-12, Reaffirmed: CMS Rep. 07, A-16, Appended: Res. 128, A-17, Reaffirmation: A-18, Reaffirmed in lieu of: Res. 807, I-18

Emergency Medical Treatment and Active Labor Act (EMTALA) H-130.950
Our AMA: (1) will seek revisions to the Emergency Medical Treatment and Active Labor Act ((EMTALA)) and its implementing regulations that will provide increased due process protections to physicians before sanctions are imposed under (EMTALA); (2) expeditiously identify solutions to the patient care and legal problems created by current Emergency Medical Treatment and Active Labor Act ((EMTALA)) rules and regulations; (3) urgently seeks return to the original congressional intent of (EMTALA) to prevent hospitals with emergency departments from turning away or transferring patients without health insurance; and (4) strongly opposes any regulatory or legislative changes that would further increase liability for failure to comply with ambiguous (EMTALA) requirements.
Sub. Res. 214, A-97, Reaffirmation: I-98, Reaffirmation: A-99, Appended: Sub. Res. 235 and Reaffirmation A-00, Reaffirmation: A-07, Reaffirmed: BOT Rep. 22, A-17)

Emergency Transfer Responsibilities H-130.957
Our AMA supports seeking amendments to Section 1867 of the Social Security Act, pertaining to patient transfer, to:
(1) require that the Office of the Inspector General (IG) request and receive the review of the Quality Improvement Organization (QIO) prior to imposing sanctions;
(2) make the QIO determination in alleged patient transfer violations binding upon the IG;
(3) expand the scope of QIO review to include a determination on whether the medical benefits reasonably expected from the provision of appropriate medical treatment at another facility outweighed the potential risks;
(4) restore the knowing standard of proof for physician violation;
(5) recognize appropriate referral of patients from emergency departments to physician offices;
(6) clarify ambiguous terms such as emergency medical transfer and stabilized transfer;
(7) clarify ambiguous provisions regarding the extent of services which must be provided in examining/treating a patient;
(8) clarify the appropriate role of the on-call specialist, including situations where the on-call specialist may be treating other patients; and
(9) clarify that a discharge from an emergency department is not a transfer within the meaning of the act.

Sub. Res. 78, A-91, Reaffirmation: A-00, Reaffirmed: BOT Rep. 6, A-10; Modified: BOT Rep. 04, A-20

Repeal of COBRA Anti-Physician Provisions H-130.959
It is the policy of the AMA (1) to seek legal or legislative opportunities to clarify that Section 1867 of the Social Security Act applies only to inappropriate transfers from hospital emergency departments and not to issues of malpractice; and (2) to continue to seek appropriate modifications of Section 1867 of the Social Security Act to preclude liability for discharges from the hospital, including emergency department and outpatient facility.
Sub. Res. 145, I-90, Reaffirmed: Sunset Report, I-00, Reaffirmed: BOT Rep. 6, A-10; Reaffirmed: BOT Rep. 04, A-20

Health Care Payment for Undocumented Persons D-440.985
Our AMA shall assist states on the issue of the lack of reimbursement for care given to undocumented immigrants in an attempt to solve this problem on a national level.
Res. 148, A-02, Reaffirmation: A-07, Reaffirmed: CMS Rep. 1, A-17, Reaffirmation: A-19; Reaffirmation: I-19

Opposition to Criminalization of Medical Care Provided to Undocumented Immigrant Patients H-440.876
1. Our AMA: (a) opposes any policies, regulations or legislation that would criminalize or punish physicians and other health care providers for the act of giving medical care to patients who are undocumented immigrants; (b) opposes any policies, regulations, or legislation requiring physicians and other health care providers to collect and report data regarding an individual patient's legal resident status; and (c) opposes proof of citizenship as a condition of providing health care. 2. Our AMA will work with local and state medical societies to immediately, actively and publicly oppose any legislative proposals that would criminalize the provision of health care to undocumented residents.
Res. 920, I-06, Reaffirmed and Appended: Res. 140, A-07, Modified: CCB/CLRPD, Rep. 2, A-14

Federal Funding for Safety Net Care for Undocumented Aliens H-160.956
Our AMA will lobby Congress to adequately appropriate and dispense funds for the current programs that provide reimbursement for the health care of undocumented aliens.
Sub. Res. 207, A-93, Reaffirmed: BOT Rep. 17, I-94, Reaffirmed: Ref Com B, A-96, Reaffirmation: A-02, Reaffirmation: A-07, Reaffirmed: BOT Rep. 22, A-17, Reaffirmation: A-19; Reaffirmation: I-19

Presence and Enforcement Actions of Immigration and Customs Enforcement (ICE) in Healthcare D-160.921
Our AMA: (1) advocates for and supports legislative efforts to designate healthcare facilities as sensitive locations by law; (2) will work with appropriate stakeholders to educate medical providers on the rights of undocumented patients while receiving medical care, and the designation of healthcare facilities as sensitive locations where U.S. Immigration and Customs Enforcement (ICE) enforcement actions should not occur; (3) encourages healthcare facilities to clearly demonstrate and promote their status as sensitive locations; and (4) opposes the presence of ICE enforcement at healthcare facilities.
Res. 232, I-17)

Addressing Immigrant Health Disparities H-350.957

1. Our American Medical Association recognizes the unique health needs of refugees and encourages the exploration of issues related to refugee health and support legislation and policies that address the unique health needs of refugees.
2. Our AMA: (A) urges federal and state government agencies to ensure standard public health screening and indicated prevention and treatment for immigrant children, regardless of legal status, based on medical evidence and disease epidemiology; (B) advocates for and publicizes medically accurate information to reduce anxiety, fear, and marginalization of specific populations; and (C) advocates for policies to make available and effectively deploy resources needed to eliminate health disparities affecting immigrants, refugees or asylees.
3. Our AMA will call for asylum seekers to receive all medically appropriate care, including vaccinations in a patient centered, language and culturally appropriate way upon presentation for asylum regardless of country of origin.
Res. 804, I-09, Appended: Res. 409, A-15, Reaffirmation: A-19, Appended: Res. 423, A-19; Reaffirmation: I-19

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 210
(A-22)

Introduced by: Medical Student Section

Subject: Reducing the Prevalence of Sexual Assault by Testing Sexual Assault Evidence Kits

Referred to: Reference Committee B

Whereas, Rape and/or sexual assault is common in the United States, with between 135,755 and 393,980 rapes and/or sexual assaults committed in 2017 alone[1,2]; and

Whereas, 43.6% of women and 24.8% of men have experienced some form of sexual violence, including unwanted sexual contact of any kind, in their lifetimes[3]; and

Whereas, Rape and sexual assault are associated with a wide range of medical and psychological sequelae, including direct physical trauma, PTSD, depression, social phobias, mood regulation deficiencies, impaired sexual function, anxiety, self-harm, suicidal ideation and suicide attempts[4-14]; and

Whereas, Data suggests that a significant proportion of rapes and/or sexual assaults are committed by serial offenders[15-19]; and

Whereas, Identification and incarceration of perpetrators of violent sexual crimes reduces the incidence of future sexual violence committed by these serial offenders[17-23]; and

Whereas, Sexual assault evidence kits (SAEKs), which refer to kits used to collect and store evidence from a victim of sexual assault during a sexual assault forensic examination, are extremely useful in the identification and prosecution of perpetrators of violent sexual crime and are positively associated with successful prosecutions[17,19,22,23-27]; and

Whereas, Even when suspects cannot be immediately identified on the basis of the DNA signature derived from a SAEK, law enforcement officials can upload the DNA profile to the Federal Bureau of Investigation's Combined DNA Index System (CODIS), which can assist in the later identification of the perpetrator[28]; and

Whereas, Despite the obvious utility of testing SAEKs, many remain untested and stored in law enforcement evidence warehouses ("backlogged"), with estimates placing the number of backlogged kits as high as 200,000 nationwide[19,29]; and

Whereas, The cause of backlogged SAEKs have been attributed to lack of standardized policies and procedures, including federal guidelines, inadequate training of law enforcement officers, outdated laboratory policies and lack of resources, such as funding[30]; and

Whereas, The United States Department of Justice's Violence Against Women Act of 1994 (VAWA) and its subsequent reauthorizations provides grants to programs offering medical services to sexual assault survivors contingent on those programs incurring the full cost of forensic medical exams through the offices of State Attorney's General[31-33]; and

Whereas, Standardized insurance billing procedures that include copays and other cost-sharing payments cause victims of sexual assault to be billed for part of the cost of testing forensic evidence, notwithstanding federal mandates like VAWA[34,35]; and

Whereas, The Bureau of Justice Assistance in the US Department of Justice administers the Sexual Assault Kit Initiative (SAKI), a grant program that assists police departments in testing backlogged SAEKs, has resulted in the disbursement of $43 million and the testing of 50,500 kits[40-42]; and

Whereas, Counties that have voluntarily worked to test all backlogged SAEKs in their possession have been extraordinarily successful in solving previously unsolved rapes and sexual assaults[17,19,21,22,36-40]; and

Whereas, Many of these SAEKs, if tested earlier, would have led to the identification and incarceration of serial offenders that would have prevented later assaults[17,19-22,36-38]; and

Whereas, The $9.6 million SAEK testing initiative in Cuyahoga County, Ohio financed new forensic examinations in addition to comprehensive coverage of investigations on backlogged kits with a net estimated savings of $38.7 million, highlighting the cost effectiveness of testing SAEKs[41,42]; and

Whereas, Existing AMA Policy H-80.999 outlines the rights of sexual assault victims but neither explicitly describes the right to have collected medical forensic evidence be tested in a timely manner nor addresses the backlog of untested sexual assault evidence kits; therefore be it

RESOLVED, That our American Medical Association amend Policy H-80.999, "Sexual Assault Survivors," by addition to read as follows:

H-80.999 – SEXUAL ASSAULT SURVIVORS

1. Our AMA supports the preparation and dissemination of information and best practices intended to maintain and improve the skills needed by all practicing physicians involved in providing care to sexual assault survivors.
2. Our AMA advocates for the legal protection of sexual assault survivors' rights and work with state medical societies to ensure that each state implements these rights, which include but are not limited to, the right to: (a) receive a medical forensic examination free of charge, which includes but is not limited to HIV/STD testing and treatment, pregnancy testing, treatment of injuries, and collection of forensic evidence; (b) preservation of a sexual assault evidence collection kit for at least the maximum applicable statute of limitations (c) notification of any intended disposal of a sexual assault evidence kit with the opportunity to be granted further preservation; (d) be informed of these rights and the policies governing the sexual assault evidence kit; and (e) access to emergency contraception information and treatment for pregnancy prevention.
3. Our AMA will collaborate with relevant stakeholders to develop recommendations for implementing best practices in the treatment of sexual assault survivors, including through engagement with the joint working group established for this purpose under the Survivor's Bill of Rights Act of 2016.
4. Our AMA will advocate for increased post-pubertal patient access to Sexual Assault Nurse Examiners, and other trained and qualified clinicians, in the emergency department for medical forensic examinations.
5. Our AMA will advocate at the state and federal level for (a) the immediate processing of all "backlogged" and new sexual assault examination kits; and (b) additional funding to facilitate the immediate testing of sexual assault evidence kits. (Modify Current HOD Policy)

Fiscal Note: Modest - between $1,000 - $5,000

Date Received: 04/08/22

References:

1. U.S. Department of Justice. Crime in the United States. https://ucr.fbi.gov/crime-in-the-u.s/2017/crime-in-the-u.s.-2017/topic-pages/tables/table-1. Published 2017. Accessed August 23rd, 2019.
2. Morgan R, Truman J. Criminal Victimization, 2017 U.S. Department of Justice;2018.
3. Smith S, Zhang X, Basile K, et al. National Intimate Partner and Sexual Violence Survey: 2015 Data Brief. National Center for Injury Prevention and Control;2018.
4. Rosellini AJ, Street AE, Ursano RJ, et al. Sexual Assault Victimization and Mental Health Treatment, Suicide Attempts, and Career Outcomes Among Women in the US Army. Am J Public Health. 2017;107(5):732-739.
5. Kmett JA, Eack SM. Characteristics of Sexual Abuse Among Individuals With Serious Mental Illnesses. J Interpers Violence. 2018;33(17):2725-2744.
6. Santiago JM, McCall-Perez F, Gorcey M, Beigel A. Long-term psychological effects of rape in 35 rape victims. Am J Psychiatry. 1985;142(11):1338-1340.
7. Resick P. The Psychological Impact of Rape. Journal of Interpersonal Violence. 1993;8(2):223-255.
8. Segal DL. Self-reported history of sexual coercion and rape negatively impacts resilience to suicide among women students. Death Stud. 2009;33(9):848-855.
9. Choquet M, Darves-Bornoz JM, Ledoux S, Manfredi R, Hassler C. Self-reported health and behavioral problems among adolescent victims of rape in France: results of a cross-sectional survey. Child Abuse Negl. 1997;21(9):823-832.
10. Ackard DM, Neumark-Sztainer D. Date violence and date rape among adolescents: associations with disordered eating behaviors and psychological health. Child Abuse Negl. 2002;26(5):455-473.
11. Davidson JR, Hughes DC, George LK, Blazer DG. The association of sexual assault and attempted suicide within the community. Arch Gen Psychiatry. 1996;53(6):550-555.
12. Luster T, Small SA. Sexual abuse history and problems in adolescence: Exploring the effects of moderating variables. J Marriage Fam. 1997;59(1):131-142.
13. Romans SE, Martin JL, Anderson JC, Herbison GP, Mullen PE. Sexual abuse in childhood and deliberate self-harm. Am J Psychiatry. 1995;152(9):1336-1342.

14. Wiederman MW, Sansone RA, Sansone LA. History of trauma and attempted suicide among women in a primary care setting. Violence Vict. 1998;13(1):3-9.
15. Rape Abuse & Incest National Network. Perpetrators of Sexual Violence: Statistics. https://www.rainn.org/statistics/perpetrators-sexual-violence. Published 2019. Accessed August 23rd, 2019.
16. Foubert JD, Clark-Taylor A, Wall AF. Is Campus Rape Primarily a Serial or One-Time Problem? Evidence From a Multicampus Study. Violence Against Women. 2019:1077801219833820.
17. Lovell R, Luminais M, Flannery DJ, Bell R, Kyker B. Describing the process and quantifying the outcomes of the Cuyahoga County sexual assault kit initiative. J Crim Just. 2018;57:106-115.
18. Lovell R, Butcher F, Flannery D. Cuyahoga County Sexual Assault Kit Pilot Project (SAK): Report on Serial and One-Time Sexual Offenders. 2016.
19. "An Epidemic of Disbelief" [press release]. 2019.
20. End the Backlog. Test Rape Kits. Stop Serial Rapists. http://www.endthebacklog.org/backlog-why-rape-kit-testing-important/test-rape-kits-stop-serial-rapists. Published 2019. Accessed August 23rd, 2019.
21. Office of Wayne County Prosecutor Kym Worthy. Wayne County Sexual Assault Kit Task Force FAQ August 2018. 2018.
22. City of Memphis Sexual Assault Kit Task Force. Monthly Report April 2019. 2019.
23. Newman S. Why men rape. Aeon Media Group. https://aeon.co/essays/until-we-treat-rapists-as-ordinary-criminals-we-wont-stop-them. Published 2017. Accessed August 23rd, 2019.
24. Rape Abuse & Incest National Network. What Is a Rape Kit? https://www.rainn.org/articles/rape-kit. Published 2019. Accessed August 23rd, 2019.
25. Gray-Eurom K, Seaberg DC, Wears RL. The prosecution of sexual assault cases: correlation with forensic evidence. Ann Emerg Med. 2002;39(1):39-46.
26. Kjærulff MLBG, Bonde U, Astrup BC. The significance of the forensic clinical examination on the judicial assessment of rape complaints - developments and trends. Forensic Sci Int. 2019;297:90-99.
27. Campbell R, Patterson D, Bybee D, Bybee D, Dworkin E. Predicting Sexual Assault Prosecution Outcomes: The Role of Medical Forensic Evidence Collected by Sexual Assault Nurse Examiners. Criminal Justice and Behavior. 2009;36(7):712-727.
28. U.S. Department of Justice. Frequently Asked Questions on CODIS and NDIS. https://www.fbi.gov/services/laboratory/biometric-analysis/codis/codis-and-ndis-fact-sheet. Published 2019. Accessed August 23rd, 2019.
29. End the Backlog. How big is the backlog where you live? http://www.endthebacklog.org/. Published 2019. Accessed August 23rd, 2019.
30. Begun Center for Violence Prevention Research and Education at the Jack JaMMSaCWRU. Sexual Assault Kit Initiative (SAKI). https://case.edu/socialwork/begun/research-and-evaluation/gender-based-violence/sexual-assault-kit-initiative-saki. Published 2019. Accessed August 23rd, 2019.
31. Lovell R, Cyleste Collins, Margaret McGuire, Laura Overman, Luminais M, Flannery D. Understanding Intimate Partner Sexual Assaults: Findings from Sexual Assault Kits. Journal of Aggression, Maltreatment & Trauma 2018;28(1).
32. Lovell R, Flannery D, Luminais M. Lessons learned: Serial sex offenders identified from backlogged sexual assault kits (SAKs). In: Vazsonyi AT, Flannery DJ, DeLisi M, eds. The Cambridge handbook of violent behavior and aggression. Second edition. ed. Cambridge, United Kingdom ; New York, NY: Cambridge University Press; 2018:xvi, 807 pages.
33. U.S. News & World Report. Backlogged Rape Test Kits Produce Several Possible Leads. U.S. News & World Report,2018.
34. Clark D, Lovell R. Collaborative Partnerships and the DNA Testing of Unsubmitted SAKs. Police Chief2019.
35. Burns J. It's Official: Testing Rape Kits Prevents Assault And Saves Everybody Millions. https://www.forbes.com/sites/janetwburns/2016/09/14/its-official-testing-rape-kits-prevents-assault-and-saves-everybody-millions/#4fe212bf78b2. Published 2016. Accessed August 23rd, 2019.
36. Case Western Reserve University: The Daily. Testing backlogged sexual assault kits prevents future rapes and saves victims and communities millions. 2016.
37. Sacco, LN. The Violence Against Women Act (VAWA): Historical Overview, Funding and Reauthorization. Congressional Research Service. https://fas.org/sgp/crs/misc/R45410.pdf. Accessed August 10, 2019. Published April 23, 2019.
38. Background on VAWA 2005, VAWA 2013 and Forensic Compliance. End Violence Against Women International. https://www.evawintl.org/PAGEID2/Forensic-Compliance/Background. Published 2019. Accessed August 24, 2019.
39. Violence Against Women Reauthorization Act of 2013. Government Publishing Office. https://www.govinfo.gov/content/pkg/BILLS-113s47enr/pdf/BILLS-113s47enr.pdf. Published 2013.
40. U.S. Department of Justice Bureau of Justice Assistance. Sexual Assault Kit Initiative (SAKI). https://www.bja.gov/ProgramDetails.aspx?Program_ID=117. Published 2019. Accessed August 23rd, 2019.
41. U.S. Department of Justice Bureau of Justice Assistance. Over 47,000 Kits Tested Through BJA's Sexual Assault Kit Initiative since 2015. https://www.bja.gov/SuccessStory/Over-47000-Kits-Tested-Through-BJAs-Sexual-Assaul-Kit-Initiative-since-2015.html?utm_source=announcements_bja.gov&utm_medium=web&utm_campaign=successstories. Published 2019. Accessed August 23rd, 2019.
42. Sexual Assault Kit Initiative (SAKI). SAKI is enhancing the criminal justice response to sexual assault and ensuring justice for victims. https://sakitta.org/. Published 2019. Accessed August 23rd, 2019.
43. Tennessee, AM, et al. The Monetary Cost of Sexual Assault to Privately Insured US Women in 2013. American Journal of Public Health. June 2017;(6)107;983-988.
44. Andrews, M. Years After Sexual Assault, Survivors Hounded To Pay Bills For The Rape Kit Exam. National Public Radio. https://www.npr.org/sections/health-shots/2019/07/10/739925186/years-after-sexual-assault-survivors-hounded-to-pay-bills-for-the-rape-kit-exam. Published July 10, 2019. Accessed August 10, 2019.

RELEVANT AMA POLICY

Sexual Assault Survivors H-80.999
1. Our AMA supports the preparation and dissemination of information and best practices intended to maintain and improve the skills needed by all practicing physicians involved in providing care to sexual assault survivors.
2. Our AMA advocates for the legal protection of sexual assault survivors' rights and work with state medical societies to ensure that each state implements these rights, which include but are not limited to, the right to: (a) receive a medical forensic examination free of charge, which includes but is not limited to HIV/STD testing and treatment, pregnancy testing, treatment of injuries, and collection of forensic evidence; (b) preservation of a sexual assault evidence collection kit for at least the maximum applicable statute of limitation; (c) notification of any intended disposal of a sexual assault evidence kit with the opportunity to be granted further preservation; (d) be informed of these rights and the policies governing the sexual assault evidence kit; and (e) access to emergency contraception information and treatment for pregnancy prevention.
3. Our AMA will collaborate with relevant stakeholders to develop recommendations for implementing best practices in the treatment of sexual assault survivors, including through engagement with the joint working group established for this purpose under the Survivor's Bill of Rights Act of 2016.
4. Our AMA will advocate for increased post-pubertal patient access to Sexual Assault Nurse Examiners, and other trained and qualified clinicians, in the emergency department for medical forensic examinations.
Sub. Res. 101, A-80; Reaffirmed: CLRPD Rep. B, I-90; Reaffirmed: Sunset Report, I-00; Reaffirmed: CSAPH Rep. 1, A-10; Modified: Res. 202, I-17; Appended: Res. 902, I-18

Sexual Assault Survivor Services H-80.998
Our AMA supports the function and efficacy of sexual assault survivor services, supports state adoption of the sexual assault survivor rights established in the Survivors' Bill of Rights Act of 2016, encourages sexual assault crisis centers to continue working with local police to help sexual assault survivors, and encourages physicians to support the option of having a counselor present while the sexual assault survivor is receiving medical care.
Res. 56, A-83; Reaffirmed: CLRPD Rep. 1, I-93; Reaffirmed: CSA Rep. 8, A-05; Reaffirmed: CSAPH Rep. 1, A-15; Modified: Res. 202, I-17

Addressing Sexual Assault on College Campuses H-515.956
Our AMA: (1) supports universities' implementation of evidence-driven sexual assault prevention programs that specifically address the needs of college students and the unique challenges of the collegiate setting; (2) will work with relevant stakeholders to address the issues of rape, sexual abuse, and physical abuse on college campuses; and (2) will strongly express our concerns about the problems of rape, sexual abuse, and physical abuse on college campuses.
Res. 402, A-16; Appended: Res. 424, A-18

HIV, Sexual Assault and Violence H-20.900
Our AMA: (1) believes that HIV testing and Post-Exposure Prophylaxis (PEP) should be offered to all survivors of sexual assault who present within 72 hours of a substantial exposure risk, that these survivors should be encouraged to be retested in six months if the initial test is negative, and that strict confidentiality of test results be maintained; and (2) supports: (a) education of physicians about the effective use of HIV Post-Exposure Prophylaxis (PEP) and the U.S. PEP Clinical Practice Guidelines, and (b) increased access to, and coverage for, PEP for HIV, as well as enhanced public education on its effective use.
CSA Rep. 4, A-03; Modified: CSAPH Rep. 1, A-13; Modified: Res. 905, I-18

Access to Emergency Contraception H-75.985
It is the policy of our AMA: (1) that physicians and other health care professionals should be encouraged to play a more active role in providing education about emergency contraception, including access and informed consent issues, by discussing it as part of routine family planning and contraceptive counseling; (2) to enhance efforts to expand access to emergency contraception, including making emergency contraception pills more readily available through pharmacies, hospitals, clinics, emergency rooms, acute care centers, and physicians' offices; (3) to recognize that information about emergency contraception is part of the comprehensive information to be provided as part of the emergency treatment of sexual assault victims; (4) to support educational programs for physicians and patients regarding treatment options for the emergency treatment of sexual assault victims, including information about emergency contraception; and (5) to encourage writing advance prescriptions for these pills as requested by their patients until the pills are available over-the-counter.
CMS Rep. 1, I-00; Appended: Res. 408, A-02; Modified: Res. 443, A-04; Reaffirmed: CSAPH Rep. 1, A-14

Insurance Discrimination Against Victims of Domestic Violence H-185.976
Our AMA: (1) opposes the denial of insurance coverage to victims of domestic violence and abuse and seeks federal legislation to prohibit such discrimination; and (2) advocates for equitable coverage and appropriate reimbursement for all health care, including mental health care, related to family and intimate partner violence.
Res. 814, I-94; Appended: Res. 419, I-00; Reaffirmation A-09; Reaffirmed: CMS Rep. 01, A-19

AMA Code of Medical Ethics 8.10 Preventing, Identifying and Treating Violence and Abuse
All patients may be at risk for interpersonal violence and abuse, which may adversely affect their health or ability to adhere to medical recommendations. In light of their obligation to promote the well-being of patients, physicians have an ethical obligation to take appropriate action to avert the harms caused by violence and abuse.
To protect patients' well-being, physicians individually should:
(a) Become familiar with:
(i) how to detect violence or abuse, including cultural variations in response to abuse;
(ii) community and health resources available to abused or vulnerable persons;
(iii) public health measures that are effective in preventing violence and abuse;
(iv) legal requirements for reporting violence or abuse.
(b) Consider abuse as a possible factor in the presentation of medical complaints.
(c) Routinely inquire about physical, sexual, and psychological abuse as part of the medical history.
(d) Not allow diagnosis or treatment to be influenced by misconceptions about abuse, including beliefs that abuse is rare, does not occur in "normal" families, is a private matter best resolved without outside interference, or is caused by victims' own actions.
(e) Treat the immediate symptoms and sequelae of violence and abuse and provide ongoing care for patients to address long-term consequences that may arise from being exposed to violence and abuse.
(f) Discuss any suspicion of abuse sensitively with the patient, whether or not reporting is legally mandated, and direct the patient to appropriate community resources.
(g) Report suspected violence and abuse in keeping with applicable requirements. Before doing so, physicians should:
(i) inform patients about requirements to report;

(ii) obtain the patient's informed consent when reporting is not required by law. Exceptions can be made if a physician reasonably believes that a patient's refusal to authorize reporting is coerced and therefore does not constitute a valid informed treatment decision.
(h) Protect patient privacy when reporting by disclosing only the minimum necessary information.
Collectively, physicians should:
(i) Advocate for comprehensive training in matters pertaining to violence and abuse across the continuum of professional education.
(j) Provide leadership in raising awareness about the need to assess and identify signs of abuse, including advocating for guidelines and policies to reduce the volume of unidentified cases and help ensure that all patients are appropriately assessed.
(k) Advocate for mechanisms to direct physicians to community or private resources that might be available to aid their patients.
(l) Support research in the prevention of violence and abuse and collaborate with public health and community organizations to reduce violence and abuse.
(m) Advocate for change in mandatory reporting laws if evidence indicates that such reporting is not in the best interests of patients.
Issued: 2016

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 211
(A-22)

Introduced by: American Academy of Neurology, American Academy of Orthopaedic Surgeons, American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Physical Medicine and Rehabilitation, American Association of Neurological Surgeons, American College of Cardiology, American College of Emergency Physicians, American College of Physicians, American College of Surgeons, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, American Society for Surgery of the Hand, American Society of Echocardiography, American Society of Nuclear Cardiology, American Urological Association, California, Congress of Neurological Surgeons, North American Spine Society, Society for Cardiovascular Angiography & Interventions, Society of Cardiovascular Computed Tomography, Washington

Subject: Repeal or Modification of the Medicare Appropriate Use Criteria (AUC) Program

Referred to: Reference Committee B

Whereas, In 2014, Congress passed the Protecting Access to Medicare Act (PAMA) [Public Law 113-93], establishing the Medicare Appropriate Use Criteria (AUC) Program for advanced diagnostic imaging; and

Whereas, Eight years after PAMA's enactment, the Centers for Medicare & Medicaid Services (CMS) continues to face challenges in completing the rulemaking and implementation of the AUC program, fueling existing concerns about the complexity of the law, associated costs, and regulatory burden sustained by physicians and other health care providers to meet the program requirements; and

Whereas, The AUC program, if ever fully implemented, would impact a substantial number of clinicians, as it would apply to every clinician who orders or furnishes an advanced diagnostic imaging test, unless a statutory or hardship exemption applies; and

Whereas, Practitioners whose ordering patterns are considered outliers will be subject to prior authorization--at a time when physicians are working to advance policies that reduce the administrative burdens associated with prior authorization; and

Whereas, The program will be a financial burden for many practices, as it is estimated to cost $75,000 or more for a practice to implement a Clinical Decision Support Mechanism (CDSM) that complies with the AUC Program rules[1]; and

Whereas, The law is prescriptive, requiring clinicians to use only CDSMs qualified by CMS and only AUC developed by certain qualified entities--preventing the use of other clinical decision support tools and evidenced-based guidelines for advanced diagnostic imaging developed by medical societies and other health care institutions; and

[1] Association for Medical Imaging Management; 2017 https://ahralink.files.wordpress.com/2017/03/cds-survey- 2017.pdf

Whereas, The AUC program creates a complex exchange of information between clinicians that is not yet supported by interoperable electronic health record systems and relies on claims-based reporting at a time when CMS is migrating from claims reporting for quality data; and

Whereas, Since PAMA's enactment, the AUC program has become obsolete given the subsequent enactment of the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 and the rise of new health care payment and delivery models via the Quality Payment Program (QPP) (alternative payment models and Merit-based Incentive Payment System) designed to hold clinicians responsible for health care resource use; and

Whereas, Five years after the program's intended start date, technical challenges, including the need for claims processing edits to prevent claim denials, have further eroded physician confidence in and support for the program; and

Whereas, Awareness of the program among physicians and other health care professionals remains low, which is supported by CMS' estimate--based on CY2020 Medicare claims during the program's education and operations testing phase--that between 9-10 percent of all claims subject to the AUC program reported information sufficient to be considered compliant with the program; and

Whereas, In the CY 2022 Medicare Physician Fee Schedule final rule, CMS finalized its proposal to begin the payment penalty phase of the AUC program until the later of January 1, 2023, or the January 1 of the year following the end of the COVID-19 public health emergency; and

Whereas, Congress and CMS must seriously consider the degree to which the AUC program and QPP requirements overlap and create duplicative reporting burdens for physicians already overwhelmed by the variety of other administrative burdens associated with care delivery; and

Whereas, There is widespread agreement in the medical community that the program cannot be implemented as originally envisioned without imposing undue burden and cost on physician practices; therefore be it

RESOLVED, That our American Medical Association Policy H-320.940, "Medicare's Appropriate Use Criteria Program," be amended by addition and deletion to read as follows:

> Our AMA will ~~continue to~~ advocate to Congress for ~~delay the effective date~~ either the full repeal of the Medicare Appropriate Use Criteria (AUC) Program or legislative modifications to the program in such a manner that ~~until the Centers for Medicare & Medicaid Services (CMS) can~~ adequately addresses technical and workflow challenges~~, with its implementation and any interaction between~~ maximizes alignment with the Quality Payment Program (QPP), and ~~the use of advanced diagnostic imaging appropriate use criteria.~~ creates provider flexibility for the consultation of AUC or advanced diagnostic imaging guidelines using a mechanism best suited for their practice, specialty and workflow. (Modify Current HOD Policy)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 04/08/22

RELEVANT AMA POLICY

Medicare's Appropriate Use Criteria Program H-320.940
Our AMA will continue to advocate to delay the effective date of the Medicare Appropriate Use Criteria (AUC) Program until the Centers for Medicare & Medicaid Services (CMS) can adequately address technical and workflow challenges with its implementation and any interaction between the Quality Payment Program (QPP) and the use of advanced diagnostic imaging appropriate use criteria.
Citation: Res. 229, A-17; Reaffirmed - BOT Action in response to referred for decision: Res. 245, A-19 and Res. 247, A-19

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 212
(A-22)

Introduced by: Michigan

Subject: Medication for Opioid Use Disorder in Physician Health Programs

Referred to: Reference Committee B

Whereas, Physician Health Programs (PHPs) are designed to allow physicians with potentially impairing conditions who either come forward or are referred to be given the opportunity for evaluation, rehabilitation, treatment, and monitoring without disciplinary action in an anonymous, confidential, and respectful manner; and

Whereas, The PHP model is intended to ensure participants receive effective clinical care for mental, physical, and substance abuse disorders and access to a variety of clinical interventions and support; and

Whereas, Currently, physicians referred to PHPs who are diagnosed with opioid use disorder (OUD) involving monitoring or sanctions may be subjected to punitive action by their respective licensing boards; and

Whereas, The stigma associated with illness and impairment, particularly impairment resulting from mental illness, including substance use disorders, can be a powerful obstacle to seeking treatment, especially in the medical community where the presence of this stigma has been described in the literature; and

Whereas, The US Food and Drug Administration recommends approved medications for the treatment of opioid use disorder (MOUD) including methadone, buprenorphine, and naltrexone be available to all patients; and

Whereas, MOUD has been proven to help maintain recovery and prevent death in patients with opioid use disorder (OUD); and

Whereas, It is reported that patients who use MOUD remain in therapy longer than those who do not, and are less likely to use illicit opioids; and

Whereas, A 2019 report from the National Academies of Sciences, Engineering, and Medicine stated that “there is no scientific evidence that justifies withholding medications from OUD patients in any setting” and that such practices amount to “denying appropriate medical treatment,” and that such practices amount to “denying appropriate medical treatment”; and

Whereas, Clinicians should consider a patient’s preferences, past treatment history, current state of illness, and treatment setting when deciding between the use of methadone, buprenorphine, and naltrexone; and

Whereas, Additional considerations apply to health professionals who are actively engaged in, or planning to return to, safety sensitive work; and

Whereas, Treatment programs offering the best possible outcomes are critical to ensuring a pathway to recovery and continuation of clinical practice in a safe and ethical manner with patient protection at the forefront; and

Whereas, The American Society of Addiction Medicine's *Public Policy Statement on Physicians and other Healthcare Professionals with Addiction* includes the recommendation that "Healthcare professionals should be offered the full range of evidence-based treatments, including medication for addiction, in whatever setting they receive treatment. Regulatory agencies (including state licensing boards), professional liability insurers, and credentialing bodies should not discriminate against the type of treatment an individual receives based on unjustified assumptions that certain treatments cause impairment;" therefore be it

RESOLVED, That our American Medical Association reaffirm policy H-95.913, "Discrimination Against Physicians in Treatment with Medication for Opioid Use Disorders" (Reaffirm HOD Policy); and be it further

RESOLVED, That our AMA modify policy D-405.990, "Educating Physicians About Physician Health Programs and Advocating for Standards," by addition to read as follows:

Our AMA will:
(1) work closely with the Federation of State Physician Health Programs (FSPHP) to educate our members as to the availability and services of state physician health programs to continue to create opportunities to help ensure physicians and medical students are fully knowledgeable about the purpose of physician health programs and the relationship that exists between the physician health program and the licensing authority in their state or territory;
(2) continue to collaborate with relevant organizations on activities that address physician health and wellness;
(3) in conjunction with the FSPHP, develop <u>model</u> state <u>legislation and/or</u> legislative guidelines addressing the design and implementation of physician health programs <u>including, but not limited to, the allowance for safe-haven or non-reporting of physicians to a licensing board, and/or acceptance of Physician Health Program compliance as an alternative to disciplinary action when public safety is not at risk, and especially for any physicians who voluntarily self-report their physical, mental, and substance use disorders and engage with a Physician Health Program and who successfully complete the terms of participation</u>;
(4) work with FSPHP to develop messaging for all Federation members to consider regarding elimination of stigmatization of mental illness and illness in general in physicians and physicians in training;
(5) continue to work with and support FSPHP efforts already underway to design and implement the physician health program review process, Performance Enhancement and Effectiveness Review (PEER™), to improve accountability, consistency and excellence among its state member PHPs. The AMA will partner with the FSPHP to help advocate for additional national sponsors for this project; and
(6) continue to work with the FSPHP and other appropriate stakeholders on issues of affordability, cost effectiveness, and diversity of treatment options. (Modify Current HOD Policy)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 04/08/22

RELEVANT AMA POLICY

Discrimination Against Physicians in Treatment with Medication for Opioid Use Disorders (MOUD) H-95.913
1. Our AMA affirms: (a) that no physician or medical student should be presumed to be impaired by substance or illness solely because they are diagnosed with a substance use disorder; and (b) that no physician or medical student should be presumed impaired because they and their treating physician have chosen medication for opioid use disorder (MOUD) to address the substance use disorder, including but not limited to methadone and buprenorphine.
2. Our AMA strongly encourages the leadership of physician health and wellness programs, state medical boards, hospital and health system credentialing bodies, and employers to help end stigma and discrimination against physicians and medical students with substance use disorders and allow and encourage the usage of medication for opioid use disorder (MOUD), including but not limited to methadone or buprenorphine, when clinically appropriate and as determined by the physician or medical student (as patient) and their treating physician, without penalty (such as restriction of privileges, licensure, ability to prescribe medications or other treatments, or other limits on their ability to practice medicine), solely because the physician's or medical student's treatment plan includes MOUD.
3. Our AMA will survey physician health programs and state medical boards and report back about the prevalence of MOUD among physicians under monitoring for OUD, types of MAT utilized, and practice limitations or other punitive measures, if any, imposed solely on the basis of medication choice.
Citation: Res. 001, A-21

Educating Physicians About Physician Health Programs and Advocating for Standards D-405.990
Our AMA will:
(1) work closely with the Federation of State Physician Health Programs (FSPHP) to educate our members as to the availability and services of state physician health programs to continue to create opportunities to help ensure physicians and medical students are fully knowledgeable about the purpose of physician health programs and the relationship that exists between the physician health program and the licensing authority in their state or territory;
(2) continue to collaborate with relevant organizations on activities that address physician health and wellness;
(3) in conjunction with the FSPHP, develop state legislative guidelines addressing the design and implementation of physician health programs;
(4) work with FSPHP to develop messaging for all Federation members to consider regarding elimination of stigmatization of mental illness and illness in general in physicians and physicians in training;
(5) continue to work with and support FSPHP efforts already underway to design and implement the physician health program review process, Performance Enhancement and Effectiveness Review (PEER™), to improve accountability, consistency and excellence among its state member PHPs. The AMA will partner with the FSPHP to help advocate for additional national sponsors for this project; and
(6) continue to work with the FSPHP and other appropriate stakeholders on issues of affordability, cost effectiveness, and diversity of treatment options.

Citation: Res. 402, A-09; Modified: CSAPH Rep. 2, A-11; Reaffirmed in lieu of Res. 412, A-12; Appended: BOT action in response to referred for decision Res. 403, A-12; Reaffirmed: BOT Rep. 15, A-19; Modified: Res. 321, A-19

Physician Impairment H-95.955
(1) The AMA defines physician impairment as any physical, mental or behavioral disorder that interferes with ability to engage safely in professional activities and will address all such conditions in its Physician Health Program.
(2) The AMA encourages state medical society-sponsored physician health and assistance programs to take appropriate steps to address the entire range of illnesses with the potential to cause impairment that affect physicians, to develop case finding mechanisms for all types of physician impairments, and to collect data on the prevalence of conditions affecting physician health.
(3) The AMA encourages additional research in the area of physician illness with the potential to cause impairment, particularly in the type and impact of external factors adversely affecting physicians, including workplace stress, litigation issues, and restructuring of the health care delivery systems.
Citation: CSA Rep. 1, A-95; Reaffirmed: BOT Rep. 17, I-99; Reaffirmed: CSAPH Rep. 1, A-09; Reaffirmed: BOT Rep. 15, A-19; Modified: CSAPH Rep. 01, A-19

Support the Elimination of Barriers to Medication-Assisted Treatment for Substance Use Disorder D-95.968
1. Our AMA will: (a) advocate for legislation that eliminates barriers to, increases funding for, and requires access to all appropriate FDA-approved medications or therapies used by licensed drug treatment clinics or facilities; and (b) develop a public awareness campaign to increase awareness that medical treatment of substance use disorder with medication-assisted treatment is a first-line treatment for this chronic medical disease.
2. Our AMA supports further research into how primary care practices can implement medication-assisted treatment (MAT) into their practices and disseminate such research in coordination with primary care specialties.
3. The AMA Opioid Task Force will increase its evidence-based educational resources focused on methadone maintenance therapy (MMT) and publicize those resources to the Federation.
Citation: Res. 222, A-18; Appended: BOT Rep. 02, I-19

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 213
(A-22)

Introduced by: Michigan

Subject: Resentencing for Individuals Convicted of Marijuana-Based Offenses

Referred to: Reference Committee B

Whereas, Incarceration is a key issue under the domain of Social and Community Context in the Social Determinants of Health topic area of Healthy People 2020 due to numerous disparities in inmate mental and physical health compared to the population, as well as the increased rate of mental health disorders in the children of incarcerated parents; and

Whereas, There is a clear link between incarceration and health, with incarcerated individuals showing higher risk of chronic conditions such as cardiovascular disease, hypertension, and cancer compared to the general population; a study in March 2013 found that each additional year an individual spends in prison corresponds with a decline in life expectancy by two years; and

Whereas, Incarcerated populations are particularly vulnerable to the coronavirus disease 2019 (COVID-19) given the demographics of those experiencing incarceration in addition to the inability to properly "social distance", high population turnover, unsanitary living conditions, poor ventilation systems, inability or inadequacy to properly test and track COVID-19 cases and exposure which have led to an estimated 113,664 COVID-19 cases and 887 related deaths among incarcerated people as of August 2020; and

Whereas, Arrests for marijuana possession, regardless of whether the person was later convicted on these charges, have been shown to negatively impact opportunities such as finding employment, housing, and obtaining student loans, which can lead to widespread and multifactorial individual health consequences; furthermore, criminalization of drug use is associated with increased stigma and discrimination of drug users and that stigma and discrimination is also a causal factor for decreased mental and physical health; and

Whereas, Nationally, African Americans are three times more likely to be arrested for marijuana possession than Whites, a finding that cannot be explained by differences in use; and

Whereas, A 2014 report by the National Research Council found that mandatory minimum sentences for drug offenders “have few, if any, deterrent effects;” and

Whereas, Eighteen states, two territories, and the District of Columbia have legalized the use of recreational and medicinal marijuana, and in the past four years, 23 states have passed laws addressing expungement of certain marijuana convictions, pairing these laws with other policies to its decriminalization or legalization; and

Whereas, In 2018, California became the first state to enact legislation ordering its Department of Justice to conduct a review of criminal records and identify past convictions eligible for sentence dismissal or re-designation in accordance with the Adult Use of Marijuana Act; the outcomes of this legislation showed that reductions in criminal penalties for drug possession

reduce racial and ethnic disparities in the criminal justice system, allowing for improvements in health inequalities linked to social determinants of health; and

Whereas, Illinois passed a bill in May 2019, to expunge convictions for non-violent crimes of possession, manufacturing, and distribution of up to 30 grams and possession up to 500 grams, and Colorado and Massachusetts have approved legislation allowing individuals convicted for possession to petition to seal criminal records of misdemeanor offenses that are no longer considered crimes; and

Whereas, A recent study examining the impact of this type of expungement found that those who do obtain expungement have extremely low subsequent crime rates and experience a significant increase in their wage and employment trajectories and an overall positive impact on the lives of those affected; however, of those legally eligible for expungement, only 6.5 percent obtain it within five years of eligibility, findings that support the development of “automatic” expungement procedures; and

Whereas, Those who have received resentencing for past offenses, including decriminalized marijuana-based charges, have experienced an increase of 22 percent in wages on average within one year of resentencing as well as lower subsequent crime rates that compare favorably to the general population; and

Whereas, Our AMA has policy (H-95.924) supporting public health-based strategies, rather than incarceration, in the handling of individuals possessing cannabis for personal us and encouraging research on the impact of legalization and decriminalization of cannabis in an effort to promote public health and public safety; and

Whereas, Legislation has been considered at the federal level to, among other provisions, remove marijuana from the list of controlled substances under the Controlled Substances Act and create an opportunity for individuals with marijuana law convictions to petition for expungement and resentencing; therefore be it

RESOLVED, That our American Medical Association adopt policy supporting the expungement, destruction, or sealing of criminal records for marijuana offenses that would now be considered legal (New HOD Policy); and be it further

RESOLVED, That our AMA adopt policy supporting the elimination of violations or other penalties for persons under parole, probation, pre-trial, or other state or local criminal supervision for a marijuana offense that would now be considered legal. (New HOD Policy)

Fiscal Note: Minimal - less than $1,000

Received: 04/08/22

Sources:

1. N. R. Council, The Growth of Incarceration in the United States. Washington, D.C.: National Academies Press, 2014.
2. P. Trust, “More Imprisonment Does Not Reduce State Drug Problems,” 2018.
3. State Medical Marijuana Laws, NCSL. Accessed at: https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
4. “Incarceration | Healthy People 2020.” [Online]. Available: https://www.healthypeople.gov/2020/topics-objectives/topic/social-determinants-health/interventions-resources/incarceration. [Accessed: 31-Jan-2020].
5. N. Freudenberg, “Jails, prisons, and the health of urban populations: A review of the impact of the correctional system on community health,” Journal of Urban Health, vol. 78, no. 2. pp. 214-235, 2001, doi: 10.1093/jurban/78.2.214.
6. E. J. Patterson, “The dose-response of time served in prison on mortality: New York State, 1989-2003,” Am. J. Public Health, vol. 103, no. 3, pp. 523-528, Mar. 2013, doi: 10.2105/AJPH.2012.301148.
7. M. Massoglia and B. Remster, “Linkages Between Incarceration and Health.” Public Health Rep., vol. 134, no. 1_suppl, pp. 8S-14S, doi: 10.1177/0033354919826563.
8. C. Strassle et al., "Covid-19 Vaccine Trials and Incarcerated People: The Ethics of Inclusion," N. Engl. J. Med., vol. 383, no. 20, pp. 1897-1899, Nov. 2020, doi: 10.1056/nejmp2025955.
9. C. Franco-Paredes et al., "Decarceration and community re-entry in the COVID-19 era," The Lancet Infectious Diseases, vol. 21, no. 1. Lancet Publishing Group, pp. e11-16, 01-Jan-2021, doi: 10.1016/S1473-3099(20)30730-1.
10. S. Burris, “Disease Stigma in U.S. Public Health Law,” J. Law, Med. Ethics, vol. 30, no. 2, pp. 179-190, Jun. 2002, doi: 10.1111/j.1748-720X.2002.tb00385.x.
11. J. Ahern, J. Stuber, and S. Galea, Stigma, discrimination and the health of illicit drug users,” Drug Alcohol Depend., vol. 88, no. 2-3, pp. 188-196, May 2007, doi: 10.1016/J.DRUGALCDEP.2006.10.014.
12. G. Taras, “High Time for Change: How Legalizing Marijuana Could Help Narrow the Racial Divide in the United States,” Comp. L., vol. 24, pp. 565-598, 2016, doi: 10.3868/s050-004-015-0003-8.
13. D. J. Roelfs, E. Shor, K. W. Davidson, and J. E. Schwartz, “Losing life and livelihood: A systematic review and meta-analysis of unemployment and all-cause mortality,” Soc. Sci. Med., vol. 72, no. 6, pp. 840-854, Mar. 2011, doi: 10.1016/j.socscimed.2011.01.005.
14. B. Graetz, “Health consequences of employment and unemployment: Longitudinal evidence for young men and women,” Soc. Sci. Med., vol. 36, no. 6, pp. 715-724, Mar. 1993, doi: 10.1016/0277-9536(93)90032-Y.
15. National Conference of State Legislatures, “Marijuana Overview,” 2018.
16. D. Schlussel, "Marijuana expungement accelerates across the country," Collateral Consequences of Criminal Conviction and Restoration of Rights, 20-Nov-2020.
17. S. Rense, "15 States, D.C. Legalized Weed U.S. - Where Is Marijuana Legal 2020?," Esquire, 04-Nov-2020.
18. A. C. Mooney et al., “Racial/Ethnic Disparities in Arrests for Drug Possession After California Proposition 47, 2011-2016,” Am. J. Public Health, vol. 108, no. 8, pp. 987-993, Aug. 2018, doi: 10.2105/AJPH.2018.304445.
19. A. Bonta, S. Skinner, S. Wiener, A. Gonzalez Fletcher, and A. Quirk, An act to add Section 11361.9 to the Health and Safety Code, relating to cannabis. California Secretary of State, 2018.
20. Illinois, HB1438: Adult Use Cannabis Summary. 2019, pp. 1-14.
21. J. J. Prescott and S. B. Starr, “Expungement of Criminal Convictions: An Empirical Study,” SSRN Electron. J., Mar. 2019, doi: 10.2139/ssrn.3353620.
22. A. Knopf, “Legalization of marijuana takes another step forward,” Alcohol. Drug Abus. Wkly., vol. 31, no. 45, pp. 5-6, Nov. 2019, doi: 10.1002/adaw.32550.
23. Harris, Booker, Merkley, Wyden, and Warren, S. 2227: MORE Act of 2019 (Introduced version). 2019.
24. Congressional Research Service, “The MORE Act: House Plans Historic Vote on Federal Marijuana Legalization,” Nov. 2020.

RELEVANT AMA POLICY

Cannabis Legalization for Adult Use (commonly referred to as recreational use) H-95.924
Our AMA: (1) believes that cannabis is a dangerous drug and as such is a serious public health concern; (2) believes that the sale of cannabis for adult use should not be legalized (with adult defined for these purposes as age 21 and older); (3) discourages cannabis use, especially by persons vulnerable to the drug's effects and in high-risk populations such as youth, pregnant women, and women who are breastfeeding; (4) believes states that have already legalized cannabis (for medical or adult use or both) should be required to take steps to regulate the product effectively in order to protect public health and safety including but not limited to: regulating retail sales, marketing, and promotion intended to encourage use; limiting the potency of cannabis extracts and concentrates; requiring packaging to convey meaningful and easily understood units of consumption, and requiring that for commercially available edibles, packaging must be child-resistant and come with messaging about the hazards about unintentional ingestion in children and youth; (5) laws and regulations related to legalized cannabis use should consistently be evaluated to determine their effectiveness; (6) encourages local, state, and federal public health agencies to improve surveillance efforts to ensure data is available on the short- and long-term health effects of cannabis, especially emergency department visits and hospitalizations, impaired driving, workplace impairment and worker-related injury and safety, and prevalence of psychiatric and addictive disorders, including cannabis use disorder; (7) supports public health based strategies, rather than incarceration, in the handling of individuals possessing cannabis for personal use; (8) encourages research on the impact of legalization and decriminalization of cannabis in an effort to promote public health and public safety; (9) encourages dissemination of information on the public health impact of legalization and decriminalization of cannabis; (10) will advocate for stronger public health messaging on the health effects of cannabis and cannabinoid inhalation and ingestion, with an emphasis on reducing initiation and frequency of cannabis use among adolescents, especially high potency products; use among women who are pregnant or contemplating pregnancy; and avoiding cannabis-impaired driving; (11) supports social equity programs to address the impacts of cannabis prohibition and enforcement policies that have disproportionately impacted marginalized and minoritized communities; and (12) will coordinate with other health organizations to develop resources on the impact of cannabis on human health and on methods for counseling and educating patients on the use cannabis and cannabinoids.
Citation: CSAPH Rep. 05, I-17; Appended: Res. 913, I-19; Modified: CSAPH Rep. 4, I-20

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 214
(A-22)

Introduced by: Ohio

Subject: Eliminating Unfunded or Unproven Mandates and Regulations

Referred to: Reference Committee B

Whereas, Beginning in 2020, Centers for Medicare and Medicaid Services (CMS) will be demanding that “providers” utilize approved “technology” using practice guidelines when ordering imaging studies; and

Whereas, Such guidelines represent an unfunded mandate for physicians already struggling with massive governmental regulatory burden and underpayment; and

Whereas, These technologies or “Augmented Intelligence,” are limited in their ability to apply clinical context, thus limiting a physician’s ability to order appropriate testing under unique circumstances and stagnating their work-flow, placing patients at risk; and

Whereas, The technology required for this mandatory decision support is extremely expensive, especially for smaller and independent physician practices; therefore be it

RESOLVED, That our American Medical Association advocate for policies that allow for physician judgment and documented medical decision-making to supersede government regulation--including the utilization of Augmented Intelligence--in instances of disputes in patient care (Directive to Take Action); and be it further

RESOLVED, That our AMA advocate for policies that require “proof of concept,” in the form of independently demonstrated quality improvement, prior to the implementation of any government, insurance company or other third party mandate or regulation on patient care and the physician-patient relationship (Directive to Take Action); and be it further

RESOLVED, That our AMA advocate for policies requiring government, insurance company or other third party entities to fully fund any mandates or regulations imposed on patient care and the physician-patient relationship. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 04/08/22

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 215
(A-22)

Introduced by: American College of Cardiology, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography

Subject: Transforming Professional Licensure to the 21st Century

Referred to: Reference Committee B

Whereas, The US Supreme Court in 1889 affirmed the power of individual states to regulate medical practice within their borders, in conjunction with the exercise of appropriate professional responsibility by local medical societies and all practicing physicians, to protect the public health and safety; and

Whereas, The Flexner Report of 1911 transformed the nature and process of medical education in America to a comprehensive national standard, with national medical board examinations, nationally accredited residency programs and national certifications from medical specialty boards; and

Whereas, Individual state medical boards, having verified an applicant's standardized general medical training, professional character and compliance with local state regulations, issue broad general medical licenses which are not specialty specific nor tailored to anticipated need for direct physical interaction or face-to-face contact between the patient and the professional being licensed; and

Whereas, Individual state medical boards also evaluate a licensed physician's ongoing professional conduct, reviewing complaints from patients, malpractice data, information from hospitals and other health care institution and reports from government agencies, imposing discipline as necessary to protect the public; and

Whereas, Congress established the National Practitioner Data Bank in 1986 as a nationwide repository for reports containing information on medical malpractice payments and certain adverse actions related to health care practitioners, providers, and suppliers in order to improve health care quality, protect the public and reduce health care fraud and abuse, preventing practitioners from moving state to state without disclosure or discovery of previous damaging performance; and

Whereas, The Federation of State Medical Boards, the Federation Credential Verification Service, the National Board of Medical Examiners, the Interstate Medical Licensing Compact and other national organizations serve to streamline and facilitate collaboration among the 70 independent state-based medical boards authorized to regulate medical practice within their borders; and

Whereas, Current state licensing procedures, while constantly improving, fail to promote efficient use of modern telecommunication and delivery of a broad range of health care services across state lines, are unnecessarily complex, nonuniform, redundant, expensive, time

consuming, and poorly focused on actual patient care, resulting in the inhibition of free flow of professional expertise and services across state lines; and

Whereas, Telemedicine has developed rapidly over the last decades into an integrated system of healthcare delivery that incorporates many different remote diagnostic and monitoring devices and other technologies that are not dependent on in-person or face-to-face patient encounters; and

Whereas, Incentives to reduce the high cost of medical care have led to shorter hospital stays, increased use of outpatient facilities and home care with less intense in-person physician supervision, and more frequent collaborative care delivered by non-physician professionals; and

Whereas, Telemedicine has been proven effective in many scenarios, in remote or rural settings, urban areas with limited public transportation, in nursing homes, detention centers, prisons, and for people with physical and mental disabilities limiting their mobility; and

Whereas, The use of telemedicine has grown exponentially during the COVID pandemic to protect both patients and caregivers from spread of infectious disease; and

Whereas, Telemedicine may be especially helpful in addressing disparities in access to medical care based on economic, racial, ethnic, and geographic factors; and

Whereas, There is a worsening shortage of physicians particularly in rural or urban communities that lack comprehensive, supportive, up-to-date medical services and cultural, educational, and recreational amenities outside the workplace; and

Whereas, Current AMA policy H-480.969 requires full and unrestricted licensure in the state of residence where telemedicine is practiced, where the patient is physically located, with certain exceptions; and

Whereas, Current AMA policy H-160.950 requires a physician to be responsible for managing the health care of patients in all practice settings, including medication prescriptive authority, and to be immediately available at all times for supervision and consultation by a nurse practitioner; and

Whereas, Half of the states allow nurse practitioners to practice independently without physician supervision; and

Whereas, 70% of physicians are now employed by large groups, hospitals, private capital groups, insurance companies and ERISA-qualified managed care organizations which often care for patients in many states and employ non-physicians to assist in patient care, using many varying protocols for physician supervision of non-physician professionals, and assessment of an individual physician's competence; and

Whereas, Recent and continuing changes in the ownership and structure of physician practice can raise licensing issues related to conflicts of interest, anti-competitive activity, restraint of trade and interference with interstate commerce related to restriction of physician licensing; and

Whereas, Policy objectives for licensing and interstate health care delivery should incorporate the best practices of individual states, recognizing rapid evolution in the structure of health care delivery including current capabilities of telemedicine in various medical specialties and by non-physician professionals, into a single comprehensive policy that promotes accessible, quality,

affordable, appropriately accredited and accountable care, distributed to all members of our society; therefore be it

RESOLVED, That our American Medical Association address the issue of state licensure in a comprehensive manner including studying the best mechanisms to ensure interstate licensure for practitioners practicing in multiple states, optimizing state licensure practices to allow for seamless telemedicine practice across state lines, and addressing long delays in practitioners obtaining state licensures which lead to delays in medical care (Directive to Take Action); and be it further

RESOLVED, That our AMA research the feasibility of convening a meeting of appropriate stakeholders, including but not limited to state medical boards, medical specialty societies, state medical societies, payers, organizations representing non-physician medical professionals, Centers for Medicare and Medicaid Services-approved accrediting agencies, and patients to develop recommendations to modernize the state medical licensure system including creating mechanisms for multi-state licensure, streamlining the process of obtaining medical licensure, and facilitate practice across state lines (Directive to Take Action); and be it further

RESOLVED, That our AMA report back on these recommendations by the 2022 Interim Meeting. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 04/06/22

RELEVANT AMA POLICY

Guidelines for Integrated Practice of Physician and Nurse Practitioner H-160.950
Our AMA endorses the following guidelines and recommends that these guidelines be considered and quoted only in their entirety when referenced in any discussion of the roles and responsibilities of nurse practitioners: (1) The physician is responsible for the supervision of nurse practitioners and other advanced practice nurses in all settings.
(2) The physician is responsible for managing the health care of patients in all practice settings.
(3) Health care services delivered in an integrated practice must be within the scope of each practitioner's professional license, as defined by state law.
(4) In an integrated practice with a nurse practitioner, the physician is responsible for supervising and coordinating care and, with the appropriate input of the nurse practitioner, ensuring the quality of health care provided to patients.
(5) The extent of involvement by the nurse practitioner in initial assessment, and implementation of treatment will depend on the complexity and acuity of the patients' condition, as determined by the supervising/collaborating physician.
(6) The role of the nurse practitioner in the delivery of care in an integrated practice should be defined through mutually agreed upon written practice protocols, job descriptions, and written contracts.
(7) These practice protocols should delineate the appropriate involvement of the two professionals in the care of patients, based on the complexity and acuity of the patients' condition.
(8) At least one physician in the integrated practice must be immediately available at all times for supervision and consultation when needed by the nurse practitioner.
(9) Patients are to be made clearly aware at all times whether they are being cared for by a physician or a nurse practitioner.
(10) In an integrated practice, there should be a professional and courteous relationship between physician and nurse practitioner, with mutual acknowledgment of, and respect for each other's contributions to patient care.
(11) Physicians and nurse practitioners should review and document, on a regular basis, the care of all patients with whom the nurse practitioner is involved. Physicians and nurse practitioners must work closely enough together to become fully conversant with each other's practice patterns.
Citation: (CMS Rep. 15 - I-94; BOT Rep. 6, A-95; Reaffirmed: Res. 240, A-00; Reaffirmation A-00; Reaffirmed: BOT Rep. 28, A-09; Reaffirmed: BOT Rep. 9, I-11; Reaffirmed: Joint CME-CMS Rep., I-12; Reaffirmed: BOT Rep. 16, A-13)

Independent Practice of Medicine by Advanced Practice Registered Nurses H-35.988
Our AMA, in the public interest, opposes enactment of legislation to authorize the independent practice of medicine by any individual who has not completed the states requirements for licensure to engage in the practice of medicine

and surgery in all of its branches. Our AMA opposes enactment of the Advanced Practice Registered Nurse (APRN) Multistate Compact, due to the potential of the APRN Compact to supersede state laws that require APRNs to practice under physician supervision, collaboration or oversight.
Citation: Sub. Res. 53, I-82; Reaffirmed: A-84; Reaffirmed: CLRPD Rep. A, I-92; Reaffirmed: BOT Rep. 28, A-03; Reaffirmed: BOT Rep. 9, I-11; Modified: Res. 214, I-17; Modified: BOT Rep. 15, A-18

Physician Assistants and Nurse Practitioners H-160.947
Our AMA will develop a plan to assist the state and local medical societies in identifying and lobbying against laws that allow advanced practice nurses to provide medical care without the supervision of a physician.
The suggested Guidelines for Physician/Physician Assistant Practice are adopted to read as follows (these guidelines shall be used in their entirety):
(1) The physician is responsible for managing the health care of patients in all settings.
(2) Health care services delivered by physicians and physician assistants must be within the scope of each practitioner's authorized practice, as defined by state law.
(3) The physician is ultimately responsible for coordinating and managing the care of patients and, with the appropriate input of the physician assistant, ensuring the quality of health care provided to patients.
(4) The physician is responsible for the supervision of the physician assistant in all settings.
(5) The role of the physician assistant in the delivery of care should be defined through mutually agreed upon guidelines that are developed by the physician and the physician assistant and based on the physician's delegatory style.
(6) The physician must be available for consultation with the physician assistant at all times, either in person or through telecommunication systems or other means.
(7) The extent of the involvement by the physician assistant in the assessment and implementation of treatment will depend on the complexity and acuity of the patient's condition and the training, experience, and preparation of the physician assistant, as adjudged by the physician.
(8) Patients should be made clearly aware at all times whether they are being cared for by a physician or a physician assistant.
(9) The physician and physician assistant together should review all delegated patient services on a regular basis, as well as the mutually agreed upon guidelines for practice.
(10) The physician is responsible for clarifying and familiarizing the physician assistant with his/her supervising methods and style of delegating patient care.
Citation: BOT Rep. 6, A-95; Reaffirmed: Res 240 and Reaffirmation A-00; Reaffirmed: Res. 213, A-02; Modified: CLRPD Rep. 1, A-03; Reaffirmed: BOT Rep. 9, I-11; Reaffirmed: Joint CME-CMS Rep., I-12; Reaffirmed: BOT Rep. 16, A-13

Opposition to the Department of Veterans Affairs Proposed Rulemaking on APRN Practices D-35.979
1. Our AMA will express to the U.S. Department of Veterans Affairs (VA) that the plan to substitute physicians by using Advanced Practice Registered Nurses (APRNs) in independent practice, not in physician-led teams, is antithetical to multiple established policies of our AMA and thus should not be implemented.
2. Our AMA staff will assess the feasibility of seeking federal legislation that prevents the VA from enacting regulations for veterans' medical care that is not consistent with physician-led health care teams or to mandate that the VA adopt policy regarding the same.
3. Our AMA will call upon Congress and the Administration to disapprove or otherwise overturn rules and regulations at the federal level that would expand the scope of practice of APRNs, and comment to the Director of Regulation Management within the Department of Veterans Affairs of this position during the current comment period.
4. Our AMA will collaborate with other medical professional organizations to vigorously oppose the final adoption of the VA's proposed rulemaking expanding the role of APRNs within the VA.
Citation: Res. 239, A-16

COVID-19 Emergency and Expanded Telemedicine Regulations D-480.963
Our AMA: (1) will continue to advocate for the widespread adoption of telehealth services in the practice of medicine for physicians and physician-led teams post SARS-COV-2; (2) will advocate that the Federal government, including the Centers for Medicare & Medicaid Services (CMS) and other agencies, state governments and state agencies, and the health insurance industry, adopt clear and uniform laws, rules, regulations, and policies relating to telehealth services that: (a) provide equitable coverage that allows patients to access telehealth services wherever they are located, and (b) provide for the use of accessible devices and technologies, with appropriate privacy and security protections, for connecting physicians and patients; (3) will advocate for equitable access to telehealth services, especially for at-risk and under-resourced patient populations and communities, including but not limited to supporting increased funding and planning for telehealth infrastructure such as broadband and internet-connected devices for both physician practices and patients; and (4) supports the use of telehealth to reduce health disparities and promote access to health care.
Citation: Alt. Res. 203, I-20; Reaffirmed: CMS Rep. 7, A-21

Increasing Access to Broadband Internet to Reduce Health Disparities H-478.980

Our AMA will advocate for the expansion of broadband and wireless connectivity to all rural and underserved areas of the United States while at all times taking care to protecting existing federally licensed radio services from harmful interference that can be caused by broadband and wireless services.
Citation: Res. 208, I-18; Reaffirmed: CMS Rep. 7, A-21

Established Patient Relationships and Telemedicine D-480.964
Our AMA will:
1) work with state medical associations to encourage states that are not part of the Interstate Medical Licensure Compact to consider joining the Compact as a means of enhancing patient access to and proper regulation of telemedicine services;
(2) advocate to the Interstate Medical Licensure Compact Commission and Federation of State Medical Boards for reduced application fees and secondary state licensure(s) fees processed through the Interstate Medical Licensure Compact;
(3) work with interested state medical associations to encourage states to pass legislation enhancing patient access to and proper regulation of telemedicine services, in accordance with AMA Policy H-480.946, "Coverage of and Payment for Telemedicine"; and
(4) continue to support state efforts to expand physician licensure recognition across state lines in accordance with the standards and safeguards outlined in Policy H-480.946.
Citation: CMS Rep. 1, I-19; Appended: CMS Rep. 8, A-21

State Authority and Flexibility in Medical Licensure for Telemedicine D-480.999
Our AMA will continue its opposition to a single national federalized system of medical licensure.
Citation: (CME Rep. 7, A-99; Reaffirmed and Modified: CME Rep. 2, A-09; Reaffirmed in lieu of Res. 920, I-13; Reaffirmed: BOT Rep. 3, I-14)

Principles of and Actions to Address Primary Care Workforce H-200.949
1. Our patients require a sufficient, well-trained supply of primary care physicians--family physicians, general internists, general pediatricians, and obstetricians/gynecologists--to meet the nation’s current and projected demand for health care services.
2. To help accomplish this critical goal, our American Medical Association (AMA) will work with a variety of key stakeholders, to include federal and state legislators and regulatory bodies; national and state specialty societies and medical associations, including those representing primary care fields; and accreditation, certification, licensing, and regulatory bodies from across the continuum of medical education (undergraduate, graduate, and continuing medical education).
3. Through its work with these stakeholders, our AMA will encourage development and dissemination of innovative models to recruit medical students interested in primary care, train primary care physicians, and enhance both the perception and the reality of primary care practice, to encompass the following components: a) Changes to medical school admissions and recruitment of medical students to primary care specialties, including counseling of medical students as they develop their career plans; b) Curriculum changes throughout the medical education continuum; c) Expanded financial aid and debt relief options; d) Financial and logistical support for primary care practice, including adequate reimbursement, and enhancements to the practice environment to ensure professional satisfaction and practice sustainability; and e) Support for research and advocacy related to primary care.
4. Admissions and recruitment: The medical school admissions process should reflect the specific institution’s mission. Those schools with missions that include primary care should consider those predictor variables among applicants that are associated with choice of these specialties.
5. Medical schools, through continued and expanded recruitment and outreach activities into secondary schools, colleges, and universities, should develop and increase the pool of applicants likely to practice primary care by seeking out those students whose profiles indicate a likelihood of practicing in primary care and underserved areas, while establishing strict guidelines to preclude discrimination.
6. Career counseling and exposure to primary care: Medical schools should provide to students career counseling related to the choice of a primary care specialty, and ensure that primary care physicians are well-represented as teachers, mentors, and role models to future physicians.
7. Financial assistance programs should be created to provide students with primary care experiences in ambulatory settings, especially in underserved areas. These could include funded preceptorships or summer work/study opportunities.
8. Curriculum: Voluntary efforts to develop and expand both undergraduate and graduate medical education programs to educate primary care physicians in increasing numbers should be continued. The establishment of appropriate administrative units for all primary care specialties should be encouraged.
9. Medical schools with an explicit commitment to primary care should structure the curriculum to support this objective. At the same time, all medical schools should be encouraged to continue to change their curriculum to put more emphasis on primary care.
10. All four years of the curriculum in every medical school should provide primary care experiences for all students, to feature increasing levels of student responsibility and use of ambulatory and community-based settings.

11. Federal funding, without coercive terms, should be available to institutions needing financial support to expand resources for both undergraduate and graduate medical education programs designed to increase the number of primary care physicians. Our AMA will advocate for public (federal and state) and private payers to a) develop enhanced funding and related incentives from all sources to provide education for medical students and resident/fellow physicians, respectively, in progressive, community-based models of integrated care focused on quality and outcomes (such as the patient-centered medical home and the chronic care model) to enhance primary care as a career choice; b) fund and foster innovative pilot programs that change the current approaches to primary care in undergraduate and graduate medical education, especially in urban and rural underserved areas; and c) evaluate these efforts for their effectiveness in increasing the number of students choosing primary care careers and helping facilitate the elimination of geographic, racial, and other health care disparities.
12. Medical schools and teaching hospitals in underserved areas should promote medical student and resident/fellow physician rotations through local family health clinics for the underserved, with financial assistance to the clinics to compensate their teaching efforts.
13. The curriculum in primary care residency programs and training sites should be consistent with the objective of training generalist physicians. Our AMA will encourage the Accreditation Council for Graduate Medical Education to (a) support primary care residency programs, including community hospital-based programs, and (b) develop an accreditation environment and novel pathways that promote innovations in graduate medical education, using progressive, community-based models of integrated care focused on quality and outcomes (such as the patient-centered medical home and the chronic care model).
14. The visibility of primary care faculty members should be enhanced within the medical school, and positive attitudes toward primary care among all faculty members should be encouraged.
15. Support for practicing primary care physicians: Administrative support mechanisms should be developed to assist primary care physicians in the logistics of their practices, along with enhanced efforts to reduce administrative activities unrelated to patient care, to help ensure professional satisfaction and practice sustainability.
16. There should be increased financial incentives for physicians practicing primary care, especially those in rural and urban underserved areas, to include scholarship or loan repayment programs, relief of professional liability burdens, and Medicaid case management programs, among others. Our AMA will advocate to state and federal legislative and regulatory bodies, among others, for development of public and/or private incentive programs, and expansion and increased funding for existing programs, to further encourage practice in underserved areas and decrease the debt load of primary care physicians. The imposition of specific outcome targets should be resisted, especially in the absence of additional support to the schools.
17. Our AMA will continue to advocate, in collaboration with relevant specialty societies, for the recommendations from the AMA/Specialty Society RVS Update Committee (RUC) related to reimbursement for E&M services and coverage of services related to care coordination, including patient education, counseling, team meetings and other functions; and work to ensure that private payers fully recognize the value of E&M services, incorporating the RUC-recommended increases adopted for the most current Medicare RBRVS.
18. Our AMA will advocate for public (federal and state) and private payers to develop physician reimbursement systems to promote primary care and specialty practices in progressive, community-based models of integrated care focused on quality and outcomes such as the patient-centered medical home and the chronic care model consistent with current AMA Policies H-160.918 and H-160.919.
19. There should be educational support systems for primary care physicians, especially those practicing in underserved areas.
20. Our AMA will urge urban hospitals, medical centers, state medical associations, and specialty societies to consider the expanded use of mobile health care capabilities.
21. Our AMA will encourage the Centers for Medicare & Medicaid Services to explore the use of telemedicine to improve access to and support for urban primary care practices in underserved settings.
22. Accredited continuing medical education providers should promote and establish continuing medical education courses in performing, prescribing, interpreting and reinforcing primary care services.
23. Practicing physicians in other specialties--particularly those practicing in underserved urban or rural areas--should be provided the opportunity to gain specific primary care competencies through short-term preceptorships or postgraduate fellowships offered by departments of family medicine, internal medicine, pediatrics, etc., at medical schools or teaching hospitals. In addition, part-time training should be encouraged, to allow physicians in these programs to practice concurrently, and further research into these concepts should be encouraged.
24. Our AMA supports continued funding of Public Health Service Act, Title VII, Section 747, and encourages advocacy in this regard by AMA members and the public.
25. Research: Analysis of state and federal financial assistance programs should be undertaken, to determine if these programs are having the desired workforce effects, particularly for students from disadvantaged groups and those that are underrepresented in medicine, and to gauge the impact of these programs on elimination of geographic, racial, and other health care disparities. Additional research should identify the factors that deter students and physicians from choosing and remaining in primary care disciplines. Further, our AMA should continue to monitor trends in the choice of a primary care specialty and the availability of primary care graduate medical education positions. The results of these and related research endeavors should support and further refine AMA policy to enhance primary care as a career choice.
Citation: CME Rep. 04, I-18

Telemedicine Encounters by Third Party Vendors D-480.968
1. Our AMA will develop model legislation and/or regulations requiring telemedicine services or vendors to coordinate care with the patient's medical home and/or existing treating physicians, which includes at a minimum identifying the patient's existing medical home and/or treating physicians and providing to the treating physician a copy of the medical record, with the patient's consent.
2. The model legislation and/or regulations will also require the vendor to abide by laws addressing the privacy and security of patients' medical information
3. Our AMA will include in that model state legislation the following concepts based on AMA policy: (a) A valid patient-physician relationship must be established before the provision of telemedicine services; (b) Physicians and other health practitioners delivering telemedicine services must be licensed in the state where the patient receives services, or be providing these services as otherwise authorized by that state's medical board; and (c) The standards and scope of telemedicine services should be consistent with related in-person services.
4. Our AMA will educate and advocate to AMA members on the use and implementation of telemedicine and other related technology in their practices to improve access, convenience, and continuity of care for their patients.
Citation: Res. 234, A-16

The Promotion of Quality Telemedicine H-480.969
(1) It is the policy of the AMA that medical boards of states and territories should require a full and unrestricted license in that state for the practice of telemedicine, unless there are other appropriate state-based licensing methods, with no differentiation by specialty, for physicians who wish to practice telemedicine in that state or territory. This license category should adhere to the following principles:
(a) exemption from such a licensure requirement for physician-to-physician consultations;
(b) exemption from such a licensure requirement for telemedicine practiced across state lines in the event of an emergent or urgent circumstance, the definition of which for the purposes of telemedicine should show substantial deference to the judgment of the attending and consulting physicians as well as to the views of the patient;
(c) allowances, by exemption or other means, for out-of-state physicians providing continuity of care to a patient, where there is an established ongoing relationship and previous in-person visits, for services incident to an ongoing care plan or one that is being modified; and
(d) application requirements that are non-burdensome, issued in an expeditious manner, have fees no higher than necessary to cover the reasonable costs of administering this process, and that utilize principles of reciprocity with the licensure requirements of the state in which the physician in question practices.
(2) The AMA urges the FSMB and individual states to recognize that a physician practicing certain forms of telemedicine (e.g., teleradiology) must sometimes perform necessary functions in the licensing state (e.g., interaction with patients, technologists, and other physicians) and that the interstate telemedicine approach adopted must accommodate these essential quality-related functions.
(3) The AMA urges national medical specialty societies to develop and implement practice parameters for telemedicine in conformance with: Policy 410.973 (which identifies practice parameters as "educational tools"); Policy 410.987 (which identifies practice parameters as "strategies for patient management that are designed to assist physicians in clinical decision making," and states that a practice parameter developed by a particular specialty or specialties should not preclude the performance of the procedures or treatments addressed in that practice parameter by physicians who are not formally credentialed in that specialty or specialties); and Policy 410.996 (which states that physician groups representing all appropriate specialties and practice settings should be involved in developing practice parameters, particularly those which cross lines of disciplines or specialties).
Citation: CME/CMS Rep., A-96; Amended: CME Rep. 7, A-99; Reaffirmed: CME Rep. 2, A-09; Reaffirmed: CME Rep. 6, A-10; Reaffirmed: CME Rep. 6, A-12; Reaffirmed in lieu of Res. 805, I-12; Reaffirmed: BOT Rep. 22, A-13; Reaffirmed in lieu of Res. 920, I-13; Reaffirmed: CMS Rep. 7, A-14; Reaffirmed: BOT Rep. 3, I-14; Reaffirmed: CMS Rep. 1, I-19; Modified: CMS Rep. 8, A-21

Coverage of and Payment for Telemedicine H-480.946
1. Our AMA believes that telemedicine services should be covered and paid for if they abide by the following principles:
a) A valid patient-physician relationship must be established before the provision of telemedicine services, through:
- A face-to-face examination, if a face-to-face encounter would otherwise be required in the provision of the same service not delivered via telemedicine; or
- A consultation with another physician who has an ongoing patient-physician relationship with the patient. The physician who has established a valid physician-patient relationship must agree to supervise the patient's care; or
- Meeting standards of establishing a patient-physician relationship included as part of evidence-based clinical practice guidelines on telemedicine developed by major medical specialty societies, such as those of radiology and pathology.
Exceptions to the foregoing include on-call, cross coverage situations; emergency medical treatment; and other exceptions that become recognized as meeting or improving the standard of care. If a medical home does not exist, telemedicine providers should facilitate the identification of medical homes and treating physicians where in-person services can be delivered in coordination with the telemedicine services.

b) Physicians and other health practitioners delivering telemedicine services must abide by state licensure laws and state medical practice laws and requirements in the state in which the patient receives services.
c) Physicians and other health practitioners delivering telemedicine services must be licensed in the state where the patient receives services, or be providing these services as otherwise authorized by that state's medical board.
d) Patients seeking care delivered via telemedicine must have a choice of provider, as required for all medical services.
e) The delivery of telemedicine services must be consistent with state scope of practice laws.
f) Patients receiving telemedicine services must have access to the licensure and board certification qualifications of the health care practitioners who are providing the care in advance of their visit.
g) The standards and scope of telemedicine services should be consistent with related in-person services.
h) The delivery of telemedicine services must follow evidence-based practice guidelines, to the degree they are available, to ensure patient safety, quality of care and positive health outcomes.
i) The telemedicine service must be delivered in a transparent manner, to include but not be limited to, the identification of the patient and physician in advance of the delivery of the service, as well as patient cost-sharing responsibilities and any limitations in drugs that can be prescribed via telemedicine.
j) The patient's medical history must be collected as part of the provision of any telemedicine service.
k) The provision of telemedicine services must be properly documented and should include providing a visit summary to the patient.
l) The provision of telemedicine services must include care coordination with the patient's medical home and/or existing treating physicians, which includes at a minimum identifying the patient's existing medical home and treating physicians and providing to the latter a copy of the medical record.
m) Physicians, health professionals and entities that deliver telemedicine services must establish protocols for referrals for emergency services.
2. Our AMA believes that delivery of telemedicine services must abide by laws addressing the privacy and security of patients' medical information.
3. Our AMA encourages additional research to develop a stronger evidence base for telemedicine.
4. Our AMA supports additional pilot programs in the Medicare program to enable coverage of telemedicine services, including, but not limited to store-and-forward telemedicine.
5. Our AMA supports demonstration projects under the auspices of the Center for Medicare and Medicaid Innovation to address how telemedicine can be integrated into new payment and delivery models.
6. Our AMA encourages physicians to verify that their medical liability insurance policy covers telemedicine services, including telemedicine services provided across state lines if applicable, prior to the delivery of any telemedicine service.
7. Our AMA encourages national medical specialty societies to leverage and potentially collaborate in the work of national telemedicine organizations, such as the American Telemedicine Association, in the area of telemedicine technical standards, to the extent practicable, and to take the lead in the development of telemedicine clinical practice guidelines.
Citation: CMS Rep. 7, A-14; Reaffirmed: BOT Rep. 3, I-14; Reaffirmed in lieu of Res. 815, I-15; Reaffirmed: CME Rep. 06, A-16; Reaffirmed: CMS Rep. 06, I-16; Reaffirmed: Res. 111, A-17; Reaffirmation: A-18; Reaffirmed: CMS Rep. 1, I-19; Reaffirmed: CMS Rep. 8, A-21

Evolving Impact of Telemedicine H-480.974
Our AMA:
(1) will evaluate relevant federal legislation related to telemedicine;
(2) urges CMS, AHRQ, and other concerned entities involved in telemedicine to fund demonstration projects to evaluate the effect of care delivered by physicians using telemedicine-related technology on costs, quality, and the physician-patient relationship;
(3) urges professional organizations that serve medical specialties involved in telemedicine to develop appropriate practice parameters to address the various applications of telemedicine and to guide quality assessment and liability issues related to telemedicine;
(4) encourages professional organizations that serve medical specialties involved in telemedicine to develop appropriate educational resources for physicians for telemedicine practice;
(5) encourages development of a code change application for CPT codes or modifiers for telemedical services, to be submitted pursuant to CPT processes;
(6) will work with CMS and other payers to develop and test, through these demonstration projects, appropriate reimbursement mechanisms;
(7) will develop a means of providing appropriate continuing medical education credit, acceptable toward the Physician's Recognition Award, for educational consultations using telemedicine;
(8) will work with the Federation of State Medical Boards and the state and territorial licensing boards to develop licensure guidelines for telemedicine practiced across state boundaries; and
(9) will leverage existing expert guidance on telemedicine by collaborating with the American Telemedicine Association (www.americantelemed.org) to develop physician and patient specific content on the use of telemedicine services--encrypted and unencrypted.

Citation: CMS/CME Rep., A-94; Reaffirmation A-01; Reaffirmation A-11; Reaffirmed: CMS Rep. 7, A-11; Reaffirmed in lieu of Res. 805, I-12; Appended: BOT Rep. 26, A-13; Modified: BOT Rep. 22, A-13; Reaffirmed: CMS Rep. 7, A-14; Reaffirmed: CME Rep. 06, A-16; Reaffirmation: A-18

Addressing Equity in Telehealth H-480.937
Our AMA:
(1) recognizes access to broadband internet as a social determinant of health;
(2) encourages initiatives to measure and strengthen digital literacy, with an emphasis on programs designed with and for historically marginalized and minoritized populations;
(3) encourages telehealth solution and service providers to implement design functionality, content, user interface, and service access best practices with and for historically minoritized and marginalized communities, including addressing culture, language, technology accessibility, and digital literacy within these populations;
(4) supports efforts to design telehealth technology, including voice-activated technology, with and for those with difficulty accessing technology, such as older adults, individuals with vision impairment and individuals with disabilities;
(5) encourages hospitals, health systems and health plans to invest in initiatives aimed at designing access to care via telehealth with and for historically marginalized and minoritized communities, including improving physician and non-physician provider diversity, offering training and technology support for equity-centered participatory design, and launching new and innovative outreach campaigns to inform and educate communities about telehealth;
(6) supports expanding physician practice eligibility for programs that assist qualifying health care entities, including physician practices, in purchasing necessary services and equipment in order to provide telehealth services to augment the broadband infrastructure for, and increase connected device use among historically marginalized, minoritized and underserved populations;
(7) supports efforts to ensure payers allow all contracted physicians to provide care via telehealth;
(8) opposes efforts by health plans to use cost-sharing as a means to incentivize or require the use of telehealth or in-person care or incentivize care from a separate or preferred telehealth network over the patient's current physicians; and
(9) will advocate that physician payments should be fair and equitable, regardless of whether the service is performed via audio-only, two-way audio-video, or in-person.
Citation: CMS Rep. 7, A-21

1.2.12 Ethical Practice in Telemedicine
Innovation in technology, including information technology, is redefining how people perceive time and distance. It is reshaping how individuals interact with and relate to others, including when, where, and how patients and physicians engage with one another.
Telehealth and telemedicine span a continuum of technologies that offer new ways to deliver care. Yet as in any mode of care, patients need to be able to trust that physicians will place patient welfare above other interests, provide competent care, provide the information patients need to make well-considered decisions about care, respect patient privacy and confidentiality, and take steps to ensure continuity of care. Although physicians fundamental ethical responsibilities do not change, the continuum of possible patient-physician interactions in telehealth/telemedicine give rise to differing levels of accountability for physicians.
All physicians who participate in telehealth/telemedicine have an ethical responsibility to uphold fundamental fiduciary obligations by disclosing any financial or other interests the physician has in the telehealth/telemedicine application or service and taking steps to manage or eliminate conflicts of interests. Whenever they provide health information, including health content for websites or mobile health applications, physicians must ensure that the information they provide or that is attributed to them is objective and accurate.
Similarly, all physicians who participate in telehealth/telemedicine must assure themselves that telemedicine services have appropriate protocols to prevent unauthorized access and to protect the security and integrity of patient information at the patient end of the electronic encounter, during transmission, and among all health care professionals and other personnel who participate in the telehealth/telemedicine service consistent with their individual roles.
Physicians who respond to individual health queries or provide personalized health advice electronically through a telehealth service in addition should:
(a) Inform users about the limitations of the relationship and services provided.
(b) Advise site users about how to arrange for needed care when follow-up care is indicated.
(c) Encourage users who have primary care physicians to inform their primary physicians about the online health consultation, even if in-person care is not immediately needed.
Physicians who provide clinical services through telehealth/telemedicine must uphold the standards of professionalism expected in in-person interactions, follow appropriate ethical guidelines of relevant specialty societies and adhere to applicable law governing the practice of telemedicine. In the context of telehealth/telemedicine they further should:
(d) Be proficient in the use of the relevant technologies and comfortable interacting with patients and/or surrogates electronically.

(e) Recognize the limitations of the relevant technologies and take appropriate steps to overcome those limitations. Physicians must ensure that they have the information they need to make well-grounded clinical recommendations when they cannot personally conduct a physical examination, such as by having another health care professional at the patients site conduct the exam or obtaining vital information through remote technologies.
(f) Be prudent in carrying out a diagnostic evaluation or prescribing medication by:
(i) establishing the patients identity;
(ii) confirming that telehealth/telemedicine services are appropriate for that patients individual situation and medical needs;
(iii) evaluating the indication, appropriateness and safety of any prescription in keeping with best practice guidelines and any formulary limitations that apply to the electronic interaction; and
(iv) documenting the clinical evaluation and prescription.
(g) When the physician would otherwise be expected to obtain informed consent, tailor the informed consent process to provide information patients (or their surrogates) need about the distinctive features of telehealth/telemedicine, in addition to information about medical issues and treatment options. Patients and surrogates should have a basic understanding of how telemedicine technologies will be used in care, the limitations of those technologies, the credentials of health care professionals involved, and what will be expected of patients for using these technologies.
(h) As in any patient-physician interaction, take steps to promote continuity of care, giving consideration to how information can be preserved and accessible for future episodes of care in keeping with patientspreferences (or the decisions of their surrogates) and how follow-up care can be provided when needed. Physicians should assure themselves how information will be conveyed to the patients primary care physician when the patient has a primary care physician and to other physicians currently caring for the patient.
Collectively, through their professional organizations and health care institutions, physicians should:
(i) Support ongoing refinement of telehealth/telemedicine technologies, and the development and implementation of clinical and technical standards to ensure the safety and quality of care.
(j) Advocate for policies and initiatives to promote access to telehealth/telemedicine services for all patients who could benefit from receiving care electronically.
(k) Routinely monitor the telehealth/telemedicine landscape to:
(i) identify and address adverse consequences as technologies and activities evolve; and
(ii) identify and encourage dissemination of both positive and negative outcomes.
AMA Principles of Medical Ethics: I,IV,VI,IX
The Opinions in this chapter are offered as ethics guidance for physicians and are not intended to establish standards of clinical practice or rules of law.
Issued: 2016

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 216
(A-22)

Introduced by: Medical Student Section

Subject: Advocating for the Elimination of Hepatitis C Treatment Restrictions

Referred to: Reference Committee B

Whereas, An estimated 2.4 million Americans are living with Hepatitis C Virus (HCV) infection, and acute HCV infection rates doubled from 2012 to 2019[1,2]; and

Whereas, Even with improvements in HCV treatment, projections for the next 35 years estimate that 157,000 U.S. patients will develop hepatocellular carcinoma, 203,000 will develop decompensated cirrhosis, and 320,000 will die due to HCV[3]; and

Whereas, The prevalence of HCV among Medicaid enrollees is 7.5 times higher than prevalence among the commercially insured population, demonstrating the disproportionate impact of HCV on marginalized populations[4]; and

Whereas, Structural barriers to accessing HCV therapy persist, as many state Medicaid programs, prisons and jails, and private insurers implement non-medically indicated restrictions, including *fibrosis restrictions* (requirement that patients have severe liver damage before receiving HCV treatment coverage), *sobriety restrictions* (requirement of abstinence from drugs and/or alcohol before HCV treatment), and *prescriber restrictions* (limitations on the type of clinician that can prescribe HCV treatment, such as requiring primary care doctors to consult with or request direct prescription from a hepatologist)[5,6]; and

Whereas, Consensus guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend with Level 1A evidence that nearly all people with acute or chronic HCV should receive treatment with direct-acting antivirals (DAAs), which can cure over 95% of individuals with HCV[7]; and

Whereas, The AASLD/IDSA guidelines emphasize with Level 1A evidence that “there are no data to support the utility of pretreatment screening for illicit drug or alcohol use in identifying a population more likely to successfully complete HCV therapy”[7]; and

Whereas, The AASLD/IDSA guidelines emphasize with Level 1A evidence that initiating therapy in patients with lower-stage fibrosis augments the clinical and public health benefits of virologic cure, and treatment delay may decrease the benefit of virologic cure[7]; and

Whereas, While treatment restrictions were primarily created to help payors mitigate the high cost of HCV treatment regimens, numerous studies have demonstrated that these restrictive policies are more costly and less effective than unrestricted strategies[8-13]; and

Whereas, In spite of expert consensus that HCV treatment restrictions are neither medically indicated nor effective, as of April 2021, four states still have fibrosis restrictions, 28 states have sobriety restrictions, and 18 states have prescriber restrictions[5,6]; and

Whereas, A 2018 study found that 35.5% of patients across 45 states (including 52.4% of commercial enrollees, 34.5% of Medicaid enrollees, and 14.7% of Medicare enrollees) who received prescriptions for DAAs were denied DAA coverage due to fibrosis, sobriety, or prescriber restrictions[14]; and

Whereas, The wholesale cost of a DAA treatment course has dropped over the last decade from $80,000+ to as low as $20,000[15]; and

Whereas, The Centers for Medicare and Medicaid Services issued a letter to states in 2015 that HCV treatment access restrictions may violate Medicaid statutory requirements[16]; and

Whereas, The U.S. Department of Health and Human Services' Viral Hepatitis National Strategic Plan for 2021-2025 includes a disparities goal of reducing the proportion of states with fibrosis, sobriety, and prescriber restrictions[17]; and

Whereas, Restricted access to HCV treatment disproportionately exacerbates health and financial inequities for American Indian/Alaska Native (AIAN) populations, who face double the acute HCV incidence rates of non-Hispanic whites and the highest rates of HCV-related mortality of any racial/ethnic group, as well as other structurally vulnerable immigrant and minoritized communities[18-20]; and

Whereas, While there is a legal responsibility to provide healthcare to AIAN patients served by the Indian Health Service (IHS), the agency serves as a payor of last resort, meaning federal and state-level coverage restrictions (i.e., via Medicare and Medicaid) can adversely impact IHS and AIAN populations[20-23]; and

Whereas, Our AMA supports increased funding and negotiation for affordable pricing of HCV treatment "so that all Americans for whom HCV treatment would have a substantial proven benefit will be able to receive this treatment" (H-440.845), which should include nearly all people with HCV in accordance with expert guidelines[7]; therefore be it

RESOLVED, That our American Medical Association amend policy H-440.845, "Advocacy for Hepatitis C Virus Education, Prevention, Screening and Treatment," by addition to read as follows:

Advocacy for Hepatitis C Virus Education, Prevention, Screening and Treatment, H-440.845

Our AMA will: (1) encourage the adoption of birth year-based screening practices for hepatitis C, in alignment with Centers for Disease Control and Prevention (CDC) recommendations; (2) encourage the CDC, Indian Health Service (IHS), and state Departments of Public Health to develop and coordinate Hepatitis C Virus infection educational and prevention efforts; (3) support hepatitis C virus (HCV) prevention, screening, and treatment programs that are targeted toward maximum public health benefit; (4) advocate, in collaboration with state and specialty medical societies, as well as patient advocacy groups, for the elimination of sobriety requirements, fibrosis restrictions, and prescriber restrictions for coverage of HCV treatment by public and private payors; (54) support programs aimed at training providers in the treatment and management of patients infected with HCV; (65) support adequate funding by, and negotiation for affordable pricing for HCV antiviral treatments between the government, insurance companies, and other third party payers, so that all Americans for whom HCV treatment would have a substantial proven benefit will be able to receive this treatment;

(7~~6~~) recognize correctional physicians, and physicians in other public health settings, as key stakeholders in the development of HCV treatment guidelines; (8~~7~~) encourage equitable reimbursement for those providing treatment; (9) encourage the allocation of targeted funding to increase HCV treatment for IHS patients insured by plans subject to HCV treatment restrictions. (Modify Current HOD Policy)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 04/08/22

References:

1. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. Hepatol Baltim Md. 2019;69(3):1020-1031. doi:10.1002/hep.30297
2. Centers for Disease Control and Prevention. Figure 3.1 of 2019 Viral Hepatitis Surveillance report. Published May 27, 2021. Accessed August 21, 2021. https://www.cdc.gov/hepatitis/statistics/2019surveillance/Figure3.1.htm
3. Chhatwal J, Wang X, Ayer T, et al. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64(5):1442-1450. doi:10.1002/hep.28571
4. Johnson RL, Blumen HE, Ferro C. The Burden of Hepatitis C Virus Disease in Commercial and Managed Medicaid Populations. Millman, Inc.; 2015. Accessed August 21, 2021. https://us.milliman.com/-/media/milliman/importedfiles/uploadedfiles/insight/2015/milliman- hcv-burden.ashx
5. Hepatitis C Treatment Restrictions. HepVu. Published May 19, 2021. Accessed August 21, 2021. https://hepvu.org/hepatitis-c-treatment-restrictions/
6. Center for Health Law and Policy Innovation (CHLPI), National Viral Hepatitis Roundtable (NVHR). Hepatitis C: The State of Medicaid Access.; 2021. Accessed August 21, 2021. https://stateofhepc.org/wp-content/uploads/2021/06/HCV_State-of-Medicaid-Access_May- 2021-Progress-Report.pdf
7. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). When and in Whom to Initiate HCV Therapy | HCV Guidance. Published November 6, 2019. Accessed August 21, 2021. https://www.hcvguidelines.org/evaluate/when-whom
8. Liao JM, Fischer MA. Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics. Am J Public Health. 2017;107(6):893-899. doi:10.2105/AJPH.2017.303748
9. Chou JW, Silverstein AR, Goldman DP. Short-term budget affordability of hepatitis C treatments for state Medicaid programs. BMC Health Serv Res. 2019;19(1):140. doi:10.1186/s12913-019-3956-x
10. Chidi AP, Bryce CL, Donohue JM, et al. Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health. 2016;19(4):326-334. doi:10.1016/j.jval.2016.01.010
11. Van Nuys K, Brookmeyer R, Chou JW, Dreyfus D, Dieterich D, Goldman DP. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. Health Aff (Millwood). 2015;34(10):1666-1674. doi:10.1377/hlthaff.2014.1193
12. Younossi Z, Gordon SC, Ahmed A, Dieterich D, Saab S, Beckerman R. Treating Medicaid patients with hepatitis C: clinical and economic impact. Am J Manag Care. 2017;23(2):107- 112.
13. Padula WV, Levin JS, Lee J, Anderson GF. Cost-effectiveness of Total State Coverage for Hepatitis C Medications. Am J Manag Care. 2021;27(5):e171-e177. doi:10.37765/ajmc.2021.88640
14. Gowda C, Lott S, Grigorian M, et al. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis. 2018;5(6). doi:10.1093/ofid/ofy076
15. Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int. 2018;12(3):214-222. doi:10.1007/s12072-018-9873-y
16. Center for Medicaid & CHIP Services. Assuring Medicaid Beneficiaries Access to Hepatitis C Virus (HCV) Drugs. Published online November 5, 2015. Accessed August 21, 2021. https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Prescription- Drugs/Downloads/Rx-Releases/State-Releases/state-rel-172.pdf
17. U.S. Department of Health & Human Services. Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021-2025).; 2020. https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf
18. Indian Health Service. Hepatitis C. Division of Clinical and Community Services. Accessed August 21, 2021. https://www.ihs.gov/dccs/hcv/
19. Iralu JV, Rudd CSM. Treating Hepatitis C in the Indian Health Service. Presented at the: Indian Health Services; 2016; Washington, DC.
20. Rempel JD, Uhanova J. Hepatitis C Virus in American Indian/Alaskan Native and Aboriginal Peoples of North America. Viruses. 2012;4(12):3912-3931. doi:10.3390/v4123912
21. Indian Health Service. Requirements: Alternate Resources | Eligibility. Purchased/Referred Care (PRC). Accessed August 21, 2021. https://www.ihs.gov/prc/eligibility/requirements- alternate-resources/
22. Indian Health Service. Basis for Health Services | Fact Sheets. Newsroom. Published January 2015. Accessed August 21, 2021. https://www.ihs.gov/newsroom/factsheets/basisforhealthservices/
23. Reilley B, Miller M, Hudson M, Haverkate R, Leston J. Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018. Int J Equity Health. 2019;18(1):190. doi:10.1186/s12939-019-1101-4

RELEVANT AMA POLICY

Advocacy for Hepatitis C Virus Education, Prevention, Screening and Treatment H-440.845
Our AMA will: (1) encourage the adoption of birth year-based screening practices for hepatitis C, in alignment with Centers for Disease Control and Prevention (CDC) recommendations; (2) encourage the CDC and state Departments of Public Health to develop and coordinate Hepatitis C Virus infection educational and prevention efforts; (3) support hepatitis C virus (HCV) prevention, screening, and treatment programs that are targeted toward maximum public health benefit; (4) support programs aimed at training providers in the treatment and management of patients infected with HCV; (5) support adequate funding by, and negotiation for affordable pricing for HCV antiviral treatments between the government, insurance companies, and other third party payers, so that all Americans for whom HCV treatment would have a substantial proven benefit will be able to receive this treatment; (6) recognize correctional physicians, and physicians in other public health settings, as key stakeholders in the development of HCV treatment guidelines; and (7) encourage equitable reimbursement for those providing treatment.
Citation: Res. 906, I-12; Modified: Res. 511, A-15; Modified: Res. 410, A-17

Support for Standardized Diagnosis and Treatment of Hepatitis C Virus in the Population of Incarcerated Persons H-430.985
Our AMA: (1) supports the implementation of routine screening for Hepatitis C virus (HCV) in prisons; (2) will advocate for the initiation of treatment for HCV when determined to be appropriate by the treating physician in incarcerated patients with the infection who are seeking treatment; and (3) supports negotiation for affordable pricing for therapies to treat and cure HCV among correctional facility health care providers, correctional facility health care payors, and drug companies to maximize access to these disease-altering medications.
Citation: Res. 404, A-17

Incorporating Value into Pharmaceutical Pricing H-110.986
1. Our AMA supports value-based pricing programs, initiatives and mechanisms for pharmaceuticals that are guided by the following principles: (a) value-based prices of pharmaceuticals should be determined by objective, independent entities; (b) value-based prices of pharmaceuticals should be evidence-based and be the result of valid and reliable inputs and data that incorporate rigorous scientific methods, including clinical trials, clinical data registries, comparative effectiveness research, and robust outcome measures that capture short- and long-term clinical outcomes; (c) processes to determine value-based prices of pharmaceuticals must be transparent, easily accessible to physicians and patients, and provide practicing physicians and researchers a central and significant role; (d) processes to determine value-based prices of pharmaceuticals should limit administrative burdens on physicians and patients; (e) processes to determine value-based prices of pharmaceuticals should incorporate affordability criteria to help assure patient affordability as well as limit system-wide budgetary impact; and (f) value-based pricing of pharmaceuticals should allow for patient variation and physician discretion.
2. Our AMA supports the inclusion of the cost of alternatives and cost-effectiveness analysis in comparative effectiveness research.
3. Our AMA supports direct purchasing of pharmaceuticals used to treat or cure diseases that pose unique public health threats, including hepatitis C, in which lower drug prices are assured in exchange for a guaranteed market size.
Citation: CMS Rep. 05, I-16; Reaffirmed in lieu of: Res. 207, A-17; Reaffirmed: CMS-CSAPH Rep. 01, A-17; Reaffirmed: CMS Rep. 07, A-18; Reaffirmed: CSAPH Rep. 2, I-19; Reaffirmed: CMS Rep. 4, I-19; Reaffirmed: CMS Rep. 6, I-20

US Physician Shortage H-200.954
Our AMA:
(1) explicitly recognizes the existing shortage of physicians in many specialties and areas of the US;
(2) supports efforts to quantify the geographic maldistribution and physician shortage in many specialties;
(3) supports current programs to alleviate the shortages in many specialties and the maldistribution of physicians in the US;
(4) encourages medical schools and residency programs to consider developing admissions policies and practices and targeted educational efforts aimed at attracting physicians to practice in underserved areas and to provide care to underserved populations;
(5) encourages medical schools and residency programs to continue to provide courses, clerkships, and longitudinal experiences in rural and other underserved areas as a means to support educational program objectives and to influence choice of graduates' practice locations;
(6) encourages medical schools to include criteria and processes in admission of medical students that are predictive of graduates' eventual practice in underserved areas and with underserved populations;
(7) will continue to advocate for funding from public and private payers for educational programs that provide experiences for medical students in rural and other underserved areas;
(8) will continue to advocate for funding from all payers (public and private sector) to increase the number of graduate medical education positions in specialties leading to first certification;
(9) will work with other groups to explore additional innovative strategies for funding graduate medical education positions, including positions tied to geographic or specialty need;
(10) continues to work with the Association of American Medical Colleges (AAMC) and other relevant groups to monitor the outcomes of the National Resident Matching Program; and
(11) continues to work with the AAMC and other relevant groups to develop strategies to address the current and potential shortages in clinical training sites for medical students.
(12) will: (a) promote greater awareness and implementation of the Project ECHO (Extension for Community Healthcare Outcomes) and Child Psychiatry Access Project models among academic health centers and community-based primary care physicians; (b) work with stakeholders to identify and mitigate barriers to broader implementation of these models in the United States; and (c) monitor whether health care payers offer additional payment or incentive payments for physicians who engage in clinical practice improvement activities as a result of their participation in programs such as Project ECHO and the Child Psychiatry Access Project; and if confirmed, promote awareness of these benefits among physicians.
(13) will work to augment the impact of initiatives to address rural physician workforce shortages.
Citation: Res. 807, I-03; Reaffirmation I-06; Reaffirmed: CME Rep. 7, A-08; Appended: CME Rep. 4, A-10; Appended: CME Rep. 16, A-10; Reaffirmation: I-12; Reaffirmation A-13; Appended: Res. 922, I-13; Modified: CME Rep. 7, A-14; Reaffirmed: CME Rep. 03, A-16; Appended: Res. 323, A-19; Appended: CME Rep. 3, I-21

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 217
(A-22)

Introduced by: Resident and Fellow Section

Subject: Preserving the Practice of Medicine

Referred to: Reference Committee B

Whereas, The book *Patients at Risk: The Rise of the Nurse Practitioner and Physician Assistant in Healthcare* by Niran Al-Agba, M.D. and Rebekah Bernard, M.D. published in 2020, seeks to educate patients about the safety of the providers treating them and empower physicians to regain control of the practice of medicine[1]; and

Whereas, The corporatization of medicine, at the expense of quality safe healthcare, has led to physicians being replaced by non-physician providers, especially in states with legislatively-enshrined independent practice for non-physician providers[1]; and

Whereas, News reports and articles note instances of thoracic surgeons and obstetrician gynecologists supervising social workers in the provision of group therapy[2] and plastic surgeons supervising physician assistants who advertise themselves as “dermatologists”[3]; and

Whereas, Anecdotal evidence suggests numerous non-physician providers practicing in various fields with nominal supervision by physicians who are not trained in those fields; and

Whereas, Physicians without appropriate training to supervise non-physician providers outside of their expertise defeats the purpose of scope-of-practice laws, endangering patients; and

Whereas, Studies show that care provided by non-physician providers is more expensive and invasive due to more frequent office visits, lab testing, imaging and home visits[4,5]; and

Whereas, No credible controlled trial has been performed to evaluate the quality of care provided by non-physicians vs. physicians in settings that are truly characterized as “independent practice”[5]; and

Whereas, Non-physician providers seeking independent practice inaccurately cite studies to claim non-physicians supervised by physicians have equal outcomes to physicians[5], and

Whereas, An increasing number of healthcare organizations preferentially fill the schedules of non-physician providers over physicians to increase profit[5]; and

Whereas, There are efforts by the National Organization of Nurse Practitioners Faculties by 2025 to convert Master of Science in Nursing (MSN) degrees into Doctor of Nursing Practice degrees (DNP), many of which are online programs without clear standards of curricula[6]; therefore be it

RESOLVED, That our American Medical Association oppose mandates from employers to supervise non-physician providers as a condition for physician employment and in physician employment contracts (New HOD Policy); and be it further

RESOLVED, That our AMA work with relevant regulatory agencies to ensure physicians are notified in writing when their license is being used to “supervise” non-physician providers (Directive to Take Action); and be it further

RESOLVED, That our AMA conduct a systematic study to collect and analyze publicly available physician supervision data from all sources to determine how many allied health professionals are being supervised by physicians in fields which are not a core part of those physicians’ completed residencies and fellowships (Directive to Take Action); and be it further

RESOLVED, That our AMA study the impact scope-of practice advocacy by physicians has had on physician employment and termination (Directive to Take Action); and be it further

RESOLVED, That our AMA study the views of patients on physician and non-physician care to identify best practices in educating the general population on the value of physician-led care, and study the utility of a physician-reported database to track and report institutions that replace physicians with non-physician providers in order to aid patients in seeking physician-led medical care (Directive to Take Action); and be it further

RESOLVED, That our AMA work with relevant stakeholders to commission an independent study comparing medical care provided by physician-led health care teams vs. care provided by unsupervised non-physician providers, which reports on the quality of health outcomes, cost effectiveness, and access to necessary medical care, and to publish the findings in a peer-reviewed medical journal. (Directive to Take Action)

Fiscal Note: Estimated cost of $462,000 to implement this resolution.

Received: 04/08/22

References:

1. Al-Agba, Niran, and Rebekah Bernard. *Patients at Risk: the Rise of the Nurse Practitioner and Physician Assistant in Healthcare*. Universal-Publishers, Inc., 2020
2. Ornstein C and ProPublica. Illinois leads Medicare billings for group therapy. Chicago Tribune. 13 Jul 2014. chicagotribune.com/lifestyles/health/ct-medicare-group-therapy-met-20140713-story.html. Accessed 18 Sep 2019.
3. Al-agba N. The P.A. Problem: Who You See and What You Get. The Healthcare Blog. 24 Nov 2017. https://thehealthcareblog.com/blog/2017/11/24/the-p-a-problem/. Accessed 18 Sep 2019.
4. The First U.S. Study on Nurses' Evidence-Based Practice Competencies Indicates Major Deficits That Threaten Healthcare Quality, Safety, and Patient Outcomes - PubMed (nih.gov)
5. Al-Agba, Niran, and Rebekah Bernard. Patients at Risk: the Rise of the Nurse Practitioner and Physician Assistant in Healthcare. Universal-Publishers, Inc., 2020.
6. NP to DNP: In Less Than 10 Years, All Nurse Practitioners May Need to Hold a DNP - Regis College Online

RELEVANT AMA POLICY

Practicing Medicine by Non-Physicians H-160.949
Our AMA: (1) urges all people, including physicians and patients, to consider the consequences of any health care plan that places any patient care at risk by substitution of a non-physician in the diagnosis, treatment, education, direction and medical procedures where clear-cut documentation of assured quality has not been carried out, and where such alters the traditional pattern of practice in which the physician directs and supervises the care given;
(2) continues to work with constituent societies to educate the public regarding the differences in the scopes of practice and education of physicians and non-physician health care workers;
(3) continues to actively oppose legislation allowing non-physician groups to engage in the practice of medicine without physician (MD, DO) training or appropriate physician (MD, DO) supervision;
(4) continues to encourage state medical societies to oppose state legislation allowing non-physician groups to engage in the practice of medicine without physician (MD, DO) training or

appropriate physician (MD, DO) supervision;
(5) through legislative and regulatory efforts, vigorously support and advocate for the requirement of appropriate physician supervision of non-physician clinical staff in all areas of medicine; and
(6) opposes special licensing pathways for “assistant physicians” (i.e., those who are not currently enrolled in an Accreditation Council for Graduate Medical Education training program, or have not completed at least one year of accredited graduate medical education in the U.S).
Citation: Res. 317, I-94; Modified by Res. 501, A-97; Appended: Res. 321, I-98; Reaffirmation A-99; Appended: Res. 240, Reaffirmed: Res. 708 and Reaffirmation A-00; Reaffirmed: CME Rep. 1, I-00; Reaffirmed: CMS Rep. 6, A-10; Reaffirmed: Res. 208, I-10; Reaffirmed: Res. 224, A-11; Reaffirmed: BOT Rep. 9, I-11; Reaffirmed: Res. 107, A-14; Appended: Res. 324, A-14; Modified: CME Rep. 2, A-21;

Physician Assistants and Nurse Practitioners H-160.947
Our AMA will develop a plan to assist the state and local medical societies in identifying and lobbying against laws that allow advanced practice nurses to provide medical care without the supervision of a physician.
The suggested Guidelines for Physician/Physician Assistant Practice are adopted to read as follows (these guidelines shall be used in their entirety):
(1) The physician is responsible for managing the health care of patients in all settings.
(2) Health care services delivered by physicians and physician assistants must be within the scope of each practitioner's authorized practice, as defined by state law.
(3) The physician is ultimately responsible for coordinating and managing the care of patients and, with the appropriate input of the physician assistant, ensuring the quality of health care provided to patients.
(4) The physician is responsible for the supervision of the physician assistant in all settings.
(5) The role of the physician assistant in the delivery of care should be defined through mutually agreed upon guidelines that are developed by the physician and the physician assistant and based on the physician's delegatory style.
(6) The physician must be available for consultation with the physician assistant at all times, either in person or through telecommunication systems or other means.
(7) The extent of the involvement by the physician assistant in the assessment and implementation of treatment will depend on the complexity and acuity of the patient's condition and the training, experience, and preparation of the physician assistant, as adjudged by the physician.
(8) Patients should be made clearly aware at all times whether they are being cared for by a physician or a physician assistant.
(9) The physician and physician assistant together should review all delegated patient services on a regular basis, as well as the mutually agreed upon guidelines for practice.
(10) The physician is responsible for clarifying and familiarizing the physician assistant with his/her supervising methods and style of delegating patient care.
Citation: BOT Rep. 6, A-95; Reaffirmed: Res 240 and Reaffirmation A-00; Reaffirmed: Res. 213, A-02; Modified: CLRPD Rep. 1, A-03; Reaffirmed: BOT Rep. 9, I-11; Reaffirmed: Joint CME-CMS Rep., I-12; Reaffirmed: BOT Rep. 16, A-13

Guidelines for Integrated Practice of Physician and Nurse Practitioner H-160.950
Our AMA endorses the following guidelines and recommends that these guidelines be considered and quoted only in their entirety when referenced in any discussion of the roles and responsibilities of nurse practitioners: (1) The physician is responsible for the supervision of nurse practitioners and other advanced practice nurses in all settings.
(2) The physician is responsible for managing the health care of patients in all practice settings.
(3) Health care services delivered in an integrated practice must be within the scope of each

practitioner's professional license, as defined by state law.
(4) In an integrated practice with a nurse practitioner, the physician is responsible for supervising and coordinating care and, with the appropriate input of the nurse practitioner, ensuring the quality of health care provided to patients.
(5) The extent of involvement by the nurse practitioner in initial assessment, and implementation of treatment will depend on the complexity and acuity of the patients' condition, as determined by the supervising/collaborating physician.
(6) The role of the nurse practitioner in the delivery of care in an integrated practice should be defined through mutually agreed upon written practice protocols, job descriptions, and written contracts.
(7) These practice protocols should delineate the appropriate involvement of the two professionals in the care of patients, based on the complexity and acuity of the patients' condition.
(8) At least one physician in the integrated practice must be immediately available at all times for supervision and consultation when needed by the nurse practitioner.
(9) Patients are to be made clearly aware at all times whether they are being cared for by a physician or a nurse practitioner.
(10) In an integrated practice, there should be a professional and courteous relationship between physician and nurse practitioner, with mutual acknowledgment of, and respect for each other's contributions to patient care.
(11) Physicians and nurse practitioners should review and document, on a regular basis, the care of all patients with whom the nurse practitioner is involved. Physicians and nurse practitioners must work closely enough together to become fully conversant with each other's practice patterns.
Citation: (CMS Rep. 15 - I-94; BOT Rep. 6, A-95; Reaffirmed: Res. 240, A-00; Reaffirmation A-00; Reaffirmed: BOT Rep. 28, A-09; Reaffirmed: BOT Rep. 9, I-11; Reaffirmed: Joint CME-CMS Rep., I-12; Reaffirmed: BOT Rep. 16, A-13)

Principles Guiding AMA Policy Regarding Supervision of Medical Care Delivered by Advanced Practice Nurses in Integrated Practice H-360.987
Our AMA endorses the following principles: (1) Physicians must retain authority for patient care in any team care arrangement, e.g., integrated practice, to assure patient safety and quality of care.
(2) Medical societies should work with legislatures and licensing boards to prevent dilution of the authority of physicians to lead the health care team.
(3) Exercising independent medical judgment to select the drug of choice must continue to be the responsibility only of physicians.

(4) Physicians should recognize physician assistants and advanced practice nurses under physician leadership, as effective physician extenders and valued members of the health care team.
(5) Physicians should encourage state medical and nursing boards to explore the feasibility of working together to coordinate their regulatory initiatives and activities.
(6) Physicians must be responsible and have authority for initiating and implementing quality control programs for nonphysicians delivering medical care in integrated practices.
Citation: (BOT Rep. 23, A-96; Reaffirmation A-99; Reaffirmed: Res. 240, and Reaffirmation A-00; Reaffirmed: CMS Rep. 6, A-10; Reaffirmed: BOT Rep. 9, I-11; Reaffirmation A-12; Reaffirmed: BOT Rep. 16, A-13)

Practice Agreements Between Physicians and Advance Practice Nurses and the Physician to Advance Practice Nurse Supervisory Ratio H-35.969

Our AMA will: (1) continue to work with the Federation in developing necessary state advocacy resource tools to assist the Federation in: (a) addressing the development of practice agreements between practicing physicians and advance practice nurses, and (b) responding to or developing state legislation or regulations governing these practice agreements, and that the AMA make these tools available on the AMA Advocacy Resource Center Web site; and (2) support the development of methodologically valid research comparing physician-APRN practice agreements and their respective effectiveness.
Citation: BOT Rep. 28, A-09; Reaffirmed: BOT Rep. 09, A-19;

Regulation of Advanced Practice Nurses H-35.964
1. AMA policy is that advanced practice registered nurses (APRNs) should be subject to the jurisdiction of state medical licensing and regulatory boards for regulation of their performance of medical acts.
2. Our AMA will develop model legislation to create a joint regulatory board composed of members of boards of medicine and nursing, with authority over APRNs.
Citation: BOT Action in response to referred for decision Amendment B-3 to Res. 233 A-17

Protecting Physician Led Health Care H-35.966
Our American Medical Association will continue to work with state and specialty medical associations and other organizations to collect, analyze and disseminate data on the expanded use of allied health professionals, and of the impact of this practice on healthcare access (including in poor, underserved, and rural communities), quality, and cost in those states that permit independent practice of allied health professionals as compared to those that do not. This analysis should include consideration of practitioner settings and patient risk-adjustment.
Citation: Res. 238, A-15; Reaffirmed: BOT Rep. 20, A-17;

Education Programs Offered to, for or by Allied Health Professionals Associated with a Hospital H-35.978
The AMA encourages hospital medical staffs to have a process whereby physicians will have input to and provide review of education programs provided by their hospital for the benefit of allied health professionals working in that hospital, for the education of patients served by that hospital, and for outpatient educational programs provided by that hospital.
Citation: (BOT Rep. B, A-93; Adopts Res. 317, A-92; Reaffirmed: CME Rep. 2, A-03; Reaffirmed: CME Rep. 2, A-13)

Health Workforce H-200.994
The AMA endorses the following principle on health manpower: Both physicians and allied health professionals have legal and ethical responsibilities for patient care, even though ultimate responsibility for the individual patient's medical care rests with the physician. To assure quality patient care, the medical profession and allied health professionals should have continuing dialogue on patient care functions that may be delegated to allied health professionals consistent with their education, experience and competency.
Citation: (BOT Rep. C, I-81; Reaffirmed: Sunset Report, I-98; Modified: CME Rep. 2, I-03; Reaffirmed: CME Rep. 2, A-13)

Health Care Quality Improvement Act of 1986 Amendments H-275.965
The AMA supports modification of the federal Health Care Quality Improvement Act in order to provide immunity from federal antitrust liability to those medical staffs credentialing and conducting good faith peer review for allied health professionals to the same extent that immunity applies to credentialing of physicians and dentists.
Citation: (Res. 203, A-88; Reaffirmed: Sunset Report, I-98; Reaffirmation A-05; Reaffirmed: BOT Rep. 10, A-15)

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 218
(A-22)

Introduced by: American Association of Physicians of Indian Origin

Subject: Expedited Immigrant Green Card Visa for J-1 Visa Waiver Physicians Serving in Underserved Areas

Referred to: Reference Committee B

Whereas, J-1 visa IMG resident physicians sign in for serving in underserved areas for three years to become eligible to stay in US as permanent residents instead of mandatory return to native countries as required per J-1 visa regulation; and

Whereas, Their service is extremely helpful in improving the health of US citizens especially in low income and rural communities; and

Whereas, Substantial care to COVID patients was provided by these J-1 visa waiver physicians and they saved lives; and

Whereas, The waiting period for getting the Green Card Visa for physicians of certain countries is longer than 10 years at present due to per country limit of 7% of H1b to immigrant (Green Card) availability, and the J-1 visa waiver physicians have to join the end of the very long queue of 1.2 million applicants for certain countries, and their children are becoming status less at age 21; and

Whereas, These J-1 visa waiver physicians provide a great national service to US citizens, and deserve priority in visa allotment; therefore be it

RESOLVED, That our American Medical Association lobby US Congress and the US Administration that the J-1 visa waiver physicians serving in underserved areas be given highest priority in visa conversion to green cards upon completion of their service commitment obligation and be exempted from per country limitation of H-1 to green card visa conversion. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 04/20/22

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 219
(A-22)

Introduced by: American College of Emergency Physicians

Subject: Due Process and Independent Contractors

Referred to: Reference Committee B

Whereas, Physicians often hesitate to speak out because of the prospect of losing their jobs or suffering other types of retaliation due to a possible or real threat if they expressed concerns about quality of care[1]; and

Whereas, Physicians have been retaliated against numerous times for raising concerns regarding patient safety, harassment, and/or fraud and these physicians have been affected mentally and financially as results of such retaliation and job loss and many report worsening anxiety, depression, financial hardships, family trouble and need to relocate[2]; and

Whereas, The interests of patients are best served when physicians practice in a stable, fair, equitable, and supportive environment and quality patient care is best promoted within a framework of fair and appropriate contractual relationships among various involved parties; and

Whereas, The COVID-19 pandemic put to the test physicians' ability to speak publicly about troublesome issues and in the first few weeks, healthcare facilities were struggling to obtain personal protective equipment (PPE) and to create policies that would keep patients and caregivers safe[3,4]; and

Whereas, The Joint Commission and the Health Care Quality Improvement Act of 1986 require hospitals to give physicians appropriate due process before taking an adverse action on their privileges; and

Whereas, There are also a number of state and federal laws that protect employees from discrimination or retribution for "whistle-blowing," but these protections may be weakened or inapplicable if the physician is an independent contractor[5]; and

Whereas, Our AMA Principles for Physician Employment (H-225.950) states in part "Employed physicians should be free to exercise their personal and professional judgment in voting, speaking and advocating on any manner regarding patient care interests, the profession, health care in the community, and the independent exercise of medical judgment. Employed physicians should not be deemed in breach of their employment agreements, nor be retaliated

---

[1] McNamara RM, Beier K, Blumstein H, Weiss LD, Wood J. A survey of emergency physicians regarding due process, financial pressures, and the ability to advocate for patients. J Emerg Med. 2013 Jul;45(1):111-6.e3. doi: 10.1016/j.jemermed.2012.12.019. Epub 2013 Apr 18. PMID: 23602793.
[2] https://www.nbcnews.com/health/health-care/doctor-fired-er-warns-effect-profit-firms-us-health-care-rcna19975?utm_source=pocket_mylist (last accessed April 6, 2022)
[3] https://www.medscape.com/viewarticle/950074
[4] https://verdictsearch.com/verdict/hospitals-firing-of-doctor-was-retaliation-plaintiff-alleged/
https://www.reliasmedia.com/articles/146234-enforcement-action-likely-if-hospital-retaliates-against-ed-staff
https://www.npr.org/sections/health-shots/2020/05/29/865042307/an-er-doctor-lost-his-job-after-criticizing-his-hospital-on-covid-19-now-hes-sui
[5] https://www.aaemrsa.org/get-involved/residents/key-contract-issues

against by their employers, for asserting these interests. Employed physicians also should enjoy academic freedom to pursue clinical research and other academic pursuits within the ethical principles of the medical profession and the guidelines of the organization;" and

Whereas, The State of Arizona recently passed Arizona House Bill 2622 (2021) to address many of these concerns, and several other states have enacted similar legislation, each with their own strengths and weaknesses; and

Whereas, Our AMA policies are silent on those physicians who work as independent contractors and might be subject to retaliatory actions by their contractors rather than their employer; therefore be it

RESOLVED, That our American Medical Association develop a model state legislative template and principles for federal legislation in order to protect physicians from corporate, workplace, and/or employer retaliation when reporting safety, harassment, or fraud concerns at the places of work (licensed health care institution) or in the government, which includes independent and third-party contractors providing patient services at said facilities. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 04/27/22

RELEVANT AMA POLICY

AMA Principles for Physician Employment H-225.950

1. Addressing Conflicts of Interest

a) A physician's paramount responsibility is to his or her patients. Additionally, given that an employed physician occupies a position of significant trust, he or she owes a duty of loyalty to his or her employer. This divided loyalty can create conflicts of interest, such as financial incentives to over- or under-treat patients, which employed physicians should strive to recognize and address.

b) Employed physicians should be free to exercise their personal and professional judgment in voting, speaking and advocating on any manner regarding patient care interests, the profession, health care in the community, and the independent exercise of medical judgment. Employed physicians should not be deemed in breach of their employment agreements, nor be retaliated against by their employers, for asserting these interests. Employed physicians also should enjoy academic freedom to pursue clinical research and other academic pursuits within the ethical principles of the medical profession and the guidelines of the organization.

c) In any situation where the economic or other interests of the employer are in conflict with patient welfare, patient welfare must take priority.

d) Physicians should always make treatment and referral decisions based on the best interests of their patients. Employers and the physicians they employ must assure that agreements or understandings (explicit or implicit) restricting, discouraging, or encouraging particular treatment or referral options are disclosed to patients.

(i) No physician should be required or coerced to perform or assist in any non-emergent procedure that would be contrary to his/her religious beliefs or moral convictions; and

(ii) No physician should be discriminated against in employment, promotion, or the extension of staff or other privileges because he/she either performed or assisted in a lawful, non-emergent procedure, or refused to do so on the grounds that it violates his/her religious beliefs or moral convictions.

e) Assuming a title or position that may remove a physician from direct patient-physician relationships--such as medical director, vice president for medical affairs, etc.--does not override professional ethical obligations. Physicians whose actions serve to override the individual patient care decisions of other physicians are themselves engaged in the practice of medicine and are subject to professional ethical obligations and may be legally responsible for such decisions. Physicians who hold administrative

leadership positions should use whatever administrative and governance mechanisms exist within the organization to foster policies that enhance the quality of patient care and the patient care experience.

Refer to the AMA Code of Medical Ethics for further guidance on conflicts of interest.

2. Advocacy for Patients and the Profession

a) Patient advocacy is a fundamental element of the patient-physician relationship that should not be altered by the health care system or setting in which physicians practice, or the methods by which they are compensated.

b) Employed physicians should be free to engage in volunteer work outside of, and which does not interfere with, their duties as employees.

3. Contracting

a) Physicians should be free to enter into mutually satisfactory contractual arrangements, including employment, with hospitals, health care systems, medical groups, insurance plans, and other entities as permitted by law and in accordance with the ethical principles of the medical profession.

b) Physicians should never be coerced into employment with hospitals, health care systems, medical groups, insurance plans, or any other entities. Employment agreements between physicians and their employers should be negotiated in good faith. Both parties are urged to obtain the advice of legal counsel experienced in physician employment matters when negotiating employment contracts.

c) When a physician's compensation is related to the revenue he or she generates, or to similar factors, the employer should make clear to the physician the factors upon which compensation is based.

d) Termination of an employment or contractual relationship between a physician and an entity employing that physician does not necessarily end the patient-physician relationship between the employed physician and persons under his/her care. When a physician's employment status is unilaterally terminated by an employer, the physician and his or her employer should notify the physician's patients that the physician will no longer be working with the employer and should provide them with the physician's new contact information. Patients should be given the choice to continue to be seen by the physician in his or her new practice setting or to be treated by another physician still working with the employer. Records for the physician's patients should be retained for as long as they are necessary for the care of the patients or for addressing legal issues faced by the physician; records should not be destroyed without notice to the former employee. Where physician possession of all medical records of his or her patients is not already required by state law, the employment agreement should specify that the physician is entitled to copies of patient charts and records upon a specific request in writing from any patient, or when such records are necessary for the physician's defense in malpractice actions, administrative investigations, or other proceedings against the physician.

(e) Physician employment agreements should contain provisions to protect a physician's right to due process before termination for cause. When such cause relates to quality, patient safety, or any other matter that could trigger the initiation of disciplinary action by the medical staff, the physician should be afforded full due process under the medical staff bylaws, and the agreement should not be terminated before the governing body has acted on the recommendation of the medical staff. Physician employment agreements should specify whether or not termination of employment is grounds for automatic termination of hospital medical staff membership or clinical privileges. When such cause is non-clinical or not otherwise a concern of the medical staff, the physician should be afforded whatever due process is outlined in the employer's human resources policies and procedures.

(f) Physicians are encouraged to carefully consider the potential benefits and harms of entering into employment agreements containing without cause termination provisions. Employers should never terminate agreements without cause when the underlying reason for the termination relates to quality, patient safety, or any other matter that could trigger the initiation of disciplinary action by the medical staff.

(g) Physicians are discouraged from entering into agreements that restrict the physician's right to practice medicine for a specified period of time or in a specified area upon termination of employment.

(h) Physician employment agreements should contain dispute resolution provisions. If the parties desire an alternative to going to court, such as arbitration, the contract should specify the manner in which disputes will be resolved.

Refer to the AMA Annotated Model Physician-Hospital Employment Agreement and the AMA Annotated Model Physician-Group Practice Employment Agreement for further guidance on physician employment contracts.

4. Hospital Medical Staff Relations

a) Employed physicians should be members of the organized medical staffs of the hospitals or health systems with which they have contractual or financial arrangements, should be subject to the bylaws of those medical staffs, and should conduct their professional activities according to the bylaws, standards, rules, and regulations and policies adopted by those medical staffs.

b) Regardless of the employment status of its individual members, the organized medical staff remains responsible for the provision of quality care and must work collectively to improve patient care and outcomes.

c) Employed physicians who are members of the organized medical staff should be free to exercise their personal and professional judgment in voting, speaking, and advocating on any matter regarding medical staff matters and should not be deemed in breach of their employment agreements, nor be retaliated against by their employers, for asserting these interests.

d) Employers should seek the input of the medical staff prior to the initiation, renewal, or termination of exclusive employment contracts.

Refer to the AMA Conflict of Interest Guidelines for the Organized Medical Staff for further guidance on the relationship between employed physicians and the medical staff organization.

5. Peer Review and Performance Evaluations

a) All physicians should promote and be subject to an effective program of peer review to monitor and evaluate the quality, appropriateness, medical necessity, and efficiency of the patient care services provided within their practice settings.

b) Peer review should follow established procedures that are identical for all physicians practicing within a given health care organization, regardless of their employment status.

c) Peer review of employed physicians should be conducted independently of and without interference from any human resources activities of the employer. Physicians--not lay administrators--should be ultimately responsible for all peer review of medical services provided by employed physicians.

d) Employed physicians should be accorded due process protections, including a fair and objective hearing, in all peer review proceedings. The fundamental aspects of a fair hearing are a listing of specific charges, adequate notice of the right to a hearing, the opportunity to be present and to rebut evidence, and the opportunity to present a defense. Due process protections should extend to any disciplinary action sought by the employer that relates to the employed physician's independent exercise of medical judgment.

e) Employers should provide employed physicians with regular performance evaluations, which should be presented in writing and accompanied by an oral discussion with the employed physician. Physicians should be informed before the beginning of the evaluation period of the general criteria to be considered in their performance evaluations, for example: quality of medical services provided, nature and frequency of patient complaints, employee productivity, employee contribution to the administrative/operational activities of the employer, etc.

(f) Upon termination of employment with or without cause, an employed physician generally should not be required to resign his or her hospital medical staff membership or any of the clinical privileges held during the term of employment, unless an independent action of the medical staff calls for such action, and the physician has been afforded full due process under the medical staff bylaws. Automatic rescission of medical staff membership and/or clinical privileges following termination of an employment agreement is tolerable only if each of the following conditions is met:

i. The agreement is for the provision of services on an exclusive basis; and

ii. Prior to the termination of the exclusive contract, the medical staff holds a hearing, as defined by the medical staff and hospital, to permit interested parties to express their views on the matter, with the medical staff subsequently making a recommendation to the governing body as to whether the contract should be terminated, as outlined in AMA Policy H-225.985; and

iii. The agreement explicitly states that medical staff membership and/or clinical privileges must be resigned upon termination of the agreement.

Refer to the AMA Principles for Incident-Based Peer Review and Disciplining at Health Care Organizations (AMA Policy H-375.965) for further guidance on peer review.

6. Payment Agreements

a) Although they typically assign their billing privileges to their employers, employed physicians or their chosen representatives should be prospectively involved if the employer negotiates agreements for them for professional fees, capitation or global billing, or shared savings. Additionally, employed physicians should be informed about the actual payment amount allocated to the professional fee component of the total payment received by the contractual arrangement.

b) Employed physicians have a responsibility to assure that bills issued for services they provide are accurate and should therefore retain the right to review billing claims as may be necessary to verify that such bills are correct. Employers should indemnify and defend, and save harmless, employed physicians with respect to any violation of law or regulation or breach of contract in connection with the employer's billing for physician services, which violation is not the fault of the employee.

Our AMA will disseminate the AMA Principles for Physician Employment to graduating residents and fellows and will advocate for adoption of these Principles by organizations of physician employers such as, but not limited to, the American Hospital Association and Medical Group Management Association.

BOT Rep. 6, I-12 Reaffirmed: CMS Rep. 6, I-13 Modified in lieu of Res. 2, I-13 Modified: Res. 737, A-14 Reaffirmed: BOT Rep. 21, A-16 Reaffirmed: CMS Rep. 05, A-17 Reaffirmed: CMS Rep. 07, A-19 Reaffirmed: CMS Rep. 11, A-19 Modified: BOT Rep. 13, A-19

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 220
(A-22)

Introduced by: Aerospace Medical Association

Subject: Vital Nature of Board-Certified Physicians in Aerospace Medicine

Referred to: Reference Committee B

Whereas, Aerospace medicine is an internationally recognized, unique specialty of medicine with advanced education requirements supporting all domains of aviation and space flight; and

Whereas, In over a century of support, the Aerospace Medicine Team, led by aerospace medicine physicians, has advanced the art and science of every human flight endeavor, resulting in improved safety, reduced mishaps, and enhanced mission accomplishment; and

Whereas, Aerospace medicine physicians are required to maintain their professional knowledge and standing with state medical licensure, current specialty board certifications, continuing medical education activities, and ongoing privileging; and have extensive knowledge, skills, and professional self-regulation in the full and total range of the practice of aerospace medicine; and

Whereas, In an effort to reduce costs and pass-on legal liability, there has been a trend in managed medical care, US commercial airlines/space activities and in the US governmental departments to replace aerospace medicine physicians with non-aerospace medicine and mid-level providers, resulting in significantly increased risk and reduced safety margins; and

Whereas, 193 countries are signatories to the Convention on International Civil Aviation ("Chicago Convention"), which obliges the governments to reciprocally implement certain international regulatory standards, including physician responsibility pertaining to medical fitness of license holders, prevention of ill health and management of public health events in aviation; therefore be it

RESOLVED, That our American Medical Association recognize the unique contributions and advanced qualifications of aerospace medicine professionals, and specifically oppose any and all efforts to remove, reduce or replace aerospace medicine physician leadership in civilian, corporate or government aerospace medicine programs and aircrew healthcare support teams; (Directive to Take Action) and be it further

RESOLVED, That our AMA advocate for compliance with international agreements, to include advocating against other mid-level provider scope of practice expansions that threaten the safety, health, and well-being of aircrew, patients, support personnel and the flying public. (Directive to Take Action)

Fiscal Note: Modest - between $1,000 - $5,000

Received: 04/25/22

RELEVANT AMA POLICY

The Structure and Function of Interprofessional Health Care Teams H-160.912

1. Our AMA defines 'team-based health care' as the provision of health care services by a physician-led team of at least two health care professionals who work collaboratively with each other and the patient and family to accomplish shared goals within and across settings to achieve coordinated, high-quality, patient-centered care.
2. Our AMA will advocate that the physician leader of a physician-led interprofessional health care team be empowered to perform the full range of medical interventions that she or he is trained to perform.
3. Our AMA will advocate that all members of a physician-led interprofessional health care team be enabled to perform medical interventions that they are capable of performing according to their education, training and licensure and the discretion of the physician team leader in order to most effectively provide quality patient care.
4. Our AMA adopts the following principles to guide physician leaders of health care teams:
a. Focus the team on patient and family-centered care.
b. Make clear the team's mission, vision and values.
c. Direct and/or engage in collaboration with team members on patient care.
d. Be accountable for clinical care, quality improvement, efficiency of care, and continuing education.
e. Foster a respectful team culture and encourage team members to contribute the full extent of their professional insights, information and resources.
f. Encourage adherence to best practice protocols that team members are expected to follow.
g. Manage care transitions by the team so that they are efficient and effective, and transparent to the patient and family.
h. Promote clinical collaboration, coordination, and communication within the team to ensure efficient, quality care is provided to the patient and that knowledge and expertise from team members is shared and utilized.
i. Support open communication among and between the patient and family and the team members to enhance quality patient care and to define the roles and responsibilities of the team members that they encounter within the specific team, group or network.
j. Facilitate the work of the team and be responsible for reviewing team members' clinical work and documentation.
k. Review measures of 'population health' periodically when the team is responsible for the care of a defined group.
5. Our AMA encourages independent physician practices and small group practices to consider opportunities to form health care teams such as through independent practice associations, virtual networks or other networks of independent providers.
6. Our AMA will advocate that the structure, governance and compensation of the team should be aligned to optimize the performance of the team leader and team members.
Citation: Joint CME-CMS Rep., I-12; Reaffirmation I-13; Reaffirmed: CMS Rep. 1, I-15; Reaffirmed: BOT Action in response to referred for decision: Res. 718, A-17

Models / Guidelines for Medical Health Care Teams H-160.906

1. Our AMA defines 'physician-led' in the context of team-based health care as the consistent use by a physician of the leadership knowledge, skills and expertise necessary to identify, engage and elicit from each team member the unique set of training, experience, and qualifications needed to help patients achieve their care goals, and to supervise the application of these skills.
2. Our AMA supports the following elements that should be considered when planning a team-based care model according to the needs of each physician practice:
Patient-Centered:

a. The patient is an integral member of the team.
b. A relationship is established between the patient and the team at the onset of care, and the role of each team member is explained to the patient.
c. Patient and family-centered care is prioritized by the team and approved by the physician team leader.
d. Team members are expected to adhere to agreed-upon practice protocols.
e. Improving health outcomes is emphasized by focusing on health as well as medical care.
f. Patients' access to the team, or coverage as designated by the physician-led team, is available twenty-four hours a day, seven days a week.
g. Safety protocols are developed and followed by all team members.
Teamwork:
h. Medical teams are led by physicians who have ultimate responsibility and authority to carry out final decisions about the composition of the team.
i. All practitioners commit to working in a team-based care model.
j. The number and variety of practitioners reflects the needs of the practice.
k. Practitioners are trained according to their unique function in the team.
l. Interdependence among team members is expected and relied upon.
m. Communication about patient care between team members is a routine practice.
n. Team members complete tasks according to agreed-upon protocols as directed by the physician leader.
Clinical Roles and Responsibilities:
o. Physician leaders are focused on individualized patient care and the development of treatment plans.
p. Non-physician practitioners are focused on providing treatment within their scope of practice consistent with their education and training as outlined in the agreed upon treatment plan or as delegated under the supervision of the physician team leader.
q. Care coordination and case management are integral to the team's practice.
r. Population management monitors the cost and use of care, and includes registry development for most medical conditions.
Practice Management:
s. Electronic medical records are used to the fullest capacity.
t. Quality improvement processes are used and continuously evolve according to physician-led team-based practice assessments.
u. Data analytics include statistical and qualitative analysis on cost and utilization, and provide explanatory and predictive modeling.
v. Prior authorization and precertification processes are streamlined through the adoption of electronic transactions.
Citation: CMS Rep. 6, A-14; Reaffirmed: CMS Rep. 07, A-16; Reaffirmed: CMS Rep. 05, A-17

Payment Mechanisms for Physician-Led Team-Based Health Care H-160.908
1. Our AMA advocates that physicians who lead team-based care in their practices receive the payments for health care services provided by the team and establish payment disbursement mechanisms that foster physician-led team-based care.
2. Our AMA advocates that payment models for physician-led team-based care should be determined by physicians working collaboratively with hospital and payer partners to design models best suited for their particular circumstances.
3. Our AMA advocates that physicians make decisions about payment disbursement in consideration of team member contributions, including but not limited to:
a. Volume of services provided;
b. Intensity of services provided;
c. Profession of the team member;
d. Training and experience of the team member; and

e. Quality of care provided.
4. Our AMA advocates that an effective payment system for physician-led team-based care should:
a. Reflect the value provided by the team and that any savings accrued by this value should be shared by the team;
b. Reflect the time, effort and intellectual capital provided by individual team members;
c. Be adequate to attract team members with the appropriate skills and training to maximize the success of the team; and
d. Be sufficient to sustain the team over the time frame that it is needed.
Citation: CMS Rep. 1, I-13; Reaffirmed: CMS Rep. 1, I-15; Reaffirmed: CMS Rep. 08, A-16

Support for Physician Led, Team Based Care D-35.985
Our AMA:
1. Reaffirms, will proactively advance at the federal and state level, and will encourage state and national medical specialty societies to promote policies H-35.970, H-35.973, H-35.974, H-35.988, H-35.989, H-35.992, H-35.993, H-160.919, H-160.929, H-160.947, H-160.949, H-160.950, H-360.987, H 405.969 and D-35.988.
2. Will identify and review available data to analyze the effects on patients' access to care in the opt-out states (states whose governor has opted out of the federal Medicare physician supervision requirements for anesthesia services) to determine whether there has been any increased access to care in those states.
3. Will identify and review available data to analyze the type and complexity of care provided by all non-physician providers, including CRNAs in the opt-out states (states whose governor has opted out of the federal Medicare physician supervision requirements for anesthesia services), compared to the type and complexity of care provided by physicians and/or the anesthesia care team.
4. Will advocate to policymakers, insurers and other groups, as appropriate, that they should consider the available data to best determine how non-physicians can serve as a complement to address the nation's primary care workforce needs.
5. Will continue to recognize non-physician providers as valuable components of the physician-led health care team.
6. Will continue to advocate that physicians are best qualified by their education and training to lead the health care team.
7. Will call upon the Robert Wood Johnson Foundation to publicly announce that the report entitled, "Common Ground: An Agreement between Nurse and Physician Leaders on Interprofessional Collaboration for the Future of Patient Care" was premature; was not released officially; was not signed; and was not adopted by the participants.
Citation: BOT Rep. 9, I-11; Reaffirmed: CMS Rep. 1, A-12; Reaffirmed: CMS Rep. 07, A-17; Reaffirmed: CMS Rep. 10, A-19; Reaffirmed: CMS Rep. 6, A-21